piracetam has been researched along with Epilepsy in 552 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We compare, in a routine clinical setting, brand versus generic levetiracetam (LEV) bioequivalence in patients with epilepsy and also the clinical efficacy and tolerability of the substitution." | 9.24 | Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. ( Chatzistefanidis, D; Gatzonis, S; Kyritsis, AP; Markoula, S; Patsalos, PN; Siarava, E; Siatouni, A; Verentzioti, A, 2017) |
| "To evaluate the efficacy of Levetiracetam in the management of neonatal seizures." | 9.22 | Efficacy of Levetiracetam in neonatal seizures: a systematic review. ( Hussain, AM; Sharma, D; Sharma, SS, 2022) |
| "This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study (KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy." | 9.22 | Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. ( Marson, AG; Noack-Rink, M; Pohlmann-Eden, B; Ramirez, F; Tofighy, A; Trinka, E; Werhahn, KJ; Wild, I, 2016) |
| "We sought to determine the effect of changing phenytoin therapy on bone mineral density (BMD) and 25-hydroxyvitamin D in patients with epilepsy." | 9.17 | Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. ( Geater, A; Leelawattana, R; Limapichat, K; Phabphal, K; Sathirapanya, P; Setthawatcharawanich, S, 2013) |
| "To show non-inferiority of levetiracetam to sulthiame with respect to efficacy, tolerability and safety in benign epilepsy with centrotemporal spikes in a prospective, double-blinded randomized controlled trial." | 9.17 | Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). ( Bast, T; Bonfert, M; Borggraefe, I; Heinen, F; Maßmann, K; May, TW; Neubauer, BA; Noachtar, S; Schotten, KJ; Tuxhorn, I, 2013) |
| "To estimate the effect of levetiracetam (LEV) on cognitive function and mood status in newly diagnosed epilepsy patients." | 9.17 | Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients. ( Hong, SB; Hwang, KJ; Joo, EY; Kim, D; Kim, JY; Kim, MR; Kim, YJ; Koo, DL; Lee, JM; Shin, W, 2013) |
| "The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG)." | 9.17 | Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine. ( Frøland, SS; Luef, G; Mochol, M; Mushtaq, U; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2013) |
| "Of the newer antiepileptic drugs, lamotrigine (LTG) and levetiracetam (LEV) are popular first choice drugs for epilepsy." | 9.16 | The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. ( Arnold, S; Bauer, S; Beige, A; Berrouschot, J; Burchardi, N; Eisensehr, I; Evers, S; Haag, A; Hallmeyer-Elgner, S; Hamer, HM; Klein, KM; Kovac, S; Lerche, H; Niedhammer, M; Oertel, WH; Reif, PS; Rosenow, F; Roth, E; Schade-Brittinger, C; Schröder, M; Springub, J; Strzelczyk, A; Weber, Y; Winkler, G, 2012) |
| "Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury." | 9.16 | Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinsky, S; Tsuchida, T; van den Anker, J, 2012) |
| "To evaluate the safety and tolerability of treatment with levetiracetam and determine the trough levels of levetiracetam in patients with traumatic brain injury (TBI) who are at high risk for posttraumatic epilepsy (PTE)." | 9.16 | Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinski, S; Tsuchida, T; van den Anker, J, 2012) |
| "We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE)." | 9.15 | Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. ( Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2011) |
| " This study was done to evaluate the effect of levetiracetam (LEV) on subjective sleep quality and sleep architecture in patients with epilepsy, and the results were compared with the effects of carbamazepine-CR (CBZ-CR)." | 9.15 | The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. ( Cho, YW; Kim, DH; Motamedi, GK, 2011) |
| "To investigate the efficacy and safety of levetiracetam in adults with intellectual disabilities who have uncontrolled partial or generalised epilepsy." | 9.14 | A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities. ( Beavis, J; Felce, D; Kerr, M; Meek, A, 2009) |
| "Levetiracetam given twice a day in children with refractory epilepsy reduces seizure frequency in all types of epilepsy." | 9.14 | Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. ( Carmant, L; Giroux, PC; Salas-Prato, M; Théorêt, Y, 2009) |
| "This aim of the study was to ascertain the importance of clinical parameters on the response to treatment in refractory epilepsy patients on levetiracetam (LEV)." | 9.13 | Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study. ( Auvinen, A; Fallah, M; Keränen, T; Kharazmi, E; Liimatainen, S; Peltola, J; Peltola, M, 2008) |
| "To prospectively assess the safety and efficacy of levetiracetam in patients with uncontrolled focal epilepsy, in a common practice-based setting." | 9.12 | Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. ( Despland, PA; Fejerman, N; Genton, P; Maubrey, MC; Peltola, J; Rektor, I; Sadzot, B; Schlit, AF; Steinhoff, B; van Hammée, G; van Paesschen, W; Vandervelden, C; Wroe, S, 2006) |
| "We report the results of a prospective study of the efficacy and tolerability of levetiracetam, a new antiepileptic drug with a unique mechanism of action, in comparison with controlled-release carbamazepine as first treatment in newly diagnosed epilepsy." | 9.12 | Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. ( Ben-Menachem, E; Brodie, MJ; Meencke, HJ; Perucca, E; Ryvlin, P, 2007) |
| "To assess the efficacy and tolerability of Levetiracetam (LEV) in children and adolescents with refractory epilepsy with a special interest in the long-term retention rate." | 9.12 | Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy. ( Holthausen, H; Kluger, G; von Stuelpnagel, C, 2007) |
| "Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy." | 9.12 | [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers]. ( Auriel, E; Blatt, I; Chistik, V; Margolin, N; Neufeld, M, 2007) |
| "To determine whether levetiracetam (LEV) affects plasma concentrations of carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy." | 9.12 | Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. ( De Smedt, H; Otoul, C; Stockis, A, 2007) |
| "The authors assessed the effect of concomitant antiepileptic therapy on steady-state plasma concentrations of the new anti-epileptic drug (AED) levetiracetam in a cohort of 100 adult patients with epilepsy." | 9.11 | Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. ( Albani, F; Baruzzi, A; Contin, M; Riva, R, 2004) |
| "The aim of this multicentric, prospective and uncontrolled study was to evaluate the efficacy and safety of levetiracetam in 110 children with refractory epilepsy, of whom 21 were less than 4 years old." | 9.11 | Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. ( Acampora, B; Balestri, P; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Iannetti, P; Marchiani, V; Morgese, G; Pascotto, A; Spalice, A; Verrotti, A, 2005) |
| "To further evaluate the safety, efficacy and optimal dose of levetiracetam (LEV) in daily clinical practice among patients with uncontrolled partial epilepsy with or without secondary generalization." | 9.11 | Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. ( Steinhoff, BJ; Trinka, E; Wieser, HG, 2005) |
| "To evaluate the efficacy and tolerability of Levetiracetam (LEV) in a large pediatric cohort with drug-resistant epilepsy from a prospective multicenter observational study." | 9.11 | Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. ( Bettendorf, U; Brandl, U; Gross-Selbeck, G; Härtel, C; Kluger, G; Korn-Merker, E; Kurlemann, G; May, T; Opp, J; Rating, D; Tuxhorn, I; Wiemer-Kruel, A, 2005) |
| "This retrospective study suggests that levetiracetam has a positive effect on the EEG, the behavior, and the cognition of patients with epilepsy and CSWS." | 9.11 | Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases. ( Aeby, A; Poznanski, N; Van Bogaert, P; Verheulpen, D; Wetzburger, C, 2005) |
| "Levetiracetam, one of the newer-generation antiepilepsy drugs, is not currently approved for use in children." | 9.10 | Levetiracetam in refractory pediatric epilepsy. ( Ng, YT; Wheless, JW, 2002) |
| "The aim of this prospective, uncontrolled clinical study was to evaluate the tolerability and the efficacy of levetiracetam as add-on treatment in 78 adults and 44 children with intractable epilepsy." | 9.10 | A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. ( Eriksson, AS; Johannessen, SI; Lossius, R; Nakken, KO, 2003) |
| "To evaluate the long-term clinical usefulness of levetiracetam (LEV, Keppra((R))(1)) as add-on therapy in patients with refractory epilepsy." | 9.10 | Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. ( Ben-Menachem, E; Edrich, P; Sander, JW; Schmidt, B; Van Vleymen, B, 2003) |
| "Levetiracetam appears to be well tolerated in patients with severe epilepsy and shows efficacy in a long-term follow-up." | 9.10 | Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. ( Ben-Menachem, E; Gilland, E, 2003) |
| "The novel antiepileptic drug (AED) levetiracetam (LEV, Keppra) is indicated as adjunctive therapy for partial epilepsy." | 9.10 | An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. ( Abou-Khalil, B; Hemdal, P; Privitera, MD, 2003) |
| "The aim of this study was to determine the tolerability and efficacy of two oral regimens of levetiracetam, 1000 mg and 2000 mg twice daily, as add-on treatment without titration in patients with refractory epilepsy." | 9.09 | A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. ( Betts, T; Crawford, P; Waegemans, T, 2000) |
| "The aim of this study was to determine the efficacy and tolerability of 1000-4000 mg/day of levetiracetam (LEV, Keppra) as add-on treatment for refractory epilepsy." | 9.09 | Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. ( Grant, R; Shorvon, SD, 2000) |
| " A new pyrrolidine derivative (levetiracetam), resembling piracetam, was given as antiepileptic concomitant drug to patients with chronic epilepsy." | 9.08 | Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. ( Aldenkamp, AP; Alpherts, WC; Neyens, LG, 1995) |
| " The formal evidence for levetiracetam monotherapy in children is minimal: it is potentially efficacious or effective as initial monotherapy in children with benign epilepsy with centrotemporal spikes." | 8.91 | Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review. ( Brouwer, OF; Callenbach, PM; Weijenberg, A, 2015) |
| "The adverse effects profile of levetiracetam in epilepsy is still being fully described." | 8.90 | The adverse effects profile of levetiracetam in epilepsy: a more detailed look. ( Dixon, P; Hutton, JL; Marson, AG; Mbizvo, GK, 2014) |
| " Studies were eligible for inclusion when they included children from one month to 18 years of age with a diagnosis of epilepsy, used levetiracetam, had other AEDs on a stable regimen for at least two months, reported about behavioral side-effects and had a follow-up of at least two weeks." | 8.90 | Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. ( Aldenkamp, AP; de Louw, AJ; Halma, E; IJff, DM; Klinkenberg, S; Majoie, M, 2014) |
| " The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection." | 8.87 | Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. ( Belcastro, V; Pierguidi, L; Tambasco, N, 2011) |
| "Levetiracetam has been widely used for childhood epilepsy, but there is no high quality evidence to support its use." | 8.86 | [Levetiracetam therapy for childhood epilepsy: a systematic review]. ( Dai, J; Han, L; Wang, L; Zhang, LL, 2010) |
| "To review data evaluating levetiracetam management of epilepsy during pregnancy." | 8.85 | Levetiracetam use in pregnancy. ( Forinash, AB; Longo, B; Murphy, JA, 2009) |
| "This report reviews behavioral adverse events occurring among adults receiving levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in epilepsy (1023), cognitive disorders (719), or anxiety disorders (1510) and epilepsy patients (1393) observed in long-term trials." | 8.82 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. ( Cramer, JA; De Rue, K; Devinsky, O; Edrich, P; Trimble, MR, 2003) |
| "Levetiracetam is a novel antiepileptic drug (AED) with proven efficacy against partial seizures, but there is limited information about its effectiveness against generalized seizures." | 8.82 | Levetiracetam: preliminary efficacy in generalized seizures. ( Hirsch, E; Kasteleijn-Nolst Trenité, DG, 2003) |
| "To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of levetiracetam in the treatment of epilepsy." | 8.81 | Levetiracetam: a different approach to the pharmacotherapy of epilepsy. ( Ficker, DM; Gidal, BE; Privitera, MD; Welty, TE, 2002) |
| " Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs)." | 8.31 | Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. ( Edens, M; Schelhaas, M; Ter Horst, P; Touw, D; Wammes-Van Der Heijden, E; Wegner, I, 2023) |
| "Valproic acid (VPA) and levetiracetam (LEV) are used in epilepsy treatment." | 8.12 | Successful Treatment of Symptomatic Epilepsy with Oral Valproic Acid and Levetiracetam in a Patient with Short-bowel Syndrome. ( Hayashi, M; Iijima, A; Isozaki, R; Kurishima, A; Shimozato, R; Shioda, T, 2022) |
| "The purpose of our study was the evaluation of the effect of 2,000 mg levetiracetam monotherapy over a 3-month period on nocturnal sleep in patients with epilepsy." | 8.12 | Effect of levetiracetam on nocturnal sleep in patients with epilepsy. ( Chaneva, OG; Viteva, EI, 2022) |
| "Levetiracetam (LEV) is an anti-seizure medication (ASM) known to have significant behavioral side effects in children with epilepsy." | 8.12 | Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study. ( Bartolini, L; Bassell-Hawkins, J; Lob, K; Nie, D; Patil, R, 2022) |
| " Consecutive adolescent patients with epilepsy aged 11-17 years with partial or generalized seizures, treated with either levetiracetam or valproic acid for at least 6 months, and healthy controls were recruited." | 8.12 | Irritability and its relationship with psychosocial symptoms and quality of life in adolescents with epilepsy receiving levetiracetam therapy: A case-control study. ( Tekin, E; Tekin, U; Uçar, HN, 2022) |
| "Children aged 1 to 12 years, diagnosed with epilepsy (generalized or focal seizures), treated with valproate (n = 40) and valproate with add-on levetiracetam (n = 40) were included." | 8.02 | Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy. ( Gupta, R; Halder, S; Kar, R; Labh, R; Narang, M, 2021) |
| "Levetiracetam (LEV) is a second-generation antiepileptic drug with high efficacy and tolerability in children and adults with epilepsy." | 8.02 | Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center. ( Akıncı Göktaş, Ö; Bektaş, Ö; Şahin, S; Tıraş Teber, S; Yıldırım, M; Yüksel, MF, 2021) |
| "The present study evaluated whether patients with epilepsy who received both levetiracetam (LEV) and perampanel (PER) therapy showed side effects of irritability." | 8.02 | Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy. ( Hasegawa, N; Tohyama, J, 2021) |
| "This retrospective study compared the efficacy and safety of levetiracetam monotherapy and in combination with other antiseizure medications (ASMs) in 1055 pediatric patients with epilepsy treated with levetiracetam." | 8.02 | Long-term safety, efficacy, and tolerability of levetiracetam in pediatric patients with epilepsy in Uygur, China: A retrospective analysis. ( Feng, J; Li, HJ; Ma, L; Sun, L; Sun, Y; Wang, TT; Yu, J; Yu, LH; Zhao, T, 2021) |
| "The objective was to develop and externally validate a population pharmacokinetic model of levetiracetam in adult and elderly patients with epilepsy, and to perform dosing simulations to propose individualized dosing regimens more likely to achieve therapeutic concentrations." | 7.96 | Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. ( Hernández-Mitre, MP; Jung-Cook, HH; Medellín-Garibay, SE; Milán-Segovia, RDC; Roberts, JA; Rodríguez-Leyva, I; Rodríguez-Pinal, CJ; Romano-Moreno, S; Zarazúa, S, 2020) |
| "The purpose of this study was to determine the efficacy of perampanel (PER) on secondary bilateral synchrony (SBS) and behavioral problems in adolescents with epilepsy who showed insufficient response to levetiracetam (LEV)." | 7.96 | Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam. ( Aihara, M; Hoshino, H; Kanemura, H; Sano, F; Takayama, K, 2020) |
| "We enrolled patients with epilepsy who were treated with branded levetiracetam for at least 6 months of sustained use." | 7.88 | Brand name to generic substitution of levetiracetam in patients with epilepsy. ( Dae, SJ; Gha-Hyun, L, 2018) |
| "Levetiracetam is used in the treatment of some forms of epilepsy." | 7.85 | Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. ( Company-Albir, MJ; Marqués-Miñana, MR; Poveda, JL; Ruíz-Ramos, J; Solana Altabella, A; Vicent, C, 2017) |
| "Recent adverse event reports have raised the question of increased angioedema risk associated with exposure to levetiracetam." | 7.85 | Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. ( Banda, JM; Duke, JD; Hripcsak, G; Jin, P; Khoma, Y; Reich, C; Ryan, PB; Schuemie, MJ; Schwalm, MS; Shah, NH; Suchard, MA; Wu, Y; Xu, H, 2017) |
| "To evaluate the efficacy and tolerability of levetiracetam monotherapy in dogs with structural epilepsy." | 7.85 | Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015). ( Kelly, D; Raimondi, F; Shihab, N, 2017) |
| "Levetiracetam has a high tolerability and is effective against various seizure types and epilepsy syndromes." | 7.85 | Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy. ( Arakawa, H; Hazama, K; Ida, K; Makioka, N; Motojima, T; Muramatsu, K; Ogata, T; Sawaura, N; Tomita, K, 2017) |
| "Levetiracetam (LEV) is commonly used as a mono- or adjunctive therapy for treating patients with partial and generalized epilepsy." | 7.85 | Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jung, KH; Jung, KY; Kim, TJ; Lee, S; Lee, SK; Lee, ST; Moon, J; Park, KI; Rhee, SJ; Shin, JW; Yu, KS, 2017) |
| "Objective: As a treatment for cases of developmental disorder accompanied with epilepsy, the author examined the efficacy and tolerability of combined administration of levetiracetam (LEV) on the cases." | 7.83 | Experience with levetiracetam to epilepsy cases in neurodevelopmental disorders. ( Takagi, K, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 7.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "To investigate the clinical efficacy and safety of Levetiracetam (LEV) add-on therapy for child refractory epilepsy." | 7.83 | The clinical efficacy and safety of levetiracetam add-on therapy for child refractory epilepsy. ( Chen, J; Chen, SZ; Liu, XM; Yue, X, 2016) |
| " Few case reports have been published regarding pancytopenia associated with levetiracetam treatment, and its intrinsic pathogenesis is still unknown." | 7.83 | Pancytopenia associated with levetiracetam in an epileptic woman. ( García Carretero, R; Olid-Velilla, M; Romero Brugera, M; Salamanca-Ramirez, I, 2016) |
| "Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China." | 7.81 | Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep. ( Cai, F; Chen, J; Feng, C; Hu, Y; Jiang, L, 2015) |
| "To assess the effect and tolerability of zonisamide (ZNS) as adjunctive treatment for difficult-to-treat epilepsy in adult Scandinavian patients." | 7.81 | Retention rate of zonisamide in intractable epilepsy. ( Andersen, H; Lindstrøm, P; Nakken, KO, 2015) |
| " There are multiple retrospective studies reporting good efficacy and tolerability of the anti-epileptic drug levetiracetam (LEV) in human patients with epilepsy; however, reports of LEV's tolerability and efficacy in dogs with epilepsy remain limited." | 7.81 | Assessment into the usage of levetiracetam in a canine epilepsy clinic. ( Nye, G; Packer, RM; Porter, SE; Volk, HA, 2015) |
| "TO determine neuroprotective properties of levetiracetam and simvastatin using rats with pilocaroine-induced epilepsy." | 7.81 | [Protective effects of levetiracetam and simvastatin on pilocarpine-induced epilepsy in rat models]. ( Chen, T; Li, MQ; Liu, L; Zhang, WW, 2015) |
| "To evaluate the long-term effects and tolerability of levetiracetam (LEV) in refractory epilepsy." | 7.81 | [Effectiveness and safety of long-term levetiracetam treatment in patients with refractory epilepsy]. ( Baba, H; Fuji, A; Matsuo, M; Matsuzaka, T; Moriuchi, H; Ono, T; Sato, T; Tanaka, S; Toda, K, 2015) |
| "To clarify the efficacy and safety of levetiracetam (LEV) in children with localization-related epilepsy, we performed a retrospective study in our hospital." | 7.81 | [Efficacy of Levetiracetam as an Add-on Therapy in Children with Localization-related Epilepsy]. ( Enoki, H; Okanishi, T; Yokota, T, 2015) |
| "We report on a 9-year-old girl with idiopathic epilepsy who showed forced normalization after administration of levetiracetam (LEV)." | 7.81 | A Girl with Idiopathic Epilepsy Showing Forced Normalization after Levetiracetam Administration. ( Fujino, O; Itoh, Y; Kawakami, Y; Okazaki, T; Takase, M, 2015) |
| "Our objective is to explore the effects of levetiracetam on the levels of neuropeptides, serum activity and concentrations of oxidative stress and inflammatory response proteins, and levels of brain injury marker in patients with refractory epilepsy." | 7.81 | The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy. ( Chen, W; Chen, Y; Ge, Y; Liu, X; Tan, Y, 2015) |
| "To report cases of hair loss with levetiracetam (LEV) in epilepsy patient and summarise their demographic and clinical features." | 7.80 | Hair loss with levetiracetam in five patients with epilepsy. ( Hong, Z; Zhou, D; Zou, X, 2014) |
| "Studies evaluating the effect of levetiracetam (LEV) on haematological parameters in patients with epilepsy are very limited." | 7.80 | Short-term effect of levetiracetam monotherapy on haematological parameters in children with epilepsy: a prospective study. ( Attilakos, A; Dinopoulos, A; Garoufi, A; Moustaki, M; Papaevangelou, V; Paschalidou, M; Siafakas, N; Tsirouda, M, 2014) |
| "We investigated the relationship between behavioral problems, location of electroencephalogram (EEG) paroxysmal abnormalities (PA), and treatment with levetiracetam in children with pervasive developmental disorder (PDD) and epilepsy." | 7.80 | Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( Aihara, M; Kanemura, H; Ohyama, T; Sano, F; Sugita, K, 2014) |
| "This study aimed to evaluate the effectiveness of levetiracetam (LEV) use for seizure control in patients who had undergone resective surgery for intractable epilepsy in routine clinical practice." | 7.80 | Effectiveness of levetiracetam use following resective surgery in patients with refractory epilepsy: a prospective observational study. ( An, DM; Chen, L; Lei, D; Li, JM; Li, YH; Zeng, TF; Zhang, B; Zhou, D, 2014) |
| "Body weight was measured at baseline and at the final LEV study visit." | 7.80 | Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. ( Gidal, BE; Herbeuval, AF; Magnus, L; Sheth, RD, 2003) |
| "To evaluate the long-term efficacy and safety of levetiracetam based on a large population of patients in a tertiary epilepsy centre." | 7.79 | The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. ( Chu, K; Jung, KH; Kang, BS; Kim, YS; Lee, SK; Lee, ST; Moon, HJ, 2013) |
| "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy." | 7.79 | Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. ( Arnold, S; Brandt, C; Elger, CE; Hagemann, A; May, TW; Nieder, E; Pohlmann-Eden, B; Schulze-Bonhage, A; Straub, HB; Tergau, F; Witte-Bölt, K, 2013) |
| " The aim of this study is to determine the changes of bone metabolism and BMD in epilepsy patients who are undergoing levetiracetam (LEV) monotherapy." | 7.79 | Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. ( Hong, SB; Joo, EY; Kim, D; Koo, DL, 2013) |
| "We aimed to compare apparent steady-state oral clearance (CL/F) of the antiepileptic drug levetiracetam (LEV) in elderly (66-80 years, n=105) and very elderly (81-96 years, n=70) vs nonelderly (30-65 years, n=97) patients with epilepsy." | 7.78 | Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Mohamed, S; Riva, R, 2012) |
| "The objective of this retrospective study was to report our experience with the use of levetiracetam as an adjuvant therapy in a population of 42 children presenting a drug-resistant epilepsy." | 7.78 | [Experience with levetiracetam in the treatment of childhood refractory epilepsy]. ( Berquin, P; Bourel-Ponchel, E; de Broca, A; Delignières, A; Doumbia-Ouattara, M; Le Moing, AG; Querne, L, 2012) |
| "To establish a population pharmacokinetics (PPK) model of levetiracetam in Chinese children with epilepsy." | 7.78 | Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ( Lu, W; Shang, DW; Wang, L; Wang, YH; Wei, MJ; Wu, Y, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "To assess the efficacy and tolerability of levetiracetam (Lev) in children with epilepsy." | 7.77 | Efficacy and tolerability of levetiracetam in children with epilepsy. ( Chen, S; Li, J; Xiao, N, 2011) |
| "To monitor the effect of adding levetiracetam in paediatric patients with hemiplegic cerebral palsy and uncontrolled epilepsy." | 7.77 | Levetiracetam in children and adolescents with epilepsy and hemiplegic cerebral palsy. ( Harbord, MG, 2011) |
| "To describe the clinical outcomes of a compulsory switch from branded to generic levetiracetam (LEV) among people with epilepsy (PWE) in an outpatient setting." | 7.77 | Clinical experience with generic levetiracetam in people with epilepsy. ( Chaluvadi, S; Chiang, S; Friedman, DE; Goldsmith, CE; Tran, L, 2011) |
| "This study explored the effects of levetiracetam (LEV) on the expression of nerve cell adhesion molecule (NCAM) and growth-associated protein 43 (GAP-43) mRNA in the hippocampus of rats with epilepsy induced by lithium-pilocarpine (Li-PILO) in order to provide a basis for investigating the antiepileptic mechanism of LEV and its doseresponse." | 7.77 | [Effects of levetiracetam on the expression of NCAM and GAP-43 mRNA in the hippocampus of rats with epilepsy]. ( Jia, TM; Li, XL; Liu, T; Luan, B; Zhang, XL, 2011) |
| "To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort." | 7.77 | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. ( Aronica, E; de Groot, M; Heimans, JJ; Reijneveld, JC, 2011) |
| "The objective was to retrospectively study the efficacy and safety of levetiracetam (keppra) as an add-on treatment of pharmacoresistant forms of epilepsy in children." | 7.77 | [The retrospective study of efficacy and safety of levetiracetam as an add-on treatment of epilepsy in children]. ( Aĭvazian, SO; Shiriaev, IuS, 2011) |
| "We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months." | 7.76 | Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. ( Brázdil, M; Kocvarová, J; Kuba, R; Mastík, J; Novotná, I; Rektor, I; Tyrlíková, I, 2010) |
| "To investigate the efficacy and safety of levetiracetam adjunctive therapy in childhood intractable epilepsy, data were reviewed for 130 children who had >or=4 seizures per month, whose seizures were intractable to an initial >or=2 antiepileptic drugs, and who could be monitored for at least 6 months after levetiracetam add-on." | 7.76 | Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. ( Kang, HC; Kim, HD; Lee, JS; Lee, YJ, 2010) |
| "We review our experience with high-dose intravenous levetiracetam (IV-LEV) for acute seizure exacerbations in nine children with medically intractable epilepsy." | 7.76 | High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. ( Depositario-Cabacar, DT; Peters, JM; Pong, AW; Riviello, JJ; Rotenberg, A; Roth, J; Takeoka, M, 2010) |
| "To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma." | 7.76 | Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. ( Buttolo, L; Cenzato, M; Padovani, A; Rosati, A; Stefini, R; Todeschini, A, 2010) |
| "In 2006, intravenous levetiracetam received US Food and Drug Administration (FDA) approval for adjunctive treatment of partial onset seizures in adults with epilepsy, 16 years or older." | 7.76 | Intravenous levetiracetam in children with seizures: a prospective safety study. ( Cardenas, JF; Chapman, KE; Hastriter, EV; Khoury, EM; Ng, YT, 2010) |
| "To evaluate of the efficacy and safety of adjunctive levetiracetam (LEV) in children younger than 4 years with refractory epilepsy." | 7.76 | [Efficacy and safety of adjunctive levetiracetam in children younger than 4 years with refractory epilepsy]. ( Chen, L; Hu, Y; Huang, TS; Li, B; Liao, JX, 2010) |
| "The aim of this study was to evaluate efficacy and tolerability of levetiracetam (LEV) in patients with different epilepsy syndromes." | 7.76 | Levetiracetam in clinical practice: efficacy and tolerability in epilepsy. ( Bilo, L; de Leva, MF; Meo, R, 2010) |
| "The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG)." | 7.76 | Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. ( Gjerstad, L; Luef, G; Mørkrid, L; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2010) |
| "9 years) with epilepsy not responding to most conventional or new antiepileptic drugs were treated by adding levetiracetam to their present antiepileptic regimen and followed for a minimum period of 12 weeks." | 7.76 | Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial. ( Ghazavi, M; Ghofrani, M; Karimzadeh, P; Mahvelati, F; Tonekaboni, SH, 2010) |
| "5-year period was performed at the Columbia Comprehensive Epilepsy Center to identify children who were treated with levetiracetam doses titrated above the usual 40-60mg/kg/day." | 7.76 | Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. ( Obeid, M; Pong, AW, 2010) |
| "Levetiracetam (LEV), a newer antiepileptic drug (AED) useful for several epilepsy syndromes, binds to SV2A." | 7.75 | No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. ( Cavalleri, GL; Delanty, N; Depondt, C; Doherty, CP; Goldstein, DB; Kinirons, P; Lynch, JM; Murphy, K; O'Rourke, D; Sander, JW; Shianna, KV; Sisodiya, SM; Tate, SK; Weale, ME; Wood, NW, 2009) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 7.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 7.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in preventing clinical seizures in patients with subarachnoid hemorrhage (SAH)." | 7.75 | Utility of levetiracetam in patients with subarachnoid hemorrhage. ( Husain, AM; Shah, D, 2009) |
| "Levetiracetam is one of the newer anti-epileptic medications, which is now widely used in the treatment of childhood epilepsy." | 7.75 | Thrombocytopenia as an adverse effect of levetiracetam therapy in a child. ( Mohamed, BP; Peer Mohamed, B; Prabhakar, P, 2009) |
| "We present a simple, fast and validated method for the determination of the new generation antiepileptic drug (AED) levetiracetam (LEV) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 7.74 | Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Mohamed, S; Riva, R, 2008) |
| "To evaluate the efficacy and tolerability of levetiracetam (LEV) in the treatment of epilepsy as a monotherapy in children." | 7.74 | [Follow-up study on levetiracetam monotherapy in children with epilepsy]. ( Gao, ZJ; Jiang, YW, 2008) |
| " Three regulatory trials have demonstrated that add-on levetiracetam is efficacious in patients with localization-related epilepsy." | 7.74 | Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2007) |
| "The aim of this multicentric, retrospective, and uncontrolled study was to evaluate the efficacy and safety of levetiracetam (LEV) in 81 children younger than 4 years with refractory epilepsy." | 7.74 | Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. ( Balestri, P; Capovilla, G; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Morgese, G; Verrotti, A; Zamponi, N, 2007) |
| "To study pharmacokinetics of levetiracetam (LEV) during pregnancy, delivery, lactation, and in the neonatal period." | 7.74 | Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ( Ben-Menachem, E; Danielsson, B; Johansson, R; Källén, K; Luef, G; Ohman, I; Palm, R; Söderfeldt, B; Tomson, T, 2007) |
| "A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy." | 7.74 | [Clinical experience with levetiracetam for adults with epilepsy]. ( Barcs, G; Szucs, A, 2007) |
| "To assess the single-dose pharmacokinetics of levetiracetam and its major metabolite ucb L057 in infants and young children with epilepsy." | 7.74 | Pharmacokinetics of levetiracetam in infants and young children with epilepsy. ( Bebin, M; Chen, D; Coupez, R; Glauser, TA; Lu, ZS; Mitchell, WG; Stockis, A; Weinstock, A, 2007) |
| " Group 1 includes patients in whom levetiracetam was the only possible cause of weight loss and Group 2 those in whom other factors may have played a role." | 7.74 | Dramatic weight loss with levetiracetam. ( Coubes, P; Crespel, A; Diaz, O; Gelisse, P; Genton, P; Hillaire-Buys, D; Juntas-Morales, R, 2008) |
| "To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy." | 7.74 | Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. ( Brodtkorb, E; Helde, G; Nakken, KO; Reimers, A; Westin, AA, 2008) |
| "To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy." | 7.74 | Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ( Bailey, KS; Barone, G; Boothe, DM; Dewey, CW; Kortz, GD, 2008) |
| "Nonlinear mixed-effects modelling was used to analyse pooled data collected from 228 children with epilepsy aged 3 months to 18 years in five trials of adjunctive levetiracetam therapy." | 7.74 | Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. ( Jacqmin, P; Lacroix, B; Sargentini-Maier, ML; Stockis, A; Toublanc, N, 2008) |
| "This study provides the results of a cost-effectiveness analysis of levetiracetam as an adjunctive treatment for refractory epilepsy from the Canadian Ministry of Health perspective." | 7.73 | Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. ( Bernier, G; Blais, L; Godfroid, P; LeLorier, JJ; Sheehy, O; St-Hilaire, JM, 2005) |
| "The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies." | 7.73 | Hyponatremia from oxcarbazepine and carbamazepine. ( Dong, X; Leppik, IE; Rarick, J; White, J, 2005) |
| "To assess the anticonvulsant activity of the novel antiepileptic drug, levetiracetam (LEV) in a model of self-sustaining limbic status epilepticus, and to measure the consequence of LEV treatment on the pattern of mitochondrial dysfunction known to occur after status epilepticus (SE)." | 7.73 | Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. ( Cock, HR; Gibbs, JE; Walker, MC, 2006) |
| "To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study." | 7.73 | [Experience with levetiracetam in childhood epilepsy]. ( Fogarasi, A; Hegyi, M; Herczegfalvi, A; Kollár, K; Móser, J; Neuwirth, M; Paraicz, E; Rosdy, B; Saracz, J, 2006) |
| "The long-term efficacy and tolerability of levetiracetam (LEV) was analysed in 218 epilepsy patients." | 7.73 | Long-term levetiracetam treatment of epilepsy patients: clinical audit. ( Brázdil, M; Kocvarová, J; Kuba, R; Mastík, J; Novotná, I; Rektor, I; Tyrliková, I, 2006) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 7.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "Levetiracetam (LEV) was shown to be very efficacious and well tolerated as add-on therapy for refractory epilepsy." | 7.72 | Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. ( Dietl, T; Dinkelacker, V; Elger, CE; Lengler, U; Widman, G, 2003) |
| "To investigate the prevalence and psychopathological features of psychiatric adverse events (PAEs) in patients with learning disabilities (LD) in therapy with levetiracetam (LEV)." | 7.72 | Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. ( Mula, M; Sander, JW; Trimble, MR, 2004) |
| "The purpose was to evaluate the effects of levetiracetam (LEV) in routine therapy in learning disabled patients with therapy-resistant epilepsy." | 7.72 | Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. ( Bömmel, W; Hauser, I; Horstmann, V; Huber, B; Liem, S; May, T; Meinert, T; Robertson, E; Schulz, L; Seidel, M; Tomka-Hoffmeister, M; Wagner, W, 2004) |
| "To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults." | 7.72 | Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. ( Coppola, G; Fels, A; Habetswallner, F; Licciardi, F; Mangano, S; Nardello, R; Operto, FF; Pascotto, A; Pelliccia, A; Romano, A; Tortorella, G, 2004) |
| "The long-term continuation (retention) rate, efficacy, and safety data of the new antiepileptic drug levetiracetam (LEV) was evaluated in all patients with epilepsy exposed to the drug during its developmental program (n = 1,422)." | 7.71 | Long-term continuation of levetiracetam in patients with refractory epilepsy. ( Krakow, K; Otoul, C; Sander, JW; Walker, M, 2001) |
| "The protective and adverse effect potentials of levetiracetam ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide) in rodent models of seizures and epilepsy were compared with the profile of several currently prescribed and newly developed antiepileptic drugs." | 7.70 | Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. ( Gobert, J; Klitgaard, H; Matagne, A; Wülfert, E, 1998) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 6.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "Levetiracetam (LEV) is a new-generation anti epileptic drug (AED)." | 6.82 | [Efficacy and Safety of Levetiracetam as an Add-on Therapy for Symptomatic Refractory Epilepsy Treated in a Department of Neurosurgery]. ( Kawataki, T; Kinouchi, H; Ogiwara, M; Sato, H; Suzuki, K, 2016) |
| "01) and a shorter half-life (p=0." | 6.76 | Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. ( Alexandre, V; Feletti, F; Freitas-Lima, P; Pereira, LR; Perucca, E; Sakamoto, AC, 2011) |
| "Levetiracetam was generally well tolerated." | 6.74 | The underrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production. ( Brown, M; Legoff, D; Levin-Allen, S; Mintz, M; Mintz, P; Scornaienchi, J; Smith, C, 2009) |
| "Stroke is the most common cause of seizures in the elderly." | 6.73 | Levetiracetam monotherapy for late poststroke seizures in the elderly. ( Gomceli, YB; Inan, LE; Kutlu, G; Unal, Y, 2008) |
| "Levetiracetam treatment was safe and effective in this group of very young patients with various types of epilepsy." | 6.73 | Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. ( Krief, P; Maytal, J, 2008) |
| "Epilepsy is a common clinical problem in patients with brain tumours, strongly affecting patients' quality of life." | 6.72 | Levetiracetam therapy in patients with brain tumour and epilepsy. ( Albani, F; Baruzzi, A; Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Occhipinti, E; Pace, A; Pompili, A; Zarabla, A, 2006) |
| "Levetiracetam is a new anti-convulsant with impressive pivotal trial credentials." | 6.71 | Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. ( Barrett, M; Betts, T; Greenhill, L; Yarrow, H, 2003) |
| "Levetiracetam (LEV) is a novel antiepileptic drug (AED) with efficacy against a wide range of seizures types." | 6.71 | Levetiracetam for people with mental retardation and refractory epilepsy. ( Brodie, MJ; Kelly, K; Stephen, LJ, 2004) |
| "Levetiracetam is a broad-spectrum antiepileptic drug (AED) with a unique mechanism of action." | 6.55 | Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy. ( Ensom, MHH; Levine, M; Paquette, V; Tan, J, 2017) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 6.47 | Levetiracetam: a review of its use in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 6.47 | Spotlight on levetiracetam in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Levetiracetam is an antiepileptic drug that has been shown to be effective in various types of seizures, both partial and generalized." | 6.46 | Levetiracetam in childhood epilepsy. ( Chiarelli, F; Curatolo, P; D'Adamo, E; Parisi, P; Verrotti, A, 2010) |
| "Levetiracetam (Keppra) is an antiepileptic drug (AED) characterized by a novel mechanism of action, unique profile of activity in seizure models, and broad-spectrum clinical efficacy." | 6.45 | Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. ( Kaminski, RM; Klitgaard, H; Matagne, A; Patsalos, PN, 2009) |
| "Epilepsy is a neurological disorder consisting of recurrent seizures, resulting from excessive, uncontrolled electrical activity in the brain." | 6.43 | Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy. ( Boon, P; De Herdt, V; De Smedt, T; Dedeurwaerdere, S; Delbeke, J; Legros, B; Raedt, R; Van Hese, P; Van Laere, K; Vonck, K; Wadman, W; Waterschoot, L; Wyckhuys, T, 2006) |
| "Levetiracetam has specific characteristics that make it an optimal choice for many patient populations." | 6.42 | Role of levetiracetam in the treatment of epilepsy. ( Brodie, MJ; French, JA, 2003) |
| "Levetiracetam also has a favourable pharmacokinetic profile characterised by rapid and nearly complete absorption, very low potential for drug interactions and a prolonged pharmacodynamic effect that permits twice-daily dosing." | 6.42 | Levetiracetam: treatment in epilepsy. ( Ben-Menachem, E, 2003) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Epilepsy is one of the commonest neurological conditions." | 6.42 | Levetiracetam in the management of epilepsy. ( Leach, JP, 2004) |
| "Levetiracetam (LEV) is an anti-seizure drug (ASD)." | 5.72 | Relationship between bone density and levetiracetam monotherapy in epilepsy patients. ( Aydın, Z; Gözükızıl, ST; Yalçın, AD, 2022) |
| "Levetiracetam (LEV) has an improved pharmacological profile and is one of the most commonly used antiepileptic drugs (AEDs)." | 5.56 | Behavioral alterations associated with levetiracetam in pediatric epilepsy. ( Cortes, C; Manterola, C, 2020) |
| "This study was a randomized double-blind placebo-controlled clinical trial on 53 adult patients with epilepsy with behavioral side effects after treatment by levetiracetam." | 5.51 | Pyridoxine for treatment of levetiracetam-induced behavioral adverse events: A randomized double-blind placebo-controlled trial. ( Alizadeh-Navaei, R; Asghari, F; Cheraghmakani, H; Ghazaeian, M; Rezapour, M; Tabrizi, N, 2022) |
| "Levetiracetam is a broad-spectrum anti-epileptic drug that is effective against both focal and generalized epilepsies." | 5.48 | Levetiracetam monotherapy for the treatment of infants with epilepsy. ( Arican, P; Cavusoglu, D; Gencpinar, P; Olgac Dundar, N, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "To examine the prevalence and clinical correlates of fatigue as an adverse event (AE) of antiepileptic drug (AED) treatment in patients with epilepsy." | 5.46 | Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event? ( Agrawal, N; Cock, HR; Lozsadi, DA; Mula, M; von Oertzen, TJ; Yogarajah, M, 2017) |
| "Lacosamide (LCM) is a new antiepileptic drug (AED) used as adjunctive therapy in patients with partial seizures with or without secondary generalization, with a favorable pharmacokinetic profile that seems to be effective and well tolerated." | 5.46 | Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. ( Fabi, A; Giannarelli, D; Maialetti, A; Maschio, M; Vidiri, A; Villani, V; Zarabla, A, 2017) |
| " The aim of the study was to assess the risk of increased frequency of seizures or other adverse events after replacement of a brand-name LEV with a generic one." | 5.46 | Safety of switching from brand-name to generic levetiracetam in patients with epilepsy. ( Bosak, M; Słowik, A; Turaj, W, 2017) |
| "• Valproic acid has a cumulative effect on inhibiting brain activity in epileptogenic regions." | 5.46 | Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes. ( Dante, M; Hu, Z; Li, K; Li, Q; Li, Z; Lu, G; Wu, H; Xu, Q; Yang, F; Zhang, Q; Zhang, Z, 2017) |
| "Depression was evaluated in all experimental groups using the tail suspension and sucrose preference test on days 1, 5, 10 and 15, 2 h after pentylenetetrazole challenge." | 5.46 | Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression. ( Goel, RK; Kaur, T; Singh, T, 2017) |
| " Once patients respond to low-dose treatment, maintenance of the effective dosage may prolong response." | 5.43 | Clinical features of long-term low-dose levetiracetam treatment for epilepsy. ( Fukui, M; Nomura, S; Shimakawa, S; Tamai, H; Tanabe, T; Yoshikawa, S, 2016) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 5.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| "All LEV-induced cADRs were mild skin rashes which occurred within 28 days of LEV exposure." | 5.43 | Levetiracetam-induced cutaneous adverse drug reactions were not associated with HLA genes in a small sample of Chinese patients with epilepsy. ( An, DM; Chen, JN; Hu, FY; Ren, JC; Wang, W; Zhou, D, 2016) |
| "Epilepsy has an impact on the reproductive system." | 5.43 | Effects of levetiracetam monotherapy on sperm parameters and sex hormones: Data from newly diagnosed patients with epilepsy. ( Bayraktutan, OF; Ceylan, M; Karabulut, I; Sonkaya, AR; Yalcin, A, 2016) |
| "Hyponatremia is frequently seen in heart failure patients and has a high mortality rate." | 5.42 | The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia. ( Acaban, MB; Arı, H; Kahraman, F, 2015) |
| "Catamenial epilepsy is a periodic increase in seizure frequency in women with epilepsy during menstruation, or at any specific point in the menstrual cycle." | 5.42 | Intermittent levetiracetam treatment in five patients with catamenial epilepsy. ( Chen, K; Liang, Y; Liu, J; Sun, H; Xie, Y; Yu, N, 2015) |
| "Levetiracetam was started with a good response." | 5.40 | Levetiracetam following liver and kidney failure in late-onset anticonvulsant hypersensitivity syndrome. ( López-González, FJ; Novoa, D; Pardo, J; Pintos, E; Rodríguez-Osorio, X, 2014) |
| " Adverse events occurred in only two patients who did not require LEV discontinuation." | 5.39 | Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. ( Aihara, M; Kanemura, H; Sano, F; Sugita, K; Tando, T, 2013) |
| "Epilepsy is a chronic neurological disorder characterized by recurrent seizures, and is highly resistant to medication with up to 40% of patients continuing to experience seizures whilst taking oral antiepileptic drugs." | 5.38 | In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing levetiracetam, for the treatment of epilepsy. ( Campbell, TE; Cook, MJ; Halliday, AJ; McLean, KJ; Nelson, TS; Razal, JM; Wallace, GG, 2012) |
| "Levetiracetam (LEV) is a broad spectrum antiepileptic drug (AED) with a unique mechanism of action." | 5.37 | Levetiracetam monotherapy--outcomes from an epilepsy clinic. ( Brodie, MJ; Kelly, K; Parker, P; Stephen, LJ, 2011) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 5.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Lacosamide (Vimpat) is a newly licensed novel antiepileptic drug." | 5.36 | Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. ( Eggers, C; Hofer, T; Resch, R; Tilz, C, 2010) |
| "Levetiracetam therapy was effective in 58." | 5.36 | Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. ( Cai, F; Cao, J; Li, S; Xiao, N, 2010) |
| " LEV-SC significantly depended on daily dosage and the interval between the time the medication was taken and the time of blood extraction." | 5.36 | [Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy]. ( Bauer, J; Burr, W; Pfeiffer, C, 2010) |
| " Mean dosage was 1,643 mg/day (range 500-4,000)." | 5.35 | Intravenous levetiracetam for epileptic seizure emergencies in older people. ( Beyenburg, S; Maraite, N; Reuber, M, 2009) |
| "To develop a population pharmacokinetic model to evaluate the demographic and physiologic determinants of levetiracetam (LEV) pharmacokinetics (PK) and to suggest recommended doses of LEV in children." | 5.35 | Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. ( Chhun, S; Chiron, C; Dulac, O; Jullien, V; Pons, G; Rey, E, 2009) |
| "Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently obtained marketing authorisation for use in children." | 5.34 | Retention rate of levetiracetam in children with intractable epilepsy at 1 year. ( Buch, S; Crane, J; Donnelly, J; Gosalakkal, J; Mordekar, S; Mukhtyar, B; Peake, D; Philip, S; Rittey, C; Wheway, R; Whitehouse, WP, 2007) |
| "Levetiracetam (Lev) is a new antiepileptic drug with a distinct mechanism of action, shown in regulatory trials to be effective." | 5.33 | The long term retention of levetiracetam in a large cohort of patients with epilepsy. ( Bell, GS; Depondt, C; Duncan, JS; Koepp, MJ; Mitchell, T; Sander, JW; Yuen, AW, 2006) |
| "Levetiracetam was well tolerated and effective as add-on treatment in partial and generalised seizures." | 5.32 | [Levetiracetam in the treatment of epilepsy]. ( Brodtkorb, E; Johannessen, SI; Lossius, R; Mariero Klees, T; Nakken, KO, 2003) |
| "Levetiracetam (LEV) is a recently marketed novel anti-epileptic drug with a promising efficacy and safety profile." | 5.32 | Enterocolitis: an adverse event in refractory epilepsy patients treated with levetiracetam? ( Boon, P; Bosman, T; Claeys, P; De Clercq, M; De Reuck, J; Van Vlierberghe, H; Vonck, K, 2004) |
| "Levetiracetam has recently been approved as an adjunctive medication for partial seizures and frequently will be added to phenytoin." | 5.31 | Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. ( Baltes, E; Browne, TR; Jensen, CM; Josephs, E; Leppik, IE; Paz, J; Szabo, GK, 2000) |
| "Levetiracetam is a new anticonvulsant (AED) with a novel mechanism of action." | 5.31 | Levetiracetam psychosis in children with epilepsy. ( Bergey, GK; Freeman, JM; Kossoff, EH; Vining, EP, 2001) |
| " Before the experiments with chronic administration of levetiracetam at different doses, we determined the pharmacokinetics of the drug after i." | 5.30 | Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. ( Hönack, D; Löscher, W; Rundfeldt, C, 1998) |
| "In the GAERS model of petit mal epilepsy, levetiracetam markedly suppressed spontaneous spike-and-wave discharge (SWD) but left the underlying EEG trace normal." | 5.29 | Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. ( Boehrer, A; Gower, AJ; Hirsch, E; Marescaux, C; Noyer, M, 1995) |
| " We compare, in a routine clinical setting, brand versus generic levetiracetam (LEV) bioequivalence in patients with epilepsy and also the clinical efficacy and tolerability of the substitution." | 5.24 | Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. ( Chatzistefanidis, D; Gatzonis, S; Kyritsis, AP; Markoula, S; Patsalos, PN; Siarava, E; Siatouni, A; Verentzioti, A, 2017) |
| "To evaluate the efficacy of Levetiracetam in the management of neonatal seizures." | 5.22 | Efficacy of Levetiracetam in neonatal seizures: a systematic review. ( Hussain, AM; Sharma, D; Sharma, SS, 2022) |
| " Participants had "failed" initial monotherapy for partial epilepsy and were randomized to substitution monotherapy with levetiracetam or an older AED (carbamazepine or valproate sodium)." | 5.22 | Monotherapy with Levetiracetam Versus Older AEDs: A Randomized Comparative Trial of Effects on Bone Health. ( Christie, J; Gorelik, A; Hakami, T; Kantor, S; O'Brien, TJ; Petty, SJ; Sakellarides, M; Seibel, MJ; Todaro, M; Wark, JD; Yerra, R, 2016) |
| "This post-hoc subgroup analysis of data from an unblinded, randomized, 52-week superiority study (KOMET) compared the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients aged ≥ 60 years with newly diagnosed epilepsy." | 5.22 | Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. ( Marson, AG; Noack-Rink, M; Pohlmann-Eden, B; Ramirez, F; Tofighy, A; Trinka, E; Werhahn, KJ; Wild, I, 2016) |
| "We sought to determine the effect of changing phenytoin therapy on bone mineral density (BMD) and 25-hydroxyvitamin D in patients with epilepsy." | 5.17 | Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy. ( Geater, A; Leelawattana, R; Limapichat, K; Phabphal, K; Sathirapanya, P; Setthawatcharawanich, S, 2013) |
| "To show non-inferiority of levetiracetam to sulthiame with respect to efficacy, tolerability and safety in benign epilepsy with centrotemporal spikes in a prospective, double-blinded randomized controlled trial." | 5.17 | Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). ( Bast, T; Bonfert, M; Borggraefe, I; Heinen, F; Maßmann, K; May, TW; Neubauer, BA; Noachtar, S; Schotten, KJ; Tuxhorn, I, 2013) |
| "To estimate the effect of levetiracetam (LEV) on cognitive function and mood status in newly diagnosed epilepsy patients." | 5.17 | Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients. ( Hong, SB; Hwang, KJ; Joo, EY; Kim, D; Kim, JY; Kim, MR; Kim, YJ; Koo, DL; Lee, JM; Shin, W, 2013) |
| "The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG)." | 5.17 | Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine. ( Frøland, SS; Luef, G; Mochol, M; Mushtaq, U; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2013) |
| "Of the newer antiepileptic drugs, lamotrigine (LTG) and levetiracetam (LEV) are popular first choice drugs for epilepsy." | 5.16 | The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. ( Arnold, S; Bauer, S; Beige, A; Berrouschot, J; Burchardi, N; Eisensehr, I; Evers, S; Haag, A; Hallmeyer-Elgner, S; Hamer, HM; Klein, KM; Kovac, S; Lerche, H; Niedhammer, M; Oertel, WH; Reif, PS; Rosenow, F; Roth, E; Schade-Brittinger, C; Schröder, M; Springub, J; Strzelczyk, A; Weber, Y; Winkler, G, 2012) |
| "Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury." | 5.16 | Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinsky, S; Tsuchida, T; van den Anker, J, 2012) |
| "To evaluate the safety and tolerability of treatment with levetiracetam and determine the trough levels of levetiracetam in patients with traumatic brain injury (TBI) who are at high risk for posttraumatic epilepsy (PTE)." | 5.16 | Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinski, S; Tsuchida, T; van den Anker, J, 2012) |
| "We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE)." | 5.15 | Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. ( Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2011) |
| "Stroke patients with a cortical syndrome and a modified Rankin score ≥ 3 or NIHSS ≥ 6 were treated with either levetiracetam 1500 mg daily divided in two doses or placebo during 12 weeks following stroke." | 5.15 | Early treatment after stroke for the prevention of late epileptic seizures: a report on the problems performing a randomised placebo-controlled double-blind trial aimed at anti-epileptogenesis. ( Aldenkamp, AP; de Krom, MC; Lodder, J; van Raak, EP; van Tuijl, JH, 2011) |
| " This study was done to evaluate the effect of levetiracetam (LEV) on subjective sleep quality and sleep architecture in patients with epilepsy, and the results were compared with the effects of carbamazepine-CR (CBZ-CR)." | 5.15 | The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy. ( Cho, YW; Kim, DH; Motamedi, GK, 2011) |
| "To investigate the efficacy and safety of levetiracetam in adults with intellectual disabilities who have uncontrolled partial or generalised epilepsy." | 5.14 | A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities. ( Beavis, J; Felce, D; Kerr, M; Meek, A, 2009) |
| "All patients treated with lamotrigine, levetiracetam or topiramate in the Epilepsy Centre were identified." | 5.14 | The impact of side effects on long-term retention in three new antiepileptic drugs. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Hekster, YA; Hulsman, J; Lambrechts, D; Majoie, M; Ricker, L; Schellekens, A, 2009) |
| " The safety of intravenous levetiracetam has been established in prospective studies of adult epilepsy and healthy participants." | 5.14 | Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study. ( Clarke, D; Durmeier, M; Ellis, M; Hovinga, CA; McGregor, A; Perkins, F; Wheless, JW, 2009) |
| "Levetiracetam given twice a day in children with refractory epilepsy reduces seizure frequency in all types of epilepsy." | 5.14 | Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. ( Carmant, L; Giroux, PC; Salas-Prato, M; Théorêt, Y, 2009) |
| " The present study investigated reproductive and sexual function in patients with epilepsy (aged 18-45) treated with levetiracetam (LEV: 30 men/26 women), carbamazepine (CBZ: 63 men/30 women), or lamotrigine (LTG: 37 men/40 women) monotherapy and in healthy controls (36 men/44 women)." | 5.14 | Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. ( Bertelsen, M; Gjerstad, L; Lossius, A; Luef, G; Mørkrid, L; Rauchenzauner, M; Sandvand, F; Svalheim, S; Taubøll, E, 2009) |
| "Behavioral side effects related to the use of levetiracetam (LEV) in epilepsy are increasingly being recognized." | 5.13 | Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results. ( Greenberg, E; Khan, A; Major, P; Thiele, EA, 2008) |
| "This aim of the study was to ascertain the importance of clinical parameters on the response to treatment in refractory epilepsy patients on levetiracetam (LEV)." | 5.13 | Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study. ( Auvinen, A; Fallah, M; Keränen, T; Kharazmi, E; Liimatainen, S; Peltola, J; Peltola, M, 2008) |
| "To prospectively assess the safety and efficacy of levetiracetam in patients with uncontrolled focal epilepsy, in a common practice-based setting." | 5.12 | Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. ( Despland, PA; Fejerman, N; Genton, P; Maubrey, MC; Peltola, J; Rektor, I; Sadzot, B; Schlit, AF; Steinhoff, B; van Hammée, G; van Paesschen, W; Vandervelden, C; Wroe, S, 2006) |
| "The aim of this study was to assess the relationship between levetiracetam dose and both efficacy and safety in adult patients with refractory partial epilepsy." | 5.12 | Assessment of a dose-response relationship of levetiracetam. ( Buyle, S; Meencke, HJ, 2006) |
| "We report the results of a prospective study of the efficacy and tolerability of levetiracetam, a new antiepileptic drug with a unique mechanism of action, in comparison with controlled-release carbamazepine as first treatment in newly diagnosed epilepsy." | 5.12 | Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. ( Ben-Menachem, E; Brodie, MJ; Meencke, HJ; Perucca, E; Ryvlin, P, 2007) |
| "To assess the efficacy and tolerability of Levetiracetam (LEV) in children and adolescents with refractory epilepsy with a special interest in the long-term retention rate." | 5.12 | Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy. ( Holthausen, H; Kluger, G; von Stuelpnagel, C, 2007) |
| "Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy." | 5.12 | [Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers]. ( Auriel, E; Blatt, I; Chistik, V; Margolin, N; Neufeld, M, 2007) |
| "To determine whether levetiracetam (LEV) affects plasma concentrations of carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy." | 5.12 | Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. ( De Smedt, H; Otoul, C; Stockis, A, 2007) |
| "The authors assessed the effect of concomitant antiepileptic therapy on steady-state plasma concentrations of the new anti-epileptic drug (AED) levetiracetam in a cohort of 100 adult patients with epilepsy." | 5.11 | Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. ( Albani, F; Baruzzi, A; Contin, M; Riva, R, 2004) |
| "In this postlicensing surveillance study in a large unselected population, data were collected prospectively on all patients prescribed levetiracetam (LEV) at a regional epilepsy clinic over a 2-year period." | 5.11 | A prospective analysis of the outcome of levetiracetam in clinical practice. ( Lewis, SA; Nicolson, A; Smith, DF, 2004) |
| " We tested this hypothesis by reviewing the multiple mechanisms of action of topiramate (TPM) and levetiracetam (LEV) together with clinical behavioral side effects of patients who had been treated with TPM and LEV in a tertiary referral center for epilepsy." | 5.11 | Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. ( Aldenkamp, AP; Bootsma, HP; Kessels, AG; Leenen, LA; Leonard, BE; Majoie, HJ; Roberts, GM, 2005) |
| "The aim of this multicentric, prospective and uncontrolled study was to evaluate the efficacy and safety of levetiracetam in 110 children with refractory epilepsy, of whom 21 were less than 4 years old." | 5.11 | Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. ( Acampora, B; Balestri, P; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Iannetti, P; Marchiani, V; Morgese, G; Pascotto, A; Spalice, A; Verrotti, A, 2005) |
| "To further evaluate the safety, efficacy and optimal dose of levetiracetam (LEV) in daily clinical practice among patients with uncontrolled partial epilepsy with or without secondary generalization." | 5.11 | Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. ( Steinhoff, BJ; Trinka, E; Wieser, HG, 2005) |
| "To evaluate the efficacy and tolerability of Levetiracetam (LEV) in a large pediatric cohort with drug-resistant epilepsy from a prospective multicenter observational study." | 5.11 | Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. ( Bettendorf, U; Brandl, U; Gross-Selbeck, G; Härtel, C; Kluger, G; Korn-Merker, E; Kurlemann, G; May, T; Opp, J; Rating, D; Tuxhorn, I; Wiemer-Kruel, A, 2005) |
| "This retrospective study suggests that levetiracetam has a positive effect on the EEG, the behavior, and the cognition of patients with epilepsy and CSWS." | 5.11 | Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases. ( Aeby, A; Poznanski, N; Van Bogaert, P; Verheulpen, D; Wetzburger, C, 2005) |
| "Levetiracetam, one of the newer-generation antiepilepsy drugs, is not currently approved for use in children." | 5.10 | Levetiracetam in refractory pediatric epilepsy. ( Ng, YT; Wheless, JW, 2002) |
| "The aim of this prospective, uncontrolled clinical study was to evaluate the tolerability and the efficacy of levetiracetam as add-on treatment in 78 adults and 44 children with intractable epilepsy." | 5.10 | A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. ( Eriksson, AS; Johannessen, SI; Lossius, R; Nakken, KO, 2003) |
| "To evaluate the long-term clinical usefulness of levetiracetam (LEV, Keppra((R))(1)) as add-on therapy in patients with refractory epilepsy." | 5.10 | Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. ( Ben-Menachem, E; Edrich, P; Sander, JW; Schmidt, B; Van Vleymen, B, 2003) |
| "Levetiracetam appears to be well tolerated in patients with severe epilepsy and shows efficacy in a long-term follow-up." | 5.10 | Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. ( Ben-Menachem, E; Gilland, E, 2003) |
| "The novel antiepileptic drug (AED) levetiracetam (LEV, Keppra) is indicated as adjunctive therapy for partial epilepsy." | 5.10 | An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. ( Abou-Khalil, B; Hemdal, P; Privitera, MD, 2003) |
| "The aim of this study was to determine the tolerability and efficacy of two oral regimens of levetiracetam, 1000 mg and 2000 mg twice daily, as add-on treatment without titration in patients with refractory epilepsy." | 5.09 | A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. ( Betts, T; Crawford, P; Waegemans, T, 2000) |
| "The aim of this study was to determine the efficacy and tolerability of 1000-4000 mg/day of levetiracetam (LEV, Keppra) as add-on treatment for refractory epilepsy." | 5.09 | Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. ( Grant, R; Shorvon, SD, 2000) |
| " A new pyrrolidine derivative (levetiracetam), resembling piracetam, was given as antiepileptic concomitant drug to patients with chronic epilepsy." | 5.08 | Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. ( Aldenkamp, AP; Alpherts, WC; Neyens, LG, 1995) |
| " The point estimates of carbamazepine and lamotrigine efficacy showed their superiority with respect to all comparator antiepileptic drugs for the treatment of newly diagnosed focal epilepsy." | 4.98 | Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. ( Crescioli, G; De Masi, S; Guerrini, R; Ilvento, L; Lucenteforte, E; McGreevy, KS; Mugelli, A; Pugi, A; Rosati, A; Virgili, G, 2018) |
| "ACTH and levetiracetam had good therapeutic effects in epilepsy control in this case of de novo STXBP1 mutation." | 4.98 | Therapeutic benefits of ACTH and levetiracetam in STXBP1 encephalopathy with a de novo mutation: A case report and literature review. ( Cai, XT; Liu, S; Wang, L; Wang, Z; Yu, D; Zhou, H, 2018) |
| "The retrospective study of 231 consecutive pediatric patients to confirm that levetiracetam is effective as initial monotherapy for different types of seizures and/or epilepsy syndromes." | 4.93 | The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population. ( Çavuşoğlu, D; Dündar, NO; Gencpinar, P; Tekgül, H, 2016) |
| " The formal evidence for levetiracetam monotherapy in children is minimal: it is potentially efficacious or effective as initial monotherapy in children with benign epilepsy with centrotemporal spikes." | 4.91 | Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review. ( Brouwer, OF; Callenbach, PM; Weijenberg, A, 2015) |
| " Antiepileptic drugs (AED) such as phenytoin are often used in clinical practice with the hopes of preventing post-traumatic epilepsy." | 4.91 | Pharmacological treatments for preventing epilepsy following traumatic head injury. ( Abel, H; Campbell, LA; Pohlmann-Eden, B; Thompson, K, 2015) |
| "The adverse effects profile of levetiracetam in epilepsy is still being fully described." | 4.90 | The adverse effects profile of levetiracetam in epilepsy: a more detailed look. ( Dixon, P; Hutton, JL; Marson, AG; Mbizvo, GK, 2014) |
| " Studies were eligible for inclusion when they included children from one month to 18 years of age with a diagnosis of epilepsy, used levetiracetam, had other AEDs on a stable regimen for at least two months, reported about behavioral side-effects and had a follow-up of at least two weeks." | 4.90 | Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. ( Aldenkamp, AP; de Louw, AJ; Halma, E; IJff, DM; Klinkenberg, S; Majoie, M, 2014) |
| " The use of AEDs as a possible neuroprotective strategy in brain ischemia is receiving increasing attention and the antiepileptic drug levetiracetam, a 2S-(2-oxo-1-pyrrolidiny1) butanamide, belonging to the pyrrolidone family, could have a crucial role in regulation of epileptogenesis and neuroprotection." | 4.87 | Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy. ( Belcastro, V; Pierguidi, L; Tambasco, N, 2011) |
| "Levetiracetam is an effective adjunctive agent for refractory epilepsy." | 4.87 | Meta-analysis of randomized trials on first line and adjunctive levetiracetam. ( Akl, EA; Jichici, D; Kyu, HH; Lo, BW; Meade, MO; Upton, AM, 2011) |
| "Levetiracetam has been widely used for childhood epilepsy, but there is no high quality evidence to support its use." | 4.86 | [Levetiracetam therapy for childhood epilepsy: a systematic review]. ( Dai, J; Han, L; Wang, L; Zhang, LL, 2010) |
| " It is unclear whether or not monotherapy with the new AEDs offers higher efficacy and/or lower side effects compared to classic AEDs (phenobarbital, phenytoin, carbamazepine, or valproate) thereby significantly improving the quality of life in children with epilepsy." | 4.85 | [Role of monotherapy with new antiepileptic drugs in the treatment of childhood epilepsy]. ( Legido, A; Valencia, I, 2009) |
| "To review data evaluating levetiracetam management of epilepsy during pregnancy." | 4.85 | Levetiracetam use in pregnancy. ( Forinash, AB; Longo, B; Murphy, JA, 2009) |
| "A systematic review of FORCTs and randomised controlled trials (RCT) of topiramate, levetiracetam and gabapentin as adjuvant therapy in refractory adult epilepsy was conducted." | 4.84 | Reporting and analysis of open-label extension studies of anti-epileptic drugs. ( Hemming, K; Hutton, JL; Maguire, MJ; Marson, AG, 2008) |
| "Data were pooled from ten matched clinical trials conducted in Japan and in Europe and the USA, in which levetiracetam was administered orally to healthy subjects and subjects with epilepsy." | 4.84 | Population pharmacokinetics of levetiracetam in Japanese and Western adults. ( Jacqmin, P; Pigeolet, E; Sargentini-Maier, ML; Stockis, A, 2007) |
| "On pharmacological treatment of epilepsy in people with intellectual disabilities, there were two articles on topiramate and one on levetiracetam." | 4.83 | Update on treatment of epilepsy in people with intellectual disabilities. ( Huber, B; Seidel, M, 2006) |
| "This report reviews behavioral adverse events occurring among adults receiving levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in epilepsy (1023), cognitive disorders (719), or anxiety disorders (1510) and epilepsy patients (1393) observed in long-term trials." | 4.82 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. ( Cramer, JA; De Rue, K; Devinsky, O; Edrich, P; Trimble, MR, 2003) |
| "Levetiracetam is a novel antiepileptic drug (AED) with proven efficacy against partial seizures, but there is limited information about its effectiveness against generalized seizures." | 4.82 | Levetiracetam: preliminary efficacy in generalized seizures. ( Hirsch, E; Kasteleijn-Nolst Trenité, DG, 2003) |
| " Levetiracetam is one of the new generation of AEDs licensed as an add-on therapy for the treatment of patients with partial-onset seizures." | 4.82 | Safety profile of levetiracetam. ( Arroyo, S; Crawford, P, 2003) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "To review the pharmacology, pharmacokinetics, efficacy, and adverse effects of levetiracetam in the treatment of epilepsy." | 4.81 | Levetiracetam: a different approach to the pharmacotherapy of epilepsy. ( Ficker, DM; Gidal, BE; Privitera, MD; Welty, TE, 2002) |
| "A brief review of epilepsy as a disease, anti-epileptic drugs (AEDs) and methods of evaluation of AEDs are presented as a background for the assessment of levetiracetam which has been approved by the FDA as add-on therapy for the treatment of partial seizures with or without secondary generalisation in adults." | 4.80 | An assessment of levetiracetam as an anti-epileptic drug. ( Jain, KK, 2000) |
| " Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs)." | 4.31 | Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. ( Edens, M; Schelhaas, M; Ter Horst, P; Touw, D; Wammes-Van Der Heijden, E; Wegner, I, 2023) |
| " Levetiracetam (LEV), clinically used to treat epilepsy, may have pro-cognitive effects by restoring balance to neuronal signalling." | 4.31 | Contingency learning in zebrafish exposed to apomorphine- and levetiracetam. ( Botha, TL; Brouwer, G; Finger-Baier, K; van der Westhuizen, C; Wolmarans, W, 2023) |
| "Valproic acid (VPA) and levetiracetam (LEV) are used in epilepsy treatment." | 4.12 | Successful Treatment of Symptomatic Epilepsy with Oral Valproic Acid and Levetiracetam in a Patient with Short-bowel Syndrome. ( Hayashi, M; Iijima, A; Isozaki, R; Kurishima, A; Shimozato, R; Shioda, T, 2022) |
| "The purpose of our study was the evaluation of the effect of 2,000 mg levetiracetam monotherapy over a 3-month period on nocturnal sleep in patients with epilepsy." | 4.12 | Effect of levetiracetam on nocturnal sleep in patients with epilepsy. ( Chaneva, OG; Viteva, EI, 2022) |
| "Levetiracetam (LEV) is an anti-seizure medication (ASM) known to have significant behavioral side effects in children with epilepsy." | 4.12 | Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study. ( Bartolini, L; Bassell-Hawkins, J; Lob, K; Nie, D; Patil, R, 2022) |
| "Levetiracetam (LEV) suppresses the upregulation of proinflammatory molecules that occurs during epileptogenesis after status epilepticus (SE)." | 4.12 | Regulation of Inflammation-Related Genes through ( Hashimoto, R; Ishihara, Y; Itoh, K; Komori, R; Kono, T; Kozawa, C; Kubo, S; Matsuo, T; Yokota-Nakatsuma, A, 2022) |
| " Consecutive adolescent patients with epilepsy aged 11-17 years with partial or generalized seizures, treated with either levetiracetam or valproic acid for at least 6 months, and healthy controls were recruited." | 4.12 | Irritability and its relationship with psychosocial symptoms and quality of life in adolescents with epilepsy receiving levetiracetam therapy: A case-control study. ( Tekin, E; Tekin, U; Uçar, HN, 2022) |
| "To describe levetiracetam pharmacokinetic variability in patients with epilepsy in real clinical practice." | 4.12 | Extensive pharmacokinetic variability of Levetiracetam. ¿Are doctors aware? ( de la Fuente, E; de Toledo, M; de Toledo, MP; Ferreiros-Martinez, R; Lagares, A; Muro, I; Ovejero-Benito, MC; Ramos, C; Sobrado, M; Vieira Campos, A, 2022) |
| "Children aged 1 to 12 years, diagnosed with epilepsy (generalized or focal seizures), treated with valproate (n = 40) and valproate with add-on levetiracetam (n = 40) were included." | 4.02 | Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy. ( Gupta, R; Halder, S; Kar, R; Labh, R; Narang, M, 2021) |
| "Levetiracetam (LEV) is a second-generation antiepileptic drug with high efficacy and tolerability in children and adults with epilepsy." | 4.02 | Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center. ( Akıncı Göktaş, Ö; Bektaş, Ö; Şahin, S; Tıraş Teber, S; Yıldırım, M; Yüksel, MF, 2021) |
| "The present study evaluated whether patients with epilepsy who received both levetiracetam (LEV) and perampanel (PER) therapy showed side effects of irritability." | 4.02 | Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy. ( Hasegawa, N; Tohyama, J, 2021) |
| "This retrospective study compared the efficacy and safety of levetiracetam monotherapy and in combination with other antiseizure medications (ASMs) in 1055 pediatric patients with epilepsy treated with levetiracetam." | 4.02 | Long-term safety, efficacy, and tolerability of levetiracetam in pediatric patients with epilepsy in Uygur, China: A retrospective analysis. ( Feng, J; Li, HJ; Ma, L; Sun, L; Sun, Y; Wang, TT; Yu, J; Yu, LH; Zhao, T, 2021) |
| "The objective was to develop and externally validate a population pharmacokinetic model of levetiracetam in adult and elderly patients with epilepsy, and to perform dosing simulations to propose individualized dosing regimens more likely to achieve therapeutic concentrations." | 3.96 | Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. ( Hernández-Mitre, MP; Jung-Cook, HH; Medellín-Garibay, SE; Milán-Segovia, RDC; Roberts, JA; Rodríguez-Leyva, I; Rodríguez-Pinal, CJ; Romano-Moreno, S; Zarazúa, S, 2020) |
| "The purpose of this study was to determine the efficacy of perampanel (PER) on secondary bilateral synchrony (SBS) and behavioral problems in adolescents with epilepsy who showed insufficient response to levetiracetam (LEV)." | 3.96 | Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam. ( Aihara, M; Hoshino, H; Kanemura, H; Sano, F; Takayama, K, 2020) |
| "We enrolled patients with epilepsy who were treated with branded levetiracetam for at least 6 months of sustained use." | 3.88 | Brand name to generic substitution of levetiracetam in patients with epilepsy. ( Dae, SJ; Gha-Hyun, L, 2018) |
| "The purpose of this study was to determine the effect of lamotrigine (LTG) and levetiracetam (LEV) as mono- and polytherapy on biochemical markers of bone turnover and bone mineral density in Egyptian adult patients with epilepsy." | 3.88 | Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients. ( Akef, GH; Allah, HMS; El-Haggar, SM; Mostafa, TM, 2018) |
| "Levetiracetam (LEV) is an antiepileptic drug commonly used in the treatment of epilepsy because of its excellent safety profile in all age groups." | 3.85 | Reproductive toxicity after levetiracetam administration in male rats: Evidence for role of hormonal status and oxidative stress. ( Atli, O; Baysal, M; Ilgin, S; Kilic, G; Kilic, V; Ucarcan, S, 2017) |
| "Levetiracetam is used in the treatment of some forms of epilepsy." | 3.85 | Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. ( Company-Albir, MJ; Marqués-Miñana, MR; Poveda, JL; Ruíz-Ramos, J; Solana Altabella, A; Vicent, C, 2017) |
| "Levetiracetam, a widely used antiepileptic drug in children, has been associated with psychosocial and behavioral problems, which are also influenced by epilepsy variables, including duration or seizure frequency." | 3.85 | The influence of levetiracetam on psychosocial and behavioral functioning in children: A case-control and follow-up study. ( Aydınlı, N; Bektaş, G; Çalışkan, M; Özkan, MU; Özmen, M; Tekin, U; Yıldız, EP, 2017) |
| " Since tolerability and seizure control usually correlate with AED serum concentrations, we examined the fluctuation of levetiracetam (LEV) serum concentrations in patients with epilepsy before and after generic substitution." | 3.85 | Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting. ( Hoff, E; Källén, K; Lundgren, A; Nilsson, J; Olsson, P; Reimers, A; Reis, M; Strandberg, M, 2017) |
| "Recent adverse event reports have raised the question of increased angioedema risk associated with exposure to levetiracetam." | 3.85 | Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network. ( Banda, JM; Duke, JD; Hripcsak, G; Jin, P; Khoma, Y; Reich, C; Ryan, PB; Schuemie, MJ; Schwalm, MS; Shah, NH; Suchard, MA; Wu, Y; Xu, H, 2017) |
| "To evaluate the efficacy and tolerability of levetiracetam monotherapy in dogs with structural epilepsy." | 3.85 | Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015). ( Kelly, D; Raimondi, F; Shihab, N, 2017) |
| " The dog was receiving levetiracetam and phenobarbital for epilepsy, and serum concentrations of both were within standard therapeutic ranges." | 3.85 | Suspected Phenobarbital-Induced Pseudolymphoma in a Dog. ( Lampe, R; Manens, J; Sharp, N, 2017) |
| "Levetiracetam is a new generation antiepileptic drug used in treatment of patients with epilepsy and has adverse effects on different tissues." | 3.85 | Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period. ( Ayas, B; Elbistan, M; Guvenc, T; Kara, N; Tekcan, A; Tural, S, 2017) |
| "Levetiracetam has a high tolerability and is effective against various seizure types and epilepsy syndromes." | 3.85 | Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy. ( Arakawa, H; Hazama, K; Ida, K; Makioka, N; Motojima, T; Muramatsu, K; Ogata, T; Sawaura, N; Tomita, K, 2017) |
| "Levetiracetam (LEV) is commonly used as a mono- or adjunctive therapy for treating patients with partial and generalized epilepsy." | 3.85 | Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. ( Chu, K; Jang, IJ; Jung, KH; Jung, KY; Kim, TJ; Lee, S; Lee, SK; Lee, ST; Moon, J; Park, KI; Rhee, SJ; Shin, JW; Yu, KS, 2017) |
| "Objective: As a treatment for cases of developmental disorder accompanied with epilepsy, the author examined the efficacy and tolerability of combined administration of levetiracetam (LEV) on the cases." | 3.83 | Experience with levetiracetam to epilepsy cases in neurodevelopmental disorders. ( Takagi, K, 2016) |
| "We report a 1-month-old boy manifesting an epileptic encephalopathy with clonic seizures refractory to phenobarbital, pyridoxine and phenytoin that presented a dramatic response to levetiracetam with full epilepsy control and EEG normalization." | 3.83 | Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation. ( Barbieri, S; Cristofori, G; Dilena, R; Romeo, A; Striano, P; Tadini, L; Traverso, M; Viri, M; Zara, F, 2016) |
| " The objective of this study was to evaluate the safety and tolerability of the brand-to-generic levetiracetam switch in patients with focal or generalized epilepsy." | 3.83 | Safety of Overnight Switch from Brand-Name to Generic Levetiracetam. ( del Gaudio, L; Francavilla, T; Giudizioso, G; La Neve, A; Mencaroni, E; Minetti, C; Piccioli, M; Pinto, F; Striano, P; Striano, S; Tovo, P; Vari, MS; Verrotti, A, 2016) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "To prospectively evaluate the safety of levetiracetam oral solution and its impact on epilepsy severity in infants with different seizure types." | 3.83 | Safety of levetiracetam among infants younger than 12 months--Results from a European multicenter observational study. ( Arzimanoglou, A; Bentz, J; Garate, P; Lösch, C, 2016) |
| " We aimed to assess intrasubject variation in plasma concentrations of lamotrigine (LTG), levetiracetam (LEV) and topiramate (TPM) after generic substitution compared with a stable brand-name drug regimen in a population of patients with epilepsy." | 3.83 | Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. ( Alberghini, L; Benini, G; Candela, C; Contin, M; Riva, R, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 3.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)." | 3.83 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016) |
| "To investigate the clinical efficacy and safety of Levetiracetam (LEV) add-on therapy for child refractory epilepsy." | 3.83 | The clinical efficacy and safety of levetiracetam add-on therapy for child refractory epilepsy. ( Chen, J; Chen, SZ; Liu, XM; Yue, X, 2016) |
| " Children exposed to monotherapy levetiracetam (n = 42), topiramate (n = 27), or valproate (n = 47) and a group of children born to women who had untreated epilepsy (n = 55) were enrolled retrospectively from the UK Epilepsy and Pregnancy Register." | 3.83 | Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate. ( Baker, GA; Bromley, RL; Calderbank, R; Cheyne, CP; Clayton-Smith, J; García-Fiñana, M; Irwin, B; Morrow, JI; Rooney, C; Shallcross, R; Trayner, P, 2016) |
| " Few case reports have been published regarding pancytopenia associated with levetiracetam treatment, and its intrinsic pathogenesis is still unknown." | 3.83 | Pancytopenia associated with levetiracetam in an epileptic woman. ( García Carretero, R; Olid-Velilla, M; Romero Brugera, M; Salamanca-Ramirez, I, 2016) |
| "A novel antiepileptic drug, levetiracetam, has been reported to cause several psychiatric adverse effects in spite of its effectiveness on epilepsy." | 3.81 | Obsessive-compulsive behavior induced by levetiracetam. ( Fujikawa, M; Iwasaki, M; Jin, K; Kakisaka, Y; Kato, K; Kishimoto, Y; Nakasato, N, 2015) |
| "Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China." | 3.81 | Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep. ( Cai, F; Chen, J; Feng, C; Hu, Y; Jiang, L, 2015) |
| "To assess the effect and tolerability of zonisamide (ZNS) as adjunctive treatment for difficult-to-treat epilepsy in adult Scandinavian patients." | 3.81 | Retention rate of zonisamide in intractable epilepsy. ( Andersen, H; Lindstrøm, P; Nakken, KO, 2015) |
| "The purpose of this study was to identify clinical correlates of self-reported aggressiveness (SRA) in patients with epilepsy treated with levetiracetam (LEV) with special reference to the role of depression." | 3.81 | Self-reported aggressiveness during treatment with levetiracetam correlates with depression. ( Agrawal, N; Cock, HR; Lozsadi, DA; Mohanalingham, K; Mula, M; Mustafa, Z; von Oertzen, TJ, 2015) |
| " There are multiple retrospective studies reporting good efficacy and tolerability of the anti-epileptic drug levetiracetam (LEV) in human patients with epilepsy; however, reports of LEV's tolerability and efficacy in dogs with epilepsy remain limited." | 3.81 | Assessment into the usage of levetiracetam in a canine epilepsy clinic. ( Nye, G; Packer, RM; Porter, SE; Volk, HA, 2015) |
| "TO determine neuroprotective properties of levetiracetam and simvastatin using rats with pilocaroine-induced epilepsy." | 3.81 | [Protective effects of levetiracetam and simvastatin on pilocarpine-induced epilepsy in rat models]. ( Chen, T; Li, MQ; Liu, L; Zhang, WW, 2015) |
| "Synaptic vesicle protein 2A (SV2a) is the binding site of the antiepileptic drug levetiracetam and the only known synaptic vesicle target of an epilepsy medication." | 3.81 | Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. ( Huq, AM; Serajee, FJ, 2015) |
| "To evaluate the long-term effects and tolerability of levetiracetam (LEV) in refractory epilepsy." | 3.81 | [Effectiveness and safety of long-term levetiracetam treatment in patients with refractory epilepsy]. ( Baba, H; Fuji, A; Matsuo, M; Matsuzaka, T; Moriuchi, H; Ono, T; Sato, T; Tanaka, S; Toda, K, 2015) |
| "To clarify the efficacy and safety of levetiracetam (LEV) in children with localization-related epilepsy, we performed a retrospective study in our hospital." | 3.81 | [Efficacy of Levetiracetam as an Add-on Therapy in Children with Localization-related Epilepsy]. ( Enoki, H; Okanishi, T; Yokota, T, 2015) |
| "In a univariate analysis, seizure frequency during the year before suicide, use of antiepileptic drug polytherapy, lack of aura before seizure, diagnosis of temporal lobe epilepsy, use of levetiracetam, psychiatric comorbidity, and use of antidepressants were all significantly higher in the suicide group than in the nonsuicide group." | 3.81 | Identifying clinical correlates for suicide among epilepsy patients in South Korea: A case-control study. ( Ahn, MH; Choi, EJ; Hong, JP; Kang, JK; Lee, HB; Lee, HJ; Park, S; Park, SJ; Ryu, HU, 2015) |
| "We report on a 9-year-old girl with idiopathic epilepsy who showed forced normalization after administration of levetiracetam (LEV)." | 3.81 | A Girl with Idiopathic Epilepsy Showing Forced Normalization after Levetiracetam Administration. ( Fujino, O; Itoh, Y; Kawakami, Y; Okazaki, T; Takase, M, 2015) |
| "Our objective is to explore the effects of levetiracetam on the levels of neuropeptides, serum activity and concentrations of oxidative stress and inflammatory response proteins, and levels of brain injury marker in patients with refractory epilepsy." | 3.81 | The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy. ( Chen, W; Chen, Y; Ge, Y; Liu, X; Tan, Y, 2015) |
| "To report cases of hair loss with levetiracetam (LEV) in epilepsy patient and summarise their demographic and clinical features." | 3.80 | Hair loss with levetiracetam in five patients with epilepsy. ( Hong, Z; Zhou, D; Zou, X, 2014) |
| "To compare the cognitive and language development of children born to women with epilepsy (WWE) exposed in utero to levetiracetam (LEV) or sodium valproate (VPA) and control children born to women without epilepsy not taking medication during pregnancy." | 3.80 | In utero exposure to levetiracetam vs valproate: development and language at 3 years of age. ( Baker, GA; Bromley, RL; Cheyne, CP; García-Fiñana, M; Irwin, B; Morrow, J; Shallcross, R, 2014) |
| " Therefore, this multicenter cross-sectional study aimed to evaluate the prevalence of reproductive endocrine dysfunctions in pubertal females with epilepsy receiving VPA, lamotrigine (LTG), or levetiracetam (LEV) monotherapy." | 3.80 | Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen? ( Agostinelli, S; Baumann, M; Haberlandt, E; Luef, G; Pizzolorusso, A; Prieschl, M; Rauchenzauner, M; Roscia, S; Rostasy, K; Verrotti, A; Wildt, L, 2014) |
| "Studies evaluating the effect of levetiracetam (LEV) on haematological parameters in patients with epilepsy are very limited." | 3.80 | Short-term effect of levetiracetam monotherapy on haematological parameters in children with epilepsy: a prospective study. ( Attilakos, A; Dinopoulos, A; Garoufi, A; Moustaki, M; Papaevangelou, V; Paschalidou, M; Siafakas, N; Tsirouda, M, 2014) |
| "We investigated the relationship between behavioral problems, location of electroencephalogram (EEG) paroxysmal abnormalities (PA), and treatment with levetiracetam in children with pervasive developmental disorder (PDD) and epilepsy." | 3.80 | Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy. ( Aihara, M; Kanemura, H; Ohyama, T; Sano, F; Sugita, K, 2014) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "This study aimed to evaluate the effectiveness of levetiracetam (LEV) use for seizure control in patients who had undergone resective surgery for intractable epilepsy in routine clinical practice." | 3.80 | Effectiveness of levetiracetam use following resective surgery in patients with refractory epilepsy: a prospective observational study. ( An, DM; Chen, L; Lei, D; Li, JM; Li, YH; Zeng, TF; Zhang, B; Zhou, D, 2014) |
| "Body weight was measured at baseline and at the final LEV study visit." | 3.80 | Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. ( Gidal, BE; Herbeuval, AF; Magnus, L; Sheth, RD, 2003) |
| "The effects of the antiepileptic drugs sodium valproate (VPA) and levetiracetam (LEV) on reproductive endocrine function, sexual function, and spermatozoa were explored, together with their possible etiological mechanisms, in Chinese Han men with epilepsy." | 3.79 | Effects of antiepileptic drugs on reproductive endocrine function, sexual function and sperm parameters in Chinese Han men with epilepsy. ( Daoliang, X; Hengzhong, Z; Xiaotian, X; Yao, X; Yumei, W; Zhipan, Z, 2013) |
| "To evaluate the long-term efficacy and safety of levetiracetam based on a large population of patients in a tertiary epilepsy centre." | 3.79 | The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. ( Chu, K; Jung, KH; Kang, BS; Kim, YS; Lee, SK; Lee, ST; Moon, HJ, 2013) |
| " We present a 12-year-old girl with epilepsy who developed TEN after about 14 days of lamotrigine treatment." | 3.79 | A lamotrigine induced toxic epidermal necrolysis in a child. ( Altun, F; Bilgili, SG; Bulut, G; Burakgazi, AZ; Calka, O; Karadag, AS, 2013) |
| "The aim of this study was to investigate the change of health related quality of life (HRQoL), anxiety and depression in adult patients in whom an adjunctive treatment with levetiracetam (LEV) was converted to a LEV monotherapy." | 3.79 | Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy. ( Arnold, S; Brandt, C; Elger, CE; Hagemann, A; May, TW; Nieder, E; Pohlmann-Eden, B; Schulze-Bonhage, A; Straub, HB; Tergau, F; Witte-Bölt, K, 2013) |
| " The aim of this study is to determine the changes of bone metabolism and BMD in epilepsy patients who are undergoing levetiracetam (LEV) monotherapy." | 3.79 | Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. ( Hong, SB; Joo, EY; Kim, D; Koo, DL, 2013) |
| "Levetiracetam (LEV) is a widely used antiepileptic agent for partial refractory epilepsy in humans." | 3.79 | Inhibitory effects of levetiracetam on the high-voltage-activated L-type Ca²⁺ channels in hippocampal CA3 neurons of spontaneously epileptic rat (SER). ( Arita, K; Hanaya, R; Ishihara, K; Kurisu, K; Sasa, M; Seki, T; Serikawa, T; Yan, HD, 2013) |
| "We aimed to compare apparent steady-state oral clearance (CL/F) of the antiepileptic drug levetiracetam (LEV) in elderly (66-80 years, n=105) and very elderly (81-96 years, n=70) vs nonelderly (30-65 years, n=97) patients with epilepsy." | 3.78 | Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Mohamed, S; Riva, R, 2012) |
| " Levetiracetam (LEV) is a novel antiepileptic drug used to treat epilepsy, but its effects on spatial and emotional learning and memory are not yet well understood." | 3.78 | Positive impact of levetiracetam on emotional learning and memory in naive mice. ( Akar, FY; Celikyurt, IK; Erden, F; Komsuoglu, SS; Mulayim, S; Mutlu, O; Ulak, G, 2012) |
| "The objective of this retrospective study was to report our experience with the use of levetiracetam as an adjuvant therapy in a population of 42 children presenting a drug-resistant epilepsy." | 3.78 | [Experience with levetiracetam in the treatment of childhood refractory epilepsy]. ( Berquin, P; Bourel-Ponchel, E; de Broca, A; Delignières, A; Doumbia-Ouattara, M; Le Moing, AG; Querne, L, 2012) |
| "Levetiracetam (LEV), a new anticonvulsant agent primarily used to treat epilepsy, has been used in pain treatment but the cellular mechanism of this action remains unclear." | 3.78 | Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons. ( Ayar, A; Ozcan, M, 2012) |
| "To establish a population pharmacokinetics (PPK) model of levetiracetam in Chinese children with epilepsy." | 3.78 | Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy. ( Lu, W; Shang, DW; Wang, L; Wang, YH; Wei, MJ; Wu, Y, 2012) |
| "The purpose of this study was to compare age and comedication as factors contributing to pharmacokinetic variability between 4 newer AEDs (lamotrigine, levetiracetam, oxcarbazepine, and topiramate) among patients with refractory epilepsy." | 3.78 | Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. ( Baftiu, A; Johannessen Landmark, C; Johannessen, SI; Larsson, PG; Rytter, E; Tysse, I; Valsø, B, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| " Visual aura and aphasia persisted despite antiepileptic medication with phenytoin, oxcarbazepine, and levetiracetam." | 3.78 | Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet. ( Jääskeläinen, S; Majamaa, K; Martikainen, MH; Päivärinta, M, 2012) |
| "To assess the efficacy and tolerability of levetiracetam (Lev) in children with epilepsy." | 3.77 | Efficacy and tolerability of levetiracetam in children with epilepsy. ( Chen, S; Li, J; Xiao, N, 2011) |
| "To monitor the effect of adding levetiracetam in paediatric patients with hemiplegic cerebral palsy and uncontrolled epilepsy." | 3.77 | Levetiracetam in children and adolescents with epilepsy and hemiplegic cerebral palsy. ( Harbord, MG, 2011) |
| "Children born to women with epilepsy (WWE), exposed in utero to levetiracetam (LEV, n = 51), were assessed for early cognitive development and compared to children exposed to sodium valproate in utero (VPA, n = 44) and a group of children representative of the general population (n = 97)." | 3.77 | Child development following in utero exposure: levetiracetam vs sodium valproate. ( Baker, GA; Bonnett, LJ; Bromley, RL; Irwin, B; Morrow, J; Shallcross, R, 2011) |
| "To describe the clinical outcomes of a compulsory switch from branded to generic levetiracetam (LEV) among people with epilepsy (PWE) in an outpatient setting." | 3.77 | Clinical experience with generic levetiracetam in people with epilepsy. ( Chaluvadi, S; Chiang, S; Friedman, DE; Goldsmith, CE; Tran, L, 2011) |
| "The effect on clearance of levetiracetam (LEV) was estimated in women with epilepsy of childbearing potential using oral contraceptives (OCs)." | 3.77 | No effect of oral contraceptives on the metabolism of levetiracetam. ( Christensen, J; Sabers, A, 2011) |
| "This study explored the effects of levetiracetam (LEV) on the expression of nerve cell adhesion molecule (NCAM) and growth-associated protein 43 (GAP-43) mRNA in the hippocampus of rats with epilepsy induced by lithium-pilocarpine (Li-PILO) in order to provide a basis for investigating the antiepileptic mechanism of LEV and its doseresponse." | 3.77 | [Effects of levetiracetam on the expression of NCAM and GAP-43 mRNA in the hippocampus of rats with epilepsy]. ( Jia, TM; Li, XL; Liu, T; Luan, B; Zhang, XL, 2011) |
| "To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort." | 3.77 | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. ( Aronica, E; de Groot, M; Heimans, JJ; Reijneveld, JC, 2011) |
| "The objective was to retrospectively study the efficacy and safety of levetiracetam (keppra) as an add-on treatment of pharmacoresistant forms of epilepsy in children." | 3.77 | [The retrospective study of efficacy and safety of levetiracetam as an add-on treatment of epilepsy in children]. ( Aĭvazian, SO; Shiriaev, IuS, 2011) |
| " We previously showed that tolerance to levetiracetam (LEV) developed within 4 days after the start of the treatment in a rat model for spontaneous seizures after electrically induced status epilepticus." | 3.76 | Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats. ( Edelbroek, PM; Gorter, JA; van Vliet, EA, 2010) |
| "We retrospectively analysed 218 patients, mostly adults, presenting mostly with localisation-related epilepsy, treated with levetiracetam as adjunctive therapy or monotherapy for up to 36 months." | 3.76 | Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. ( Brázdil, M; Kocvarová, J; Kuba, R; Mastík, J; Novotná, I; Rektor, I; Tyrlíková, I, 2010) |
| "Levetiracetam (LEV, 2S-(oxo-1-pyrrolidinyl)butanamide, Keppra, UCB Pharma) is a new anti-epileptic drug used to treat certain types of seizures in epilepsy patients." | 3.76 | Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats. ( Choi, HC; Choi, SY; Jo, SM; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Song, HK, 2010) |
| "To investigate the efficacy and safety of levetiracetam adjunctive therapy in childhood intractable epilepsy, data were reviewed for 130 children who had >or=4 seizures per month, whose seizures were intractable to an initial >or=2 antiepileptic drugs, and who could be monitored for at least 6 months after levetiracetam add-on." | 3.76 | Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. ( Kang, HC; Kim, HD; Lee, JS; Lee, YJ, 2010) |
| "We review our experience with high-dose intravenous levetiracetam (IV-LEV) for acute seizure exacerbations in nine children with medically intractable epilepsy." | 3.76 | High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy. ( Depositario-Cabacar, DT; Peters, JM; Pong, AW; Riviello, JJ; Rotenberg, A; Roth, J; Takeoka, M, 2010) |
| "To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma." | 3.76 | Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. ( Buttolo, L; Cenzato, M; Padovani, A; Rosati, A; Stefini, R; Todeschini, A, 2010) |
| "In this study of older adults with epilepsy, lamotrigine was the most effective AED as measured by 12-month retention and seizure freedom, with levetiracetam a close second." | 3.76 | Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. ( Arif, H; Bazil, CW; Buchsbaum, R; Hirsch, LJ; Pierro, J; Resor, SR; Sims, J; Whalen, M, 2010) |
| "In 2006, intravenous levetiracetam received US Food and Drug Administration (FDA) approval for adjunctive treatment of partial onset seizures in adults with epilepsy, 16 years or older." | 3.76 | Intravenous levetiracetam in children with seizures: a prospective safety study. ( Cardenas, JF; Chapman, KE; Hastriter, EV; Khoury, EM; Ng, YT, 2010) |
| "To evaluate of the efficacy and safety of adjunctive levetiracetam (LEV) in children younger than 4 years with refractory epilepsy." | 3.76 | [Efficacy and safety of adjunctive levetiracetam in children younger than 4 years with refractory epilepsy]. ( Chen, L; Hu, Y; Huang, TS; Li, B; Liao, JX, 2010) |
| "The aim of this study was to evaluate efficacy and tolerability of levetiracetam (LEV) in patients with different epilepsy syndromes." | 3.76 | Levetiracetam in clinical practice: efficacy and tolerability in epilepsy. ( Bilo, L; de Leva, MF; Meo, R, 2010) |
| "The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG)." | 3.76 | Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. ( Gjerstad, L; Luef, G; Mørkrid, L; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2010) |
| "9 years) with epilepsy not responding to most conventional or new antiepileptic drugs were treated by adding levetiracetam to their present antiepileptic regimen and followed for a minimum period of 12 weeks." | 3.76 | Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial. ( Ghazavi, M; Ghofrani, M; Karimzadeh, P; Mahvelati, F; Tonekaboni, SH, 2010) |
| "5-year period was performed at the Columbia Comprehensive Epilepsy Center to identify children who were treated with levetiracetam doses titrated above the usual 40-60mg/kg/day." | 3.76 | Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. ( Obeid, M; Pong, AW, 2010) |
| " The influence of age and concomitant medications on the dose/concentration ratio of levetiracetam was examined in 103 children with epilepsy." | 3.76 | Age and comedications influence levetiracetam pharmacokinetics in children. ( Dahlin, MG; Ohman, I; Wide, K, 2010) |
| "Our study suggests that there are clinically significant differences among gabapentin, lamotrigine, levetiracetam, tiagabine, and topiramate as treatment for focal epilepsy in everyday practice." | 3.75 | Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. ( Auvinen, A; Fallah, M; Keränen, T; Peltola, J; Peltola, M; Raitanen, J, 2009) |
| " Aim of this study was to evaluate the effect of levetiracetam (LEV) on EDs, monitored with ambulatory EEG (A/EEG), in a limited series of patients with generalized epilepsy." | 3.75 | Effects of levetiracetam on generalized discharges monitored with ambulatory EEG in epileptic patients. ( Li Voti, P; Mecarelli, O; Pro, S; Pulitano, P; Randi, F; Vicenzini, E; Zarabla, A, 2009) |
| "Levetiracetam (LEV), a newer antiepileptic drug (AED) useful for several epilepsy syndromes, binds to SV2A." | 3.75 | No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. ( Cavalleri, GL; Delanty, N; Depondt, C; Doherty, CP; Goldstein, DB; Kinirons, P; Lynch, JM; Murphy, K; O'Rourke, D; Sander, JW; Shianna, KV; Sisodiya, SM; Tate, SK; Weale, ME; Wood, NW, 2009) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 3.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 3.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in preventing clinical seizures in patients with subarachnoid hemorrhage (SAH)." | 3.75 | Utility of levetiracetam in patients with subarachnoid hemorrhage. ( Husain, AM; Shah, D, 2009) |
| "Levetiracetam is one of the newer anti-epileptic medications, which is now widely used in the treatment of childhood epilepsy." | 3.75 | Thrombocytopenia as an adverse effect of levetiracetam therapy in a child. ( Mohamed, BP; Peer Mohamed, B; Prabhakar, P, 2009) |
| "Levetiracetam, the alpha-ethyl analogue of the nootropic piracetam, is a widely used antiepileptic drug (AED) that provides protection against partial seizures and is also effective in the treatment of primary generalized seizure syndromes including juvenile myoclonic epilepsy." | 3.74 | Brivaracetam: a rational drug discovery success story. ( Rogawski, MA, 2008) |
| "Both levetiracetam (LEV) and phenytoin (PHT) were associated with a low risk of early postoperative seizures and a moderate risk of later epilepsy." | 3.74 | Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. ( Bromfield, EB; Hurwitz, S; Milligan, TA, 2008) |
| "We present a simple, fast and validated method for the determination of the new generation antiepileptic drug (AED) levetiracetam (LEV) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 3.74 | Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Mohamed, S; Riva, R, 2008) |
| "The purpose of the study was to assess changes in cognitive functions and quality of life in patients with epilepsy over one year of treatment with levetiracetam (LEV) as add-on therapy." | 3.74 | Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. ( Escartín, A; García, C; López-Góngora, M; Martínez-Domeño, A, 2008) |
| "To evaluate the efficacy and tolerability of levetiracetam (LEV) in the treatment of epilepsy as a monotherapy in children." | 3.74 | [Follow-up study on levetiracetam monotherapy in children with epilepsy]. ( Gao, ZJ; Jiang, YW, 2008) |
| " Three regulatory trials have demonstrated that add-on levetiracetam is efficacious in patients with localization-related epilepsy." | 3.74 | Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2007) |
| "The aim of this multicentric, retrospective, and uncontrolled study was to evaluate the efficacy and safety of levetiracetam (LEV) in 81 children younger than 4 years with refractory epilepsy." | 3.74 | Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy. ( Balestri, P; Capovilla, G; Coppola, G; Cordelli, DM; Franzoni, E; Grosso, S; Morgese, G; Verrotti, A; Zamponi, N, 2007) |
| "To study pharmacokinetics of levetiracetam (LEV) during pregnancy, delivery, lactation, and in the neonatal period." | 3.74 | Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. ( Ben-Menachem, E; Danielsson, B; Johansson, R; Källén, K; Luef, G; Ohman, I; Palm, R; Söderfeldt, B; Tomson, T, 2007) |
| "A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy." | 3.74 | [Clinical experience with levetiracetam for adults with epilepsy]. ( Barcs, G; Szucs, A, 2007) |
| "To assess the single-dose pharmacokinetics of levetiracetam and its major metabolite ucb L057 in infants and young children with epilepsy." | 3.74 | Pharmacokinetics of levetiracetam in infants and young children with epilepsy. ( Bebin, M; Chen, D; Coupez, R; Glauser, TA; Lu, ZS; Mitchell, WG; Stockis, A; Weinstock, A, 2007) |
| "Twenty-two dogs with idiopathic epilepsy which were pharmacoresistant to phenobarbitone and bromide were treated with levetiracetam as an add-on medication." | 3.74 | The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. ( Chandler, KE; Luján Feliu-Pascual, A; Matiasek, LA; Platt, SR; Volk, HA, 2008) |
| "We analyzed all patients referred to a tertiary epilepsy centre who had been treated with topiramate from the introduction of the drug in spring 1993 up to a final assessment point mid-2002 and all patients who had been treated with LEV in the same centre from the introduction of the drug in early 2001 up to a final assessment point end-2003 using a medical information system." | 3.74 | Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2008) |
| "Levetiracetam is a new antiepileptic drug reported to be effective and well-tolerated in adults and children affected by epilepsy." | 3.74 | No kinetic interaction between levetiracetam and cyclosporine: a case report. ( Franzoni, E; Garone, C; Malaspina, E; Marchiani, V; Sarajlija, J, 2007) |
| " Group 1 includes patients in whom levetiracetam was the only possible cause of weight loss and Group 2 those in whom other factors may have played a role." | 3.74 | Dramatic weight loss with levetiracetam. ( Coubes, P; Crespel, A; Diaz, O; Gelisse, P; Genton, P; Hillaire-Buys, D; Juntas-Morales, R, 2008) |
| "Levetiracetam is a new antiepileptic drug prescribed for the treatment of patients with refractory partial seizures with or without secondary generalization as well as for the treatment of juvenile myoclonic epilepsy." | 3.74 | Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epil ( Brovedani, S; Chassoux, F; Franchon, E; Garciau, I; Kraoul, L; Lancelin, F; Landré, E; Paubel, P; Piketty, ML; Tabaouti, K, 2007) |
| "To investigate changes in levetiracetam (LEV) serum concentration/dose ratio (C/D-ratio) in relation to pregnancy." | 3.74 | Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. ( Brodtkorb, E; Helde, G; Nakken, KO; Reimers, A; Westin, AA, 2008) |
| "A retrospective chart review was performed to identify patients with childhood epilepsy who underwent a rapid titration to full doses of levetiracetam in 2 weeks or less." | 3.74 | Rapid dosage titration of levetiracetam in children. ( Neft, RA; Vaisleib, II, 2008) |
| "To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy." | 3.74 | Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. ( Bailey, KS; Barone, G; Boothe, DM; Dewey, CW; Kortz, GD, 2008) |
| "Nonlinear mixed-effects modelling was used to analyse pooled data collected from 228 children with epilepsy aged 3 months to 18 years in five trials of adjunctive levetiracetam therapy." | 3.74 | Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. ( Jacqmin, P; Lacroix, B; Sargentini-Maier, ML; Stockis, A; Toublanc, N, 2008) |
| " We could not demonstrate any association between the paradoxical effect of levetiracetam and type of epilepsy or the antiepileptic comedication used." | 3.74 | The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. ( Barcs, G; Clemens, Z; Fabó, D; Holló, A; Jakus, R; Janszky, J; Kelemen, A; Rásonyi, G; Szucs, A, 2008) |
| "The effects of brivaracetam and levetiracetam on epileptiform activity and seizure expression were examined in rat hippocampal slices, corneally kindled mice, audiogenic seizure-susceptible mice, maximal electroshock and pentylenetetrazol seizures in mice, hippocampal-kindled rats, amygdala-kindled rats and genetic absence epilepsy rats." | 3.74 | Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. ( Kenda, B; Klitgaard, H; Margineanu, DG; Matagne, A; Michel, P, 2008) |
| "This study provides the results of a cost-effectiveness analysis of levetiracetam as an adjunctive treatment for refractory epilepsy from the Canadian Ministry of Health perspective." | 3.73 | Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. ( Bernier, G; Blais, L; Godfroid, P; LeLorier, JJ; Sheehy, O; St-Hilaire, JM, 2005) |
| "The long-lasting antiseizure effects of levetiracetam (LEV) have been observed in the spontaneously epileptic rat (SER) that expresses both tonic and absence-like seizures." | 3.73 | Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). ( Ishihara, K; Ji-qun, C; Nagayama, T; Sasa, M; Serikawa, T; Yan, HD, 2005) |
| "The authors examined sodium concentrations from 97 oxcarbazepine-treated (OXC) and 451 carbamazepine-treated (CBZ) patients with epilepsy using cross-section and follow-up studies." | 3.73 | Hyponatremia from oxcarbazepine and carbamazepine. ( Dong, X; Leppik, IE; Rarick, J; White, J, 2005) |
| "To assess the anticonvulsant activity of the novel antiepileptic drug, levetiracetam (LEV) in a model of self-sustaining limbic status epilepticus, and to measure the consequence of LEV treatment on the pattern of mitochondrial dysfunction known to occur after status epilepticus (SE)." | 3.73 | Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. ( Cock, HR; Gibbs, JE; Walker, MC, 2006) |
| "To evaluate the efficacy and tolerability of levetiracetam in children with drug resistant epilepsy from a retrospective study." | 3.73 | [Experience with levetiracetam in childhood epilepsy]. ( Fogarasi, A; Hegyi, M; Herczegfalvi, A; Kollár, K; Móser, J; Neuwirth, M; Paraicz, E; Rosdy, B; Saracz, J, 2006) |
| "Keppra (levetiracetam) was used as a part of the complex therapy in 87 patients with partial epilepsy and in 17 patients with adult idiopathic generalized epilepsy." | 3.73 | [The results of the two-year experience of using keppra in therapy of adult patients with epilepsy]. ( Karlov, VA; Vlasov, PN, 2006) |
| "The long-term efficacy and tolerability of levetiracetam (LEV) was analysed in 218 epilepsy patients." | 3.73 | Long-term levetiracetam treatment of epilepsy patients: clinical audit. ( Brázdil, M; Kocvarová, J; Kuba, R; Mastík, J; Novotná, I; Rektor, I; Tyrliková, I, 2006) |
| "All patients of the epilepsy center Kempenhaeghe that received topiramate (TPM) or levetiracetam (LEV) from the introduction to mid 2004 were analyzed using a medical information system, an automated medical file." | 3.73 | The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Schellekens, A, 2006) |
| "It is not known whether the antiepileptic drug (AED) levetiracetam can be used safely in human pregnancy." | 3.73 | Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. ( Craig, J; Guthrie, E; Hunt, S; Irwin, B; Morrison, PJ; Morrow, J; Parsons, L; Robertson, I; Russell, A; Waddell, R, 2006) |
| "Levetiracetam (LEV) was shown to be very efficacious and well tolerated as add-on therapy for refractory epilepsy." | 3.72 | Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. ( Dietl, T; Dinkelacker, V; Elger, CE; Lengler, U; Widman, G, 2003) |
| "This prospective observational study explored the efficacy and tolerability of levetiracetam (LEV) in a prospective series of 200 patients with refractory epilepsy attending a single epilepsy service." | 3.72 | Levetiracetam in clinical use--a prospective observational study. ( Bird, JM; Joseph, ZA, 2003) |
| "The purpose of this analysis was to compare treatment-emergent adverse events (TEAE) related to use of levetiracetam (LEV) reported by young and elderly patients with anxiety and cognitive disorders, and young epilepsy patients." | 3.72 | Tolerability of levetiracetam in elderly patients with CNS disorders. ( Cramer, JA; Edrich, P; Krämer, G; Leppik, IE; Rue, KD, 2003) |
| "To investigate the prevalence and psychopathological features of psychiatric adverse events (PAEs) in patients with learning disabilities (LD) in therapy with levetiracetam (LEV)." | 3.72 | Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. ( Mula, M; Sander, JW; Trimble, MR, 2004) |
| "The purpose was to evaluate the effects of levetiracetam (LEV) in routine therapy in learning disabled patients with therapy-resistant epilepsy." | 3.72 | Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. ( Bömmel, W; Hauser, I; Horstmann, V; Huber, B; Liem, S; May, T; Meinert, T; Robertson, E; Schulz, L; Seidel, M; Tomka-Hoffmeister, M; Wagner, W, 2004) |
| "To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults." | 3.72 | Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. ( Coppola, G; Fels, A; Habetswallner, F; Licciardi, F; Mangano, S; Nardello, R; Operto, FF; Pascotto, A; Pelliccia, A; Romano, A; Tortorella, G, 2004) |
| "The nootropic drug piracetam was investigated in various experimental models of epilepsy." | 3.72 | Effects of piracetam alone and in combination with antiepileptic drugs in rodent seizure models. ( De Sarro, G; Fischer, W; Kittner, H; Regenthal, R; Russo, E, 2004) |
| "The purpose of this study was to assess the efficacy and safety of levetiracetam in a diverse pediatric epilepsy population." | 3.72 | Retrospective study of the use of levetiracetam in childhood seizure disorders. ( Guarino, EJ; Koukkari, MW, 2004) |
| "Slices were used to evaluate the effects of LEV on two different models of epilepsy: low-Mg2+-induced untriggered and bicuculline-evoked stimulus-triggered epileptiform burst discharges and spontaneously appearing rhythmic sharp waves." | 3.71 | Effect of levetiracetam on epileptiform discharges in human neocortical slices. ( Behne, F; Ebner, A; Gorji, A; Höhling, JM; Köhling, R; Lahl, R; Madeja, M; Panneck, HW; Speckmann, EJ; Straub, H; Tuxhorn, I; Wolf, P, 2002) |
| "The long-term continuation (retention) rate, efficacy, and safety data of the new antiepileptic drug levetiracetam (LEV) was evaluated in all patients with epilepsy exposed to the drug during its developmental program (n = 1,422)." | 3.71 | Long-term continuation of levetiracetam in patients with refractory epilepsy. ( Krakow, K; Otoul, C; Sander, JW; Walker, M, 2001) |
| " We present four patients with severe refractory epilepsy in whom introduction of levetiracetam led to disabling symptoms compatible with carbamazepine toxicity requiring either carbamazepine dose reduction or levetiracetam withdrawal." | 3.71 | Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. ( Patsalos, PN; Sander, JW; Sisodiya, SM, 2002) |
| "The protective and adverse effect potentials of levetiracetam ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide) in rodent models of seizures and epilepsy were compared with the profile of several currently prescribed and newly developed antiepileptic drugs." | 3.70 | Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. ( Gobert, J; Klitgaard, H; Matagne, A; Wülfert, E, 1998) |
| " Indeed, because of its interesting pharmacokinetic properties, it is often used outside of the labeled indications, notably in the neurocritical setting as prophylaxis of epileptic seizures." | 2.82 | Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overview. ( Amadori, E; D'Onofrio, G; Lattanzi, S; Riva, A; Rose, K; Striano, P; Verrotti, A, 2022) |
| "Five phenobarbital treated dogs were classified as true responders (≥50% reduction in seizures/month) whereas none of the levetiracetam treated dogs fulfilled this criterion." | 2.82 | A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy. ( Berendt, M; Fredsø, N; Møller, A; Sabers, A; Toft, N, 2016) |
| "Levetiracetam (LEV) is a new-generation anti epileptic drug (AED)." | 2.82 | [Efficacy and Safety of Levetiracetam as an Add-on Therapy for Symptomatic Refractory Epilepsy Treated in a Department of Neurosurgery]. ( Kawataki, T; Kinouchi, H; Ogiwara, M; Sato, H; Suzuki, K, 2016) |
| "In patients with brain tumors, the choice of antiepileptic medication is guided by tolerability and pharmacokinetic interactions." | 2.79 | Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ( Jeckelmann, S; Novy, J; Rossetti, AO; Roth, P; Stupp, R; Weller, M, 2014) |
| "01) and a shorter half-life (p=0." | 2.76 | Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy. ( Alexandre, V; Feletti, F; Freitas-Lima, P; Pereira, LR; Perucca, E; Sakamoto, AC, 2011) |
| "Levetiracetam was generally well tolerated." | 2.74 | The underrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production. ( Brown, M; Legoff, D; Levin-Allen, S; Mintz, M; Mintz, P; Scornaienchi, J; Smith, C, 2009) |
| "During the time of 6 months 28 patients underwent EEG-recording and neuropsychological testing at the three timepoints: before initiating LEV therapy, after 2 months and again after 4 months after achieving plateau dosing of LEV." | 2.74 | Impact of levetiracetam add-on therapy on different EEG occipital frequencies in epileptic patients. ( Haettig, H; Meencke, HJ; Veauthier, J, 2009) |
| "Levetiracetam-treated patients manifested an early augmentation of self-rated aggressiveness, which increased in intensity over the course of days." | 2.73 | Early detection of behavioral side effects of antiepileptic treatment using handheld computers. ( Carius, A; Frings, L; Lehmann, C; Maiwald, T; Schinkel, A; Schulze-Bonhage, A; Wagner, K, 2008) |
| "Stroke is the most common cause of seizures in the elderly." | 2.73 | Levetiracetam monotherapy for late poststroke seizures in the elderly. ( Gomceli, YB; Inan, LE; Kutlu, G; Unal, Y, 2008) |
| "Levetiracetam (LEV) is a broad-spectrum antiepileptic drug with no known interactions and a favorable profile of adverse events." | 2.73 | Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. ( Fuhr, P; Hardmeier, M; Marsch, S; Naegelin, Y; Rüegg, S; Winkler, DT, 2008) |
| "Levetiracetam treatment was safe and effective in this group of very young patients with various types of epilepsy." | 2.73 | Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. ( Krief, P; Maytal, J, 2008) |
| "Levetiracetam (LEV) is a newer AED, with a recently approved parenteral formulation, that can be initiated at doses effective in controlling seizures." | 2.73 | Tolerability and efficacy of oral loading of levetiracetam. ( Amina, S; Bergey, GK; Koubeissi, MZ; Pita, I; Werz, MA, 2008) |
| "Epilepsy is a common clinical problem in patients with brain tumours, strongly affecting patients' quality of life." | 2.72 | Levetiracetam therapy in patients with brain tumour and epilepsy. ( Albani, F; Baruzzi, A; Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Occhipinti, E; Pace, A; Pompili, A; Zarabla, A, 2006) |
" Adverse events reported after IV administration of LEV (| 2.72 | Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. ( Daoust, A; Lu, ZS; Otoul, C; Ramael, S; Stockis, A; Toublanc, N; Troenaru, M, 2006) | |
| "Levetiracetam was well tolerated, and provided stable seizure control during long-term treatment." | 2.72 | Levetiracetam: a long-term follow-up study of efficacy and safety. ( Bauer, J; Ben-Menachem, E; Da Silva, S; Fryze, W; Kasteleijn-Nolst Trenité, DG; Krämer, G, 2006) |
| "Levetiracetam is a new anti-convulsant with impressive pivotal trial credentials." | 2.71 | Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study. ( Barrett, M; Betts, T; Greenhill, L; Yarrow, H, 2003) |
| "Levetiracetam (Keppra) was evaluated in a subset of patients aged >/=65 years (n=78) enrolled in a large (n=1030) open-label, phase IV trial (the KEEPER trial)." | 2.71 | Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. ( Ferrendelli, JA; French, J; Han, J; Herbeuval, A; Leppik, I; Magnus, L; Morrell, MJ, 2003) |
| "Levetiracetam (LEV) is a novel antiepileptic drug (AED) with efficacy against a wide range of seizures types." | 2.71 | Levetiracetam for people with mental retardation and refractory epilepsy. ( Brodie, MJ; Kelly, K; Stephen, LJ, 2004) |
| "Levetiracetam was generally well tolerated." | 2.70 | Pharmacokinetic study of levetiracetam in children. ( Bebin, EM; Coupez, RM; Fountain, NB; Glauser, TA; Pellock, JM; Ritter, FJ; Shields, WD, 2001) |
| "The prevalence of epilepsy is estimated 5-10 per 1000 population and around 70% of patients with epilepsy can be sufficiently controlled by antiepileptic drugs (AEDs)." | 2.58 | Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies. ( Andres-Mach, M; Czuczwar, M; Czuczwar, SJ; Kruszyński, K; Łukawski, K; Łuszczki, JJ, 2018) |
| "Levetiracetam is a broad-spectrum antiepileptic drug (AED) with a unique mechanism of action." | 2.55 | Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy. ( Ensom, MHH; Levine, M; Paquette, V; Tan, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet." | 2.55 | Treatment of epilepsy in patients with Alzheimer's disease. ( Bonuccelli, U; Giorgi, FS; Guida, M; Vergallo, A; Zaccara, G, 2017) |
| "Lamotrigine was preferred in patients with co-morbid depression." | 2.55 | Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017) |
| "Levetiracetam was discontinued in 4." | 2.53 | Safety of Levetiracetam in Paediatrics: A Systematic Review. ( Choonara, I; Egunsola, O; Sammons, HM, 2016) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.53 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2016) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| "Levetiracetam has been used in children and infants with good efficacy, an excellent safety profile, and near-ideal pharmacokinetic characteristics." | 2.49 | Newly emerging therapies for neonatal seizures. ( Mangum, B; Pressler, RM, 2013) |
| "Levetiracetam (LEV) is a highly effective antiepileptic agent." | 2.49 | Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. ( Elger, CE; Helmstaedter, C; Hurlemann, R; Kunz, WS; Mihov, Y; Nuernberg, P; Schoch, S; Surges, R; Thiele, H; Toliat, MR, 2013) |
| "Acute seizure and status epilepticus constitute one of the major medical emergencies in children." | 2.48 | Management of acute seizure and status epilepticus in pediatric emergency. ( Sasidaran, K; Singhi, P; Singhi, S, 2012) |
| " When prescribing these drugs to patients of this age bracket, treatment should be based not only on the diagnosis and seizure type but also on the propensity of the drugs for adverse effects and their drug-drug interactions." | 2.48 | Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects. ( Dostic, M; Jankovic, SM, 2012) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 2.47 | Levetiracetam: a review of its use in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Levetiracetam has a novel structure and unique mechanisms of action." | 2.47 | Spotlight on levetiracetam in epilepsy. ( Lyseng-Williamson, KA, 2011) |
| "Levetiracetam was approved by the US FDA in 1999 after failing the traditional screening tests for antiepileptic drugs." | 2.46 | Levetiracetam: a comprehensive review. ( Crepeau, AZ; Treiman, DM, 2010) |
| "Levetiracetam is an antiepileptic drug that has been shown to be effective in various types of seizures, both partial and generalized." | 2.46 | Levetiracetam in childhood epilepsy. ( Chiarelli, F; Curatolo, P; D'Adamo, E; Parisi, P; Verrotti, A, 2010) |
| "Levetiracetam (Keppra) is an antiepileptic drug (AED) characterized by a novel mechanism of action, unique profile of activity in seizure models, and broad-spectrum clinical efficacy." | 2.45 | Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. ( Kaminski, RM; Klitgaard, H; Matagne, A; Patsalos, PN, 2009) |
| " Individualization of dosage and avoidance of unnecessary polypharmacy are essential for safe utilization of anti-epileptic drugs." | 2.44 | [Epilepsy in the elderly]. ( Yoshino, A, 2007) |
| "Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years." | 2.44 | The safety of levetiracetam. ( Safdieh, JE; Sirsi, D, 2007) |
| "Levetiracetam (LEV) is a broad-spectrum antiepileptic drug that is effective against a variety of seizure types." | 2.44 | Levetiracetam. ( Carreno, M, 2007) |
| "Levetiracetam is a new antiepileptic drug whose efficacy and tolerability are already well known in adults." | 2.43 | Levetiracetam in pediatrics. ( Vigevano, F, 2005) |
| "Epilepsy is a hetergenous syndrome characterized by recurrently and repeatedly occurring seizures." | 2.43 | A new frontier in epilepsy: novel antiepileptogenic drugs. ( Sasa, M, 2006) |
| "Epilepsy is a neurological disorder consisting of recurrent seizures, resulting from excessive, uncontrolled electrical activity in the brain." | 2.43 | Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy. ( Boon, P; De Herdt, V; De Smedt, T; Dedeurwaerdere, S; Delbeke, J; Legros, B; Raedt, R; Van Hese, P; Van Laere, K; Vonck, K; Wadman, W; Waterschoot, L; Wyckhuys, T, 2006) |
| " For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable." | 2.43 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006) |
| " Pharmacokinetic studies of levetiracetam have been conducted in healthy volunteers, in patients of all ages with epilepsy, and in certain special populations." | 2.42 | The pharmacokinetic characteristics of levetiracetam. ( Patsalos, PN, 2003) |
| "The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions." | 2.42 | The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003) |
| "Levetiracetam may allow patients to decrease the number of concomi-tant antiepileptic medications or withdraw to monotherapy." | 2.42 | Long-term experience with levetiracetam. ( Abou-Khalil, B; Lazenby, B, 2003) |
| "Treatment of seizures in pediatric patients is complicated by the fact that the etiology of the disorder and the pharmacokinetics, efficacy, and safety of antiepileptic drugs (AEDs) may differ from that in adults." | 2.42 | Preliminary efficacy of levetiracetam in children. ( Dulac, O; Glauser, TA, 2003) |
| "Most patients with epilepsy are started on one of the classic AEDs and, if it proves ineffective, another drug is tried, usually as monotherapy." | 2.42 | Preliminary efficacy of levetiracetam in monotherapy. ( Ben-Menachem, E, 2003) |
| "Levetiracetam has specific characteristics that make it an optimal choice for many patient populations." | 2.42 | Role of levetiracetam in the treatment of epilepsy. ( Brodie, MJ; French, JA, 2003) |
| "Levetiracetam also has a favourable pharmacokinetic profile characterised by rapid and nearly complete absorption, very low potential for drug interactions and a prolonged pharmacodynamic effect that permits twice-daily dosing." | 2.42 | Levetiracetam: treatment in epilepsy. ( Ben-Menachem, E, 2003) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Epilepsy is one of the commonest neurological conditions." | 2.42 | Levetiracetam in the management of epilepsy. ( Leach, JP, 2004) |
| "Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity." | 2.41 | Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002) |
| "Levetiracetam is a novel orally active antiepileptic drug with a unique preclinical profile." | 2.41 | Pharmacokinetic profile of levetiracetam: toward ideal characteristics. ( Patsalos, PN, 2000) |
| "Levetiracetam is an adjunctive treatment for partial-onset epileptic seizures." | 2.41 | Levetiracetam. ( Nash, EM; Sangha, KS, 2001) |
| "Levetiracetam is a new antiepileptic drug (AED) devoid of anticonvulsant activity in the two classic screening models for AEDs, the maximal electroshock and pentylenetetrazol seizure tests in both mice and rats." | 2.41 | Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? ( Klitgaard, H, 2001) |
| "Each antiepileptic drug has a characteristic pharmacokinetic profile, and the unique properties of each must be considered when selecting the optimal agent for a particular patient." | 2.41 | Pharmacokinetic considerations in prescribing antiepileptic drugs. ( Faught, E, 2001) |
| "A number of commonly used antiepileptic drugs (AEDs) produce severe adverse effects if they are introduced at their usual daily maintenance doses." | 2.41 | Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. ( Ferrendelli, JA, 2001) |
| "Levetiracetam is a novel antiepileptic drug (AED) with favorable pharmacologic characteristics and demonstrated activity in improving seizure control." | 2.41 | Efficacy of levetiracetam: a review of three pivotal clinical trials. ( Privitera, M, 2001) |
| "Levetiracetam is a Pregnancy Category C drug." | 2.41 | Safety profile of levetiracetam. ( Harden, C, 2001) |
| " The results of these studies indicate that higher doses need to be used for children (on a per-weight basis), and individuals with renal dysfunction require dosage modifications related to creatinine clearance." | 2.41 | Use of levetiracetam in special populations. ( French, J, 2001) |
| "The integrated summary of safety report submitted for regulatory review was examined to collate information about abnormal laboratory tests values and adverse event reports collected during the overall LEV development program." | 2.41 | A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. ( Cramer, JA; Edrich, P; French, J, 2001) |
| "Oxcarbazepine also has approval for monotherapy in partial seizures." | 2.41 | Newer therapies in the drug treatment of epilepsy. ( Biederman, TS; McAuley, JW; Moore, JL; Smith, JC, 2002) |
| "Epilepsy is one of the most common neurological disorders." | 2.39 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994) |
| "Levetiracetam (LEV) is an anti-seizure drug (ASD)." | 1.72 | Relationship between bone density and levetiracetam monotherapy in epilepsy patients. ( Aydın, Z; Gözükızıl, ST; Yalçın, AD, 2022) |
| "Levetiracetam (LEV) is an urgent control antiepileptic medication that offers relative lack of adverse effects and ease of monitoring." | 1.62 | Rapid administration of undiluted intravenous levetiracetam. ( Bonnin, S; Haller, JT; Radosevich, J, 2021) |
| "Levetiracetam has replaced sodium valproate as the most frequently prescribed ASM in pediatric patients." | 1.56 | Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018. ( Dai, H; Feng, J; Yu, L; Yu, Z, 2020) |
| "Levetiracetam (LEV) has an improved pharmacological profile and is one of the most commonly used antiepileptic drugs (AEDs)." | 1.56 | Behavioral alterations associated with levetiracetam in pediatric epilepsy. ( Cortes, C; Manterola, C, 2020) |
| "Levetiracetam was the most frequently prescribed AED (62/124, 50%)." | 1.48 | Safety of antiepileptic drugs in children and young people: A prospective cohort study. ( Choonara, I; Egunsola, O; Sammons, HM; Whitehouse, WP, 2018) |
| "Levetiracetam is a broad-spectrum anti-epileptic drug that is effective against both focal and generalized epilepsies." | 1.48 | Levetiracetam monotherapy for the treatment of infants with epilepsy. ( Arican, P; Cavusoglu, D; Gencpinar, P; Olgac Dundar, N, 2018) |
| "Carbamazepine was the most chosen antiepileptic drug for secondary prophylaxis, followed by valproate acid, and levetiracetam." | 1.48 | [A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan]. ( Abe, S; Fukuma, K; Higashida, K; Ihara, M; Nagatsuka, K; Okuno, Y; Tanaka, T; Tomari, S; Toyoda, K; Yamagami, H, 2018) |
| " At the onset of fever, the patients who presented epileptiform discharge were orally administered with LEV with a dose of 15-30 mg/kg per day twice daily for 1 week, thereafter, the dosage was gradually reduced until totally discontinued in the second week." | 1.48 | Intermittent oral levetiracetam reduced recurrence of febrile seizure accompanied with epileptiform discharge: a pilot study. ( Hu, LY; Li, H; Ma, SF; Shi, XY; Zhang, MN; Zou, LP, 2018) |
| "Aphasia is a language disorder characterised by loss of ability to produce or comprehend written or spoken language." | 1.48 | Adult-onset epileptic aphasia. ( Guerra, D; Marques Mendes, E; Mendes, A; Ribeiro, C, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| " Psychiatric symptoms occurring after initiation of AED therapy were considered as treatment emergent psychiatric adverse events (TE-PAEs) if they fulfilled the following conditions: (1) onset within 4 weeks after the beginning of AED therapy; (2) disappearance on drug discontinuation; (3) absence of any other identified possible concurrent cause." | 1.46 | Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. ( Belcastro, V; Bellocchi, S; Casiraghi, P; Gorgone, G; Mula, M; Pisani, F; Pisani, LR, 2017) |
| " Following adjunctive AED treatment, neuropsychiatric adverse effects led to AED withdrawal in 1." | 1.46 | Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. ( Brodie, MJ; Stephen, LJ; Wishart, A, 2017) |
| "To examine the prevalence and clinical correlates of fatigue as an adverse event (AE) of antiepileptic drug (AED) treatment in patients with epilepsy." | 1.46 | Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event? ( Agrawal, N; Cock, HR; Lozsadi, DA; Mula, M; von Oertzen, TJ; Yogarajah, M, 2017) |
| "Lacosamide (LCM) is a new antiepileptic drug (AED) used as adjunctive therapy in patients with partial seizures with or without secondary generalization, with a favorable pharmacokinetic profile that seems to be effective and well tolerated." | 1.46 | Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. ( Fabi, A; Giannarelli, D; Maialetti, A; Maschio, M; Vidiri, A; Villani, V; Zarabla, A, 2017) |
| "We assessed the prevalence and magnitude of neuropsychiatric adverse events (NPAEs) associated with antiepileptic drugs (AEDs) among patients with brain tumour-related epilepsy (BTRE)." | 1.46 | Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. ( Bedetti, C; Calabresi, P; Costa, C; Di Bonaventura, C; Dispenza, S; Eusebi, P; Maschio, M; Nardi Cesarini, E; Romoli, M; Siliquini, S, 2017) |
| " The aim of the study was to assess the risk of increased frequency of seizures or other adverse events after replacement of a brand-name LEV with a generic one." | 1.46 | Safety of switching from brand-name to generic levetiracetam in patients with epilepsy. ( Bosak, M; Słowik, A; Turaj, W, 2017) |
| "Levetiracetam treatment did not affect bone strength, bone mass, and bone turnover." | 1.46 | Effects of the Antiepileptic Drugs Phenytoin, Gabapentin, and Levetiracetam on Bone Strength, Bone Mass, and Bone Turnover in Rats. ( Izumo, N; Kanda, J; Kobayashi, Y; Onodera, K; Shimakura, T; Takahashi, HE; Wakabayashi, H; Yamamoto, N, 2017) |
| "• Valproic acid has a cumulative effect on inhibiting brain activity in epileptogenic regions." | 1.46 | Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes. ( Dante, M; Hu, Z; Li, K; Li, Q; Li, Z; Lu, G; Wu, H; Xu, Q; Yang, F; Zhang, Q; Zhang, Z, 2017) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "Perinatal arterial stroke is the most frequent form of cerebral infarction in children." | 1.46 | Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model. ( Auvin, S; Baud, O; Bonnin, P; Charriaut-Marlangue, C; Dupuis, N; Enderlin, J; Leger, PL; Morin, L; Perrotte, G, 2017) |
| "Depression was evaluated in all experimental groups using the tail suspension and sucrose preference test on days 1, 5, 10 and 15, 2 h after pentylenetetrazole challenge." | 1.46 | Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression. ( Goel, RK; Kaur, T; Singh, T, 2017) |
| "Levetiracetam was the most commonly used initial medication, with the majority (73%) of patients treated achieving partial or complete seizure control." | 1.46 | The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy. ( Chemali, Z; Gholipour, T; Mitchell, S; Sarkis, RA, 2017) |
| " Once patients respond to low-dose treatment, maintenance of the effective dosage may prolong response." | 1.43 | Clinical features of long-term low-dose levetiracetam treatment for epilepsy. ( Fukui, M; Nomura, S; Shimakawa, S; Tamai, H; Tanabe, T; Yoshikawa, S, 2016) |
| "Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 1.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| "All LEV-induced cADRs were mild skin rashes which occurred within 28 days of LEV exposure." | 1.43 | Levetiracetam-induced cutaneous adverse drug reactions were not associated with HLA genes in a small sample of Chinese patients with epilepsy. ( An, DM; Chen, JN; Hu, FY; Ren, JC; Wang, W; Zhou, D, 2016) |
| "Epilepsy has an impact on the reproductive system." | 1.43 | Effects of levetiracetam monotherapy on sperm parameters and sex hormones: Data from newly diagnosed patients with epilepsy. ( Bayraktutan, OF; Ceylan, M; Karabulut, I; Sonkaya, AR; Yalcin, A, 2016) |
| "Epilepsy was classified as focal in 65." | 1.43 | Epilepsy in Qatar: Causes, treatment, and outcome. ( Abuhadra, N; Al Hail, H; Al Jurdi, A; Alarcon, G; Alsamman, Y; Aqeel, F; Azar, N; Deleu, D; Elzafarany, A; Haddad, N; Laswi, M; Mahfoud, Z; Melikyan, G; Mesraoua, B; Streletz, L; Uthman, B, 2016) |
| "Levetiracetam (Lev) is a new antiepileptic drugs, proved to be effective and tolerance in regulatory trials, but these controlled trials do not always predict how useful a drug will be in day to day clinical practice, Retention rates can provide a better indication of efficacy and tolerability in everyday use." | 1.42 | Retention rates of levetiraceram in Chinese children and adolescents with epilepsy. ( Chen, YX; Feng, XF; Liu, L; Xiao, N, 2015) |
| "Weight gain and alopecia were the most common patient-reported CSEs in this study, and weight gain was the most likely cosmetic side effect to result in dosage adjustment or medication discontinuation." | 1.42 | Cosmetic side effects of antiepileptic drugs in adults with epilepsy. ( Buchsbaum, R; Chen, B; Choi, H; Detyniecki, K; Hirsch, LJ; Javed, A; Kato, K; Legge, A; Moeller, J, 2015) |
| "Hyponatremia is frequently seen in heart failure patients and has a high mortality rate." | 1.42 | The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia. ( Acaban, MB; Arı, H; Kahraman, F, 2015) |
| "Cyclobenzaprine has potential for sodium channel blockade and ventricular dysrhythmias although cardiac toxicity due to cyclobenzaprine alone is rare." | 1.42 | Cardiac sodium channel blockade after an intentional ingestion of lacosamide, cyclobenzaprine, and levetiracetam: Case report. ( Cao, D; Chua-Tuan, JL; Hoyte, CO; Iwanicki, JL, 2015) |
| "Catamenial epilepsy is a periodic increase in seizure frequency in women with epilepsy during menstruation, or at any specific point in the menstrual cycle." | 1.42 | Intermittent levetiracetam treatment in five patients with catamenial epilepsy. ( Chen, K; Liang, Y; Liu, J; Sun, H; Xie, Y; Yu, N, 2015) |
| "In four of ten rats, seizure frequency was unaltered by LEV (non-responders)." | 1.42 | Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats. ( Kang, TC; Ko, AR, 2015) |
| "Oxcarbazepine was most widely used, followed by valproic acid." | 1.42 | Trends in Antiepileptic Drug Prescriptions for Childhood Epilepsy at a Tertiary Children's Hospital in Korea, 2001-2012. ( Ah, YM; Cho, YS; Jung, AH; Kim, KJ; Lee, JY, 2015) |
| "Levetiracetam was started with a good response." | 1.40 | Levetiracetam following liver and kidney failure in late-onset anticonvulsant hypersensitivity syndrome. ( López-González, FJ; Novoa, D; Pardo, J; Pintos, E; Rodríguez-Osorio, X, 2014) |
| "Levetiracetam treatment resulted in a decrease of the percentage of CD4(+)CD25(+)-lymphocytes (26." | 1.40 | Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans. ( Bauer, S; Guenther, S; Hagge, M; Hamer, HM; Knake, S; Olmes, DG; Rosenow, F; Tackenberg, B, 2014) |
| " The canines were given three different dosage levels of anti-convulsant medication in an attempt to manipulate the excitability of the network." | 1.39 | A method for actively tracking excitability of brain networks using a fully implantable monitoring system. ( Cook, MJ; Freestone, DR; Frey, S; Giftakis, JE; Long, SN; Stypulkowski, PH, 2013) |
| " Adverse events occurred in only two patients who did not require LEV discontinuation." | 1.39 | Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy. ( Aihara, M; Kanemura, H; Sano, F; Sugita, K; Tando, T, 2013) |
| "Epilepsy is a chronic neurological disorder characterized by recurrent seizures, and is highly resistant to medication with up to 40% of patients continuing to experience seizures whilst taking oral antiepileptic drugs." | 1.38 | In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing levetiracetam, for the treatment of epilepsy. ( Campbell, TE; Cook, MJ; Halliday, AJ; McLean, KJ; Nelson, TS; Razal, JM; Wallace, GG, 2012) |
| "Complete seizure freedom was defined as a favorable outcome." | 1.38 | Levetiracetam may favorably affect seizure outcome after temporal lobectomy. ( Bingaman, W; Irwin, AI; Jehi, LE; Kayyali, H; Najm, I; Vadera, S, 2012) |
| "Levetiracetam is a commonly prescribed antiepileptic drug, and is generally well tolerated, but can eventually cause behavioral disturbances." | 1.38 | Levetiracetam-induced reversible autistic regression. ( Camacho, A; Espín, JC; Nuñez, N; Simón, R, 2012) |
| "Levetiracetam has shown good safety/tolerability and efficacy in regulatory trials." | 1.37 | The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year. ( Blazejewski, S; Blin, P; Droz-Perroteau, C; Dureau-Pournin, C; Fourrier-Réglat, A; Jové, J; Marchal, C; Moore, N; Pollet, C; Robinson, P; Vespignani, H, 2011) |
| "Pretreatment with levetiracetam failed to exert any antiepileptogenic effect." | 1.37 | Protein kinase inhibitor as a potential candidate for epilepsy treatment. ( Gajda, Z; Horváth, Z; Kéri, G; Orfi, L; Szántai-Kis, C; Szente, M; Török, R, 2011) |
| "Levetiracetam (LEV) is a broad spectrum antiepileptic drug (AED) with a unique mechanism of action." | 1.37 | Levetiracetam monotherapy--outcomes from an epilepsy clinic. ( Brodie, MJ; Kelly, K; Parker, P; Stephen, LJ, 2011) |
| " Plasma concentrations (pc), interactions between drugs in the ICU context, adverse effects and seizure occurrences were observed and recorded." | 1.37 | Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage. ( Bjeljac, M; Keller, E; Mink, S; Muroi, C; Seule, M, 2011) |
| "Levetiracetam treatment lasted 8 months." | 1.37 | Epileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction. ( Athanassiadou, F; Balakou, E; Hatzipantelis, E; Pana, ZD; Papageorgiou, T; Pavlou, E; Tragiannidis, A; Tsotoulidou, V, 2011) |
| "Levetiracetam (LEV) is a novel antiepileptic drug (AED) which was discovered in early 1980s and soon, in 1999 FDA approved LEV for the management of partial onset seizure." | 1.37 | Levetiracetam. ( Dave, P; Gohel, KH; Krishna, K; Raut, AL, 2011) |
| "Lacosamide (Vimpat) is a newly licensed novel antiepileptic drug." | 1.36 | Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. ( Eggers, C; Hofer, T; Resch, R; Tilz, C, 2010) |
| "Levetiracetam therapy was effective in 58." | 1.36 | Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. ( Cai, F; Cao, J; Li, S; Xiao, N, 2010) |
| " LEV-SC significantly depended on daily dosage and the interval between the time the medication was taken and the time of blood extraction." | 1.36 | [Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy]. ( Bauer, J; Burr, W; Pfeiffer, C, 2010) |
| " Mean dosage was 1,643 mg/day (range 500-4,000)." | 1.35 | Intravenous levetiracetam for epileptic seizure emergencies in older people. ( Beyenburg, S; Maraite, N; Reuber, M, 2009) |
| "To develop a population pharmacokinetic model to evaluate the demographic and physiologic determinants of levetiracetam (LEV) pharmacokinetics (PK) and to suggest recommended doses of LEV in children." | 1.35 | Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. ( Chhun, S; Chiron, C; Dulac, O; Jullien, V; Pons, G; Rey, E, 2009) |
| "Levetiracetam (LVM) is a novel AED that does not undergo extensive liver metabolism, does not require drug level monitoring, and is not associated with hemodynamic instability." | 1.35 | Safety and efficacy of levetiracetam for critically ill patients with seizures. ( Divertie, GD; Freeman, WD; Nau, KM; Valentino, AK, 2009) |
| "Epilepsy was most common among those with maternal deletions and unknown subtypes, with catastrophic epilepsies present in only these two subtypes." | 1.35 | Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. ( Braun, EK; Bruno, P; Conant, KD; Nespeca, MP; Said, RR; Thibert, RL; Thiele, EA, 2009) |
| " Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32 mA, 6 Hz, 3s stimulus duration) delivered via ocular electrodes and isobolographic analysis for parallel and non-parallel dose-response effects was used to characterize the consequent anticonvulsant interactions between the various drug combinations." | 1.35 | Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. ( Luszczki, JJ; Patsalos, PN; Wlaz, A; Wojda, E, 2009) |
| "Levetiracetam (LEV) is a novel antiepileptic drug (AED) that has recently obtained marketing authorisation for use in children." | 1.34 | Retention rate of levetiracetam in children with intractable epilepsy at 1 year. ( Buch, S; Crane, J; Donnelly, J; Gosalakkal, J; Mordekar, S; Mukhtyar, B; Peake, D; Philip, S; Rittey, C; Wheway, R; Whitehouse, WP, 2007) |
| " LEV and FBM brain concentrations were measured by HPLC in order to determine any pharmacokinetic contribution to the observed antiseizure effect." | 1.34 | Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model. ( Andres-Mach, MM; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2007) |
| "Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0." | 1.34 | Levetiracetam use in critically ill patients. ( Meckler, JM; Privitera, MD; Shutter, LA; Szaflarski, JP; Szaflarski, M; Yates, SL, 2007) |
| "Levetiracetam was implicated in the pathogenesis of the interstitial pneumonitis." | 1.34 | Levetiracetam-induced diffuse interstitial lung disease. ( Castaneda, GY; Jennings, T; Newsome, SD; Xue, LY, 2007) |
| "To investigate the hypothesis that some patients with epilepsy are generally prone to develop psychiatric adverse events (PAEs) during antiepileptic drug (AED) therapy irrespective of the mechanism of action of the drugs." | 1.34 | Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. ( Mula, M; Sander, JW; Trimble, MR, 2007) |
| "Levetiracetam (Lev) is a new antiepileptic drug with a distinct mechanism of action, shown in regulatory trials to be effective." | 1.33 | The long term retention of levetiracetam in a large cohort of patients with epilepsy. ( Bell, GS; Depondt, C; Duncan, JS; Koepp, MJ; Mitchell, T; Sander, JW; Yuen, AW, 2006) |
| " Brain AED concentrations were determined to ascertain any pharmacokinetic contribution to the observed antiseizure effect." | 1.33 | Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis. ( Andres, MM; Cioczek-Czuczwar, A; Czuczwar, P; Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2006) |
| "Levetiracetam was well tolerated and effective as add-on treatment in partial and generalised seizures." | 1.32 | [Levetiracetam in the treatment of epilepsy]. ( Brodtkorb, E; Johannessen, SI; Lossius, R; Mariero Klees, T; Nakken, KO, 2003) |
| "Levetiracetam (LEV) is a recently approved anticonvulsant with proven efficacy and safety in the treatment of partial seizures." | 1.32 | Discontinuation of levetiracetam because of behavioral side effects: a case-control study. ( Beniak, TE; Gumnit, RJ; Leppik, IE; Matchinsky, DJ; Rarick, J; Tran, T; Walczak, TS; White, JR, 2003) |
| "Levetiracetam (LEV) is a new antiepileptic drug approved as add-on therapy." | 1.32 | Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. ( Jürgens, U; May, TW; Rambeck, B, 2003) |
| "Levetiracetam is a new anti-epileptic drug that is currently not licensed for use in children." | 1.32 | Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. ( Appleton, RE; Tan, MJ, 2004) |
| "Levetiracetam (LEV) is a recently marketed novel anti-epileptic drug with a promising efficacy and safety profile." | 1.32 | Enterocolitis: an adverse event in refractory epilepsy patients treated with levetiracetam? ( Boon, P; Bosman, T; Claeys, P; De Clercq, M; De Reuck, J; Van Vlierberghe, H; Vonck, K, 2004) |
| "Levetiracetam has recently been approved as an adjunctive medication for partial seizures and frequently will be added to phenytoin." | 1.31 | Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. ( Baltes, E; Browne, TR; Jensen, CM; Josephs, E; Leppik, IE; Paz, J; Szabo, GK, 2000) |
| "Levetiracetam is a new anticonvulsant (AED) with a novel mechanism of action." | 1.31 | Levetiracetam psychosis in children with epilepsy. ( Bergey, GK; Freeman, JM; Kossoff, EH; Vining, EP, 2001) |
| " Before the experiments with chronic administration of levetiracetam at different doses, we determined the pharmacokinetics of the drug after i." | 1.30 | Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. ( Hönack, D; Löscher, W; Rundfeldt, C, 1998) |
| "In the GAERS model of petit mal epilepsy, levetiracetam markedly suppressed spontaneous spike-and-wave discharge (SWD) but left the underlying EEG trace normal." | 1.29 | Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. ( Boehrer, A; Gower, AJ; Hirsch, E; Marescaux, C; Noyer, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.91) | 18.7374 |
| 1990's | 9 (1.63) | 18.2507 |
| 2000's | 240 (43.48) | 29.6817 |
| 2010's | 274 (49.64) | 24.3611 |
| 2020's | 24 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Kurishima, A | 1 |
| Hayashi, M | 1 |
| Shimozato, R | 1 |
| Isozaki, R | 1 |
| Shioda, T | 1 |
| Iijima, A | 1 |
| Labh, R | 1 |
| Gupta, R | 2 |
| Narang, M | 1 |
| Halder, S | 1 |
| Kar, R | 1 |
| Chaneva, OG | 1 |
| Viteva, EI | 1 |
| Gözükızıl, ST | 1 |
| Aydın, Z | 1 |
| Yalçın, AD | 1 |
| Lob, K | 1 |
| Bassell-Hawkins, J | 1 |
| Patil, R | 1 |
| Nie, D | 1 |
| Bartolini, L | 1 |
| Komori, R | 1 |
| Matsuo, T | 1 |
| Yokota-Nakatsuma, A | 1 |
| Hashimoto, R | 1 |
| Kubo, S | 1 |
| Kozawa, C | 1 |
| Kono, T | 1 |
| Ishihara, Y | 1 |
| Itoh, K | 1 |
| Tekin, U | 2 |
| Tekin, E | 1 |
| Uçar, HN | 1 |
| D'Onofrio, G | 1 |
| Riva, A | 1 |
| Amadori, E | 1 |
| Lattanzi, S | 1 |
| Rose, K | 1 |
| Verrotti, A | 6 |
| Striano, P | 3 |
| Cheraghmakani, H | 1 |
| Rezapour, M | 1 |
| Asghari, F | 1 |
| Alizadeh-Navaei, R | 1 |
| Ghazaeian, M | 1 |
| Tabrizi, N | 1 |
| Schelhaas, M | 1 |
| Wegner, I | 1 |
| Edens, M | 1 |
| Wammes-Van Der Heijden, E | 1 |
| Touw, D | 1 |
| Ter Horst, P | 1 |
| de Toledo, M | 1 |
| de la Fuente, E | 1 |
| Ramos, C | 1 |
| Ferreiros-Martinez, R | 1 |
| Muro, I | 1 |
| Vieira Campos, A | 1 |
| de Toledo, MP | 1 |
| Lagares, A | 1 |
| Sobrado, M | 1 |
| Ovejero-Benito, MC | 1 |
| Yamamoto, Y | 1 |
| Ohta, A | 1 |
| Usui, N | 1 |
| Imai, K | 1 |
| Kagawa, Y | 1 |
| Takahashi, Y | 1 |
| van der Westhuizen, C | 1 |
| Botha, TL | 1 |
| Finger-Baier, K | 1 |
| Brouwer, G | 1 |
| Wolmarans, W | 1 |
| Swami, M | 1 |
| Kaushik, JS | 1 |
| Hernández-Mitre, MP | 1 |
| Medellín-Garibay, SE | 1 |
| Rodríguez-Leyva, I | 1 |
| Rodríguez-Pinal, CJ | 1 |
| Zarazúa, S | 1 |
| Jung-Cook, HH | 1 |
| Roberts, JA | 1 |
| Romano-Moreno, S | 1 |
| Milán-Segovia, RDC | 1 |
| Kanemura, H | 4 |
| Sano, F | 4 |
| Hoshino, H | 1 |
| Takayama, K | 1 |
| Aihara, M | 4 |
| Yu, L | 1 |
| Feng, J | 2 |
| Yu, Z | 1 |
| Dai, H | 1 |
| Sharma, D | 1 |
| Hussain, AM | 1 |
| Sharma, SS | 1 |
| Cortes, C | 1 |
| Manterola, C | 1 |
| Yıldırım, M | 2 |
| Bektaş, Ö | 1 |
| Akıncı Göktaş, Ö | 1 |
| Yüksel, MF | 1 |
| Şahin, S | 1 |
| Tıraş Teber, S | 1 |
| Hasegawa, N | 1 |
| Tohyama, J | 1 |
| Krasowski, MD | 1 |
| Long, TA | 1 |
| Snozek, CLH | 1 |
| Dizon, A | 1 |
| Magnani, B | 1 |
| Melanson, SEF | 1 |
| Zhao, T | 1 |
| Li, HJ | 1 |
| Yu, J | 1 |
| Wang, TT | 1 |
| Ma, L | 1 |
| Sun, L | 1 |
| Sun, Y | 1 |
| Yu, LH | 1 |
| Kumar, J | 1 |
| Meena, J | 1 |
| Yadav, A | 1 |
| Haller, JT | 1 |
| Bonnin, S | 1 |
| Radosevich, J | 1 |
| Belcastro, V | 4 |
| Pisani, LR | 1 |
| Bellocchi, S | 1 |
| Casiraghi, P | 1 |
| Gorgone, G | 1 |
| Mula, M | 6 |
| Pisani, F | 3 |
| Ukai, K | 1 |
| Watanabe, M | 1 |
| Tan, J | 1 |
| Paquette, V | 1 |
| Levine, M | 1 |
| Ensom, MHH | 1 |
| Markoula, S | 1 |
| Chatzistefanidis, D | 1 |
| Gatzonis, S | 2 |
| Siatouni, A | 1 |
| Siarava, E | 1 |
| Verentzioti, A | 1 |
| Kyritsis, AP | 1 |
| Patsalos, PN | 10 |
| Steinhoff, BJ | 4 |
| Bacher, M | 1 |
| Bucurenciu, I | 1 |
| Hillenbrand, B | 1 |
| Intravooth, T | 1 |
| Kornmeier, R | 1 |
| Kurth, C | 1 |
| Stockinger, J | 1 |
| Staack, AM | 1 |
| Baysal, M | 1 |
| Ilgin, S | 1 |
| Kilic, G | 1 |
| Kilic, V | 1 |
| Ucarcan, S | 1 |
| Atli, O | 1 |
| Karaś-Ruszczyk, K | 1 |
| Kuczyńska, J | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Kurkowska-Jastrzębska, I | 1 |
| Bienkowski, P | 1 |
| Restel, M | 1 |
| Samochowiec, J | 1 |
| Mierzejewski, P | 1 |
| Stephen, LJ | 3 |
| Wishart, A | 1 |
| Brodie, MJ | 5 |
| Company-Albir, MJ | 1 |
| Ruíz-Ramos, J | 1 |
| Solana Altabella, A | 1 |
| Marqués-Miñana, MR | 1 |
| Vicent, C | 1 |
| Poveda, JL | 1 |
| von Oertzen, TJ | 2 |
| Cock, HR | 3 |
| Yogarajah, M | 1 |
| Lozsadi, DA | 2 |
| Agrawal, N | 2 |
| Bektaş, G | 1 |
| Özkan, MU | 1 |
| Yıldız, EP | 1 |
| Çalışkan, M | 1 |
| Özmen, M | 2 |
| Aydınlı, N | 1 |
| Reimers, A | 2 |
| Olsson, P | 1 |
| Nilsson, J | 1 |
| Hoff, E | 1 |
| Reis, M | 1 |
| Strandberg, M | 1 |
| Lundgren, A | 1 |
| Källén, K | 2 |
| Maschio, M | 6 |
| Zarabla, A | 3 |
| Maialetti, A | 1 |
| Fabi, A | 4 |
| Vidiri, A | 3 |
| Villani, V | 1 |
| Giannarelli, D | 1 |
| Kwan, P | 1 |
| Palmini, A | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Marson, AG | 5 |
| Duke, JD | 1 |
| Ryan, PB | 1 |
| Suchard, MA | 1 |
| Hripcsak, G | 1 |
| Jin, P | 1 |
| Reich, C | 1 |
| Schwalm, MS | 1 |
| Khoma, Y | 1 |
| Wu, Y | 2 |
| Xu, H | 1 |
| Shah, NH | 1 |
| Banda, JM | 1 |
| Schuemie, MJ | 1 |
| Bedetti, C | 1 |
| Romoli, M | 1 |
| Di Bonaventura, C | 2 |
| Nardi Cesarini, E | 1 |
| Eusebi, P | 1 |
| Siliquini, S | 1 |
| Dispenza, S | 1 |
| Calabresi, P | 3 |
| Costa, C | 3 |
| Bosak, M | 1 |
| Słowik, A | 1 |
| Turaj, W | 1 |
| Taneja, R | 1 |
| Hunter, K | 1 |
| Burakgazi-Dalkilic, E | 1 |
| Carran, M | 1 |
| Kelly, D | 1 |
| Raimondi, F | 1 |
| Shihab, N | 1 |
| Lampe, R | 1 |
| Manens, J | 1 |
| Sharp, N | 1 |
| Feyissa, AM | 1 |
| Barnes Heller, H | 1 |
| Kanda, J | 1 |
| Izumo, N | 1 |
| Kobayashi, Y | 1 |
| Onodera, K | 1 |
| Shimakura, T | 1 |
| Yamamoto, N | 1 |
| Takahashi, HE | 1 |
| Wakabayashi, H | 1 |
| Sakata, S | 1 |
| Saeki, S | 1 |
| Terasaki, Y | 1 |
| Natori, Y | 1 |
| Fujii, K | 1 |
| Rosati, A | 2 |
| Ilvento, L | 1 |
| Lucenteforte, E | 1 |
| Pugi, A | 1 |
| Crescioli, G | 1 |
| McGreevy, KS | 1 |
| Virgili, G | 1 |
| Mugelli, A | 1 |
| De Masi, S | 1 |
| Guerrini, R | 1 |
| Egunsola, O | 2 |
| Choonara, I | 2 |
| Sammons, HM | 2 |
| Whitehouse, WP | 2 |
| Arican, P | 1 |
| Gencpinar, P | 2 |
| Cavusoglu, D | 2 |
| Olgac Dundar, N | 1 |
| Łukawski, K | 1 |
| Andres-Mach, M | 1 |
| Czuczwar, M | 1 |
| Łuszczki, JJ | 1 |
| Kruszyński, K | 1 |
| Czuczwar, SJ | 3 |
| Parveen, B | 1 |
| Tripathi, M | 2 |
| Vohora, D | 1 |
| Higashida, K | 1 |
| Tanaka, T | 2 |
| Yamagami, H | 1 |
| Tomari, S | 1 |
| Fukuma, K | 1 |
| Okuno, Y | 1 |
| Abe, S | 3 |
| Nagatsuka, K | 1 |
| Toyoda, K | 1 |
| Ihara, M | 1 |
| Novitskaya, Y | 1 |
| Hintz, M | 2 |
| Schulze-Bonhage, A | 5 |
| Liu, S | 1 |
| Wang, L | 4 |
| Cai, XT | 1 |
| Zhou, H | 1 |
| Yu, D | 1 |
| Wang, Z | 1 |
| Hu, LY | 1 |
| Shi, XY | 1 |
| Li, H | 1 |
| Zhang, MN | 1 |
| Ma, SF | 1 |
| Zou, LP | 1 |
| Gha-Hyun, L | 1 |
| Dae, SJ | 1 |
| Marques Mendes, E | 1 |
| Mendes, A | 1 |
| Ribeiro, C | 1 |
| Guerra, D | 1 |
| Takagi, K | 1 |
| El-Haggar, SM | 1 |
| Mostafa, TM | 1 |
| Allah, HMS | 1 |
| Akef, GH | 1 |
| Hirsch, M | 1 |
| Specht, A | 1 |
| Attilakos, A | 3 |
| Tsirouda, M | 3 |
| Dinopoulos, A | 3 |
| Prasouli, A | 1 |
| Garoufi, A | 3 |
| Baudou, E | 1 |
| Cances, C | 1 |
| Dimeglio, C | 1 |
| Hachon Lecamus, C | 1 |
| Lee, YY | 1 |
| Ko, JH | 1 |
| Chung, WH | 1 |
| Nakken, KO | 5 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Özkale, Y | 1 |
| Özkale, M | 1 |
| Saygi, S | 2 |
| Erol, I | 1 |
| López-Saca, JM | 1 |
| Vaquero, J | 1 |
| Larumbe, A | 1 |
| Urdíroz, J | 1 |
| Centeno, C | 1 |
| Phabphal, K | 1 |
| Geater, A | 1 |
| Limapichat, K | 1 |
| Sathirapanya, P | 1 |
| Setthawatcharawanich, S | 1 |
| Leelawattana, R | 1 |
| Yamashita, S | 1 |
| Chiyonobu, T | 1 |
| Yoshida, M | 1 |
| Moroto, M | 1 |
| Morita, T | 1 |
| Morioka, S | 1 |
| Kato, M | 2 |
| Saitsu, H | 1 |
| Morimoto, M | 1 |
| Hosoi, H | 1 |
| Borggraefe, I | 2 |
| Bonfert, M | 1 |
| Bast, T | 1 |
| Neubauer, BA | 1 |
| Schotten, KJ | 1 |
| Maßmann, K | 1 |
| Noachtar, S | 1 |
| Tuxhorn, I | 3 |
| May, TW | 3 |
| Heinen, F | 1 |
| Pressler, RM | 1 |
| Mangum, B | 1 |
| Popov, IuV | 1 |
| Iakovleva, IuA | 1 |
| Koo, DL | 3 |
| Hwang, KJ | 1 |
| Kim, D | 2 |
| Kim, YJ | 1 |
| Kim, JY | 1 |
| Shin, W | 1 |
| Kim, MR | 1 |
| Joo, EY | 3 |
| Lee, JM | 1 |
| Hong, SB | 3 |
| Bertsche, A | 1 |
| Neininger, MP | 1 |
| Dahse, AJ | 1 |
| Syrbe, S | 1 |
| Bernhard, MK | 1 |
| Frontini, R | 1 |
| Kiess, W | 1 |
| Bertsche, T | 1 |
| Merkenschlager, A | 1 |
| Xiaotian, X | 1 |
| Hengzhong, Z | 1 |
| Yao, X | 1 |
| Zhipan, Z | 1 |
| Daoliang, X | 1 |
| Yumei, W | 1 |
| Kim, DW | 1 |
| Lee, SY | 1 |
| Shon, YM | 1 |
| Kim, JH | 1 |
| Kang, BS | 1 |
| Moon, HJ | 1 |
| Kim, YS | 1 |
| Lee, ST | 2 |
| Jung, KH | 2 |
| Chu, K | 2 |
| Lee, SK | 2 |
| Grimminger, T | 1 |
| Pernhorst, K | 1 |
| Surges, R | 2 |
| Niehusmann, P | 1 |
| Priebe, L | 1 |
| von Lehe, M | 1 |
| Hoffmann, P | 1 |
| Cichon, S | 1 |
| Schoch, S | 2 |
| Becker, AJ | 1 |
| Dureau-Pournin, C | 2 |
| Pédespan, JM | 1 |
| Droz-Perroteau, C | 2 |
| Lavernhe, G | 1 |
| Mann, M | 1 |
| Pollet, C | 2 |
| Robinson, P | 2 |
| Jové, J | 2 |
| Moore, N | 2 |
| Fourrier-Réglat, A | 2 |
| Freestone, DR | 1 |
| Long, SN | 1 |
| Frey, S | 1 |
| Stypulkowski, PH | 1 |
| Giftakis, JE | 1 |
| Cook, MJ | 2 |
| Kikuchi, T | 1 |
| Takahashi, N | 1 |
| Nakamura, K | 1 |
| Hayasaka, K | 1 |
| Rodríguez-Osorio, X | 1 |
| Pardo, J | 1 |
| López-González, FJ | 1 |
| Novoa, D | 1 |
| Pintos, E | 1 |
| Mbizvo, GK | 1 |
| Dixon, P | 1 |
| Hutton, JL | 2 |
| Rossetti, AO | 1 |
| Jeckelmann, S | 1 |
| Novy, J | 2 |
| Roth, P | 2 |
| Weller, M | 2 |
| Stupp, R | 2 |
| Zou, X | 1 |
| Hong, Z | 1 |
| Zhou, D | 3 |
| Shallcross, R | 3 |
| Bromley, RL | 3 |
| Cheyne, CP | 2 |
| García-Fiñana, M | 2 |
| Irwin, B | 4 |
| Morrow, J | 3 |
| Baker, GA | 3 |
| Rauchenzauner, M | 6 |
| Roscia, S | 1 |
| Prieschl, M | 1 |
| Wildt, L | 2 |
| Haberlandt, E | 2 |
| Baumann, M | 1 |
| Rostasy, K | 2 |
| Agostinelli, S | 1 |
| Pizzolorusso, A | 1 |
| Luef, G | 7 |
| Yılmaz, T | 1 |
| Akça, M | 1 |
| Turan, Y | 1 |
| Ocak, H | 1 |
| Kamaşak, K | 1 |
| Paschalidou, M | 2 |
| Moustaki, M | 1 |
| Siafakas, N | 2 |
| Papaevangelou, V | 1 |
| Yazal Erdem, A | 1 |
| Azık, F | 1 |
| Tavil, B | 1 |
| Teber, S | 1 |
| Tunç, B | 1 |
| Uçkan, D | 1 |
| Ohyama, T | 1 |
| Sugita, K | 3 |
| Guenther, S | 1 |
| Bauer, S | 2 |
| Hagge, M | 1 |
| Knake, S | 2 |
| Olmes, DG | 1 |
| Tackenberg, B | 1 |
| Rosenow, F | 3 |
| Hamer, HM | 3 |
| Ito, S | 1 |
| Oguni, H | 1 |
| Ohtsuka, Y | 1 |
| Halma, E | 1 |
| de Louw, AJ | 1 |
| Klinkenberg, S | 1 |
| Aldenkamp, AP | 9 |
| IJff, DM | 1 |
| Majoie, M | 5 |
| Naha, S | 1 |
| Naha, K | 1 |
| Hande, HM | 1 |
| Vivek, G | 1 |
| Fujikawa, M | 1 |
| Kishimoto, Y | 1 |
| Kakisaka, Y | 1 |
| Jin, K | 1 |
| Kato, K | 2 |
| Iwasaki, M | 1 |
| Nakasato, N | 1 |
| Vajda, FJ | 1 |
| O'Brien, TJ | 3 |
| Lander, CM | 2 |
| Graham, J | 2 |
| Eadie, MJ | 2 |
| Wehner, T | 1 |
| Chinnasami, S | 1 |
| Bell, GS | 2 |
| Duncan, JS | 2 |
| Sander, JW | 14 |
| Tan, HJ | 1 |
| Singh, J | 1 |
| de Goede, C | 1 |
| Arık, AE | 1 |
| Bağırıcı, F | 1 |
| Sefil, F | 1 |
| Marangoz, C | 1 |
| Rémi, C | 1 |
| Lorenzl, S | 1 |
| Vyhnalek, B | 1 |
| Rastorfer, K | 1 |
| Feddersen, B | 1 |
| Yeap, LL | 1 |
| Lo, YL | 1 |
| Ali, K | 1 |
| Zeng, TF | 1 |
| Li, YH | 1 |
| An, DM | 2 |
| Chen, L | 2 |
| Lei, D | 1 |
| Zhang, B | 1 |
| Li, JM | 1 |
| Naik, GS | 1 |
| Kodagali, R | 1 |
| Mathew, BS | 1 |
| Thomas, M | 1 |
| Prabha, R | 1 |
| Mathew, V | 1 |
| Fleming, DH | 1 |
| Feng, XF | 1 |
| Chen, YX | 1 |
| Liu, L | 2 |
| Xiao, N | 3 |
| Chen, B | 1 |
| Choi, H | 1 |
| Hirsch, LJ | 3 |
| Moeller, J | 1 |
| Javed, A | 1 |
| Legge, A | 1 |
| Buchsbaum, R | 3 |
| Detyniecki, K | 1 |
| Chen, J | 2 |
| Cai, F | 2 |
| Jiang, L | 1 |
| Hu, Y | 2 |
| Feng, C | 1 |
| Lindstrøm, P | 1 |
| Andersen, H | 1 |
| Mustafa, Z | 1 |
| Mohanalingham, K | 1 |
| Packer, RM | 1 |
| Nye, G | 1 |
| Porter, SE | 1 |
| Volk, HA | 2 |
| Arı, H | 1 |
| Kahraman, F | 1 |
| Acaban, MB | 1 |
| Tacke, M | 1 |
| Li, MQ | 1 |
| Zhang, WW | 1 |
| Chen, T | 1 |
| Okumura, A | 2 |
| Arai, E | 1 |
| Kitamura, Y | 1 |
| Ikeno, M | 1 |
| Fujimaki, T | 1 |
| Yamamoto, T | 1 |
| Shimizu, T | 1 |
| Chua-Tuan, JL | 1 |
| Cao, D | 1 |
| Iwanicki, JL | 1 |
| Hoyte, CO | 1 |
| Smith, G | 1 |
| Wagner, JL | 1 |
| Edwards, JC | 1 |
| Serajee, FJ | 1 |
| Huq, AM | 1 |
| Weijenberg, A | 1 |
| Brouwer, OF | 1 |
| Callenbach, PM | 1 |
| Douros, K | 1 |
| Yuan, Y | 1 |
| Peizhi, Z | 1 |
| Maling, G | 1 |
| Wu, L | 1 |
| Yunhe, M | 1 |
| Xiang, W | 1 |
| Qing, M | 1 |
| Yanhui, L | 1 |
| Ruofei, L | 1 |
| Jiewen, L | 1 |
| Issa, NP | 1 |
| Fisher, WG | 1 |
| Narayanan, JT | 1 |
| Liu, J | 2 |
| Yu, N | 1 |
| Sun, H | 1 |
| Liang, Y | 1 |
| Xie, Y | 1 |
| Chen, K | 1 |
| Yoshikawa, S | 1 |
| Shimakawa, S | 1 |
| Fukui, M | 1 |
| Nomura, S | 1 |
| Tanabe, T | 1 |
| Tamai, H | 1 |
| Dilena, R | 1 |
| Traverso, M | 1 |
| Viri, M | 1 |
| Cristofori, G | 1 |
| Tadini, L | 1 |
| Barbieri, S | 1 |
| Romeo, A | 1 |
| Zara, F | 1 |
| Thompson, K | 1 |
| Pohlmann-Eden, B | 3 |
| Campbell, LA | 1 |
| Abel, H | 1 |
| Matsuo, M | 1 |
| Fuji, A | 1 |
| Matsuzaka, T | 1 |
| Baba, H | 1 |
| Toda, K | 1 |
| Ono, T | 1 |
| Tanaka, S | 1 |
| Sato, T | 1 |
| Moriuchi, H | 1 |
| Ko, AR | 1 |
| Kang, TC | 2 |
| Cho, YS | 1 |
| Ah, YM | 1 |
| Jung, AH | 1 |
| Kim, KJ | 2 |
| Lee, JY | 1 |
| Yates, SL | 2 |
| Fakhoury, T | 1 |
| Liang, W | 1 |
| Eckhardt, K | 1 |
| Borghs, S | 1 |
| D'Souza, J | 1 |
| Janszky, J | 2 |
| Enoki, H | 1 |
| Yokota, T | 1 |
| Okanishi, T | 1 |
| Vari, MS | 1 |
| Pinto, F | 1 |
| Mencaroni, E | 1 |
| Giudizioso, G | 1 |
| Minetti, C | 1 |
| La Neve, A | 1 |
| Francavilla, T | 1 |
| Piccioli, M | 1 |
| Striano, S | 1 |
| del Gaudio, L | 1 |
| Tovo, P | 1 |
| Vajda, FJE | 1 |
| Park, SJ | 1 |
| Lee, HB | 1 |
| Ahn, MH | 1 |
| Park, S | 1 |
| Choi, EJ | 1 |
| Lee, HJ | 1 |
| Ryu, HU | 1 |
| Kang, JK | 2 |
| Hong, JP | 1 |
| Kawakami, Y | 1 |
| Okazaki, T | 1 |
| Takase, M | 1 |
| Fujino, O | 1 |
| Itoh, Y | 1 |
| Karalok, ZS | 1 |
| Arhan, EP | 1 |
| Erdogan, KM | 1 |
| Gurkas, E | 1 |
| Fredsø, N | 1 |
| Sabers, A | 2 |
| Toft, N | 1 |
| Møller, A | 1 |
| Berendt, M | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Artemiadis, AK | 1 |
| Lambrinoudaki, I | 2 |
| Voskou, P | 1 |
| Tsivgoulis, G | 1 |
| Safouris, A | 1 |
| Bougea, A | 1 |
| Giannopoulos, S | 1 |
| Triantafyllou, N | 2 |
| Happold, C | 1 |
| Gorlia, T | 1 |
| Chinot, O | 1 |
| Gilbert, MR | 1 |
| Nabors, LB | 1 |
| Wick, W | 1 |
| Pugh, SL | 1 |
| Hegi, M | 1 |
| Cloughesy, T | 1 |
| Reardon, DA | 1 |
| Perry, JR | 1 |
| Mehta, MP | 1 |
| Hakami, T | 1 |
| Petty, SJ | 1 |
| Sakellarides, M | 1 |
| Christie, J | 1 |
| Kantor, S | 1 |
| Todaro, M | 1 |
| Gorelik, A | 1 |
| Seibel, MJ | 1 |
| Yerra, R | 1 |
| Wark, JD | 1 |
| Abou-Khalil, BW | 2 |
| Tekgül, H | 1 |
| Dündar, NO | 1 |
| Arzimanoglou, A | 1 |
| Lösch, C | 1 |
| Garate, P | 1 |
| Bentz, J | 1 |
| Selvaraj, V | 1 |
| Madabushi, JS | 1 |
| Gunasekar, P | 1 |
| Singh, SP | 1 |
| Töllner, K | 1 |
| Twele, F | 1 |
| Löscher, W | 2 |
| Contin, M | 4 |
| Alberghini, L | 1 |
| Candela, C | 1 |
| Benini, G | 1 |
| Riva, R | 4 |
| Takeuchi, T | 1 |
| Natsume, J | 1 |
| Kidokoro, H | 1 |
| Ishihara, N | 1 |
| Yamamoto, H | 1 |
| Azuma, Y | 1 |
| Ito, Y | 1 |
| Kurahashi, N | 1 |
| Tsuji, T | 1 |
| Suzuki, M | 1 |
| Itomi, K | 1 |
| Yamada, K | 1 |
| Kurahashi, H | 1 |
| Maruyama, K | 1 |
| Negoro, T | 1 |
| Watanabe, K | 1 |
| Kojima, S | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Hu, FY | 1 |
| Wang, W | 1 |
| Ren, JC | 1 |
| Chen, JN | 1 |
| Sarangi, SC | 1 |
| Kakkar, AK | 1 |
| Gupta, YK | 1 |
| Tekcan, A | 1 |
| Tural, S | 1 |
| Elbistan, M | 1 |
| Guvenc, T | 1 |
| Ayas, B | 1 |
| Kara, N | 1 |
| Chen, W | 1 |
| Tan, Y | 1 |
| Ge, Y | 1 |
| Chen, Y | 1 |
| Liu, X | 2 |
| Albsoul-Younes, A | 1 |
| Gharaibeh, L | 1 |
| Murtaja, AA | 1 |
| Masri, A | 1 |
| Alabbadi, I | 1 |
| Al-Qudah, AA | 1 |
| Liu, XM | 1 |
| Yue, X | 1 |
| Chen, SZ | 1 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Ceylan, M | 1 |
| Yalcin, A | 1 |
| Bayraktutan, OF | 1 |
| Karabulut, I | 1 |
| Sonkaya, AR | 1 |
| Motobayashi, M | 1 |
| Morita, D | 1 |
| Kurata, T | 1 |
| Shigemura, T | 1 |
| Nakazawa, Y | 1 |
| Shimozawa, N | 1 |
| Inaba, Y | 1 |
| Noack-Rink, M | 1 |
| Ramirez, F | 1 |
| Tofighy, A | 1 |
| Werhahn, KJ | 1 |
| Wild, I | 1 |
| Trinka, E | 2 |
| Zhang, Q | 1 |
| Yang, F | 1 |
| Hu, Z | 1 |
| Zhang, Z | 1 |
| Xu, Q | 1 |
| Dante, M | 1 |
| Wu, H | 1 |
| Li, Z | 1 |
| Li, Q | 1 |
| Li, K | 1 |
| Lu, G | 1 |
| Calderbank, R | 1 |
| Rooney, C | 1 |
| Trayner, P | 1 |
| Clayton-Smith, J | 1 |
| Morrow, JI | 1 |
| Haddad, N | 1 |
| Melikyan, G | 1 |
| Al Hail, H | 1 |
| Al Jurdi, A | 1 |
| Aqeel, F | 1 |
| Elzafarany, A | 1 |
| Abuhadra, N | 1 |
| Laswi, M | 1 |
| Alsamman, Y | 1 |
| Uthman, B | 1 |
| Deleu, D | 1 |
| Mesraoua, B | 1 |
| Alarcon, G | 1 |
| Azar, N | 1 |
| Streletz, L | 1 |
| Mahfoud, Z | 1 |
| Giorgi, FS | 1 |
| Guida, M | 1 |
| Vergallo, A | 1 |
| Bonuccelli, U | 1 |
| Zaccara, G | 1 |
| Redkar, N | 1 |
| Rawat, KJ | 1 |
| Shah, JH | 1 |
| Jena, AB | 1 |
| Agrawal, V | 1 |
| Muramatsu, K | 1 |
| Sawaura, N | 1 |
| Ogata, T | 1 |
| Makioka, N | 1 |
| Tomita, K | 1 |
| Motojima, T | 1 |
| Ida, K | 1 |
| Hazama, K | 1 |
| Arakawa, H | 1 |
| Wieshmann, UC | 2 |
| Baker, G | 2 |
| Habets, JGV | 1 |
| Leentjens, AFG | 1 |
| Schijns, OEMG | 1 |
| Schattner, A | 1 |
| Al-Bewerat, A | 1 |
| Wang, LN | 1 |
| Wu, LY | 1 |
| Wang, YP | 1 |
| Suzuki, K | 1 |
| Kawataki, T | 1 |
| Sato, H | 1 |
| Ogiwara, M | 1 |
| Kinouchi, H | 1 |
| García Carretero, R | 1 |
| Romero Brugera, M | 1 |
| Olid-Velilla, M | 1 |
| Salamanca-Ramirez, I | 1 |
| Morin, L | 1 |
| Enderlin, J | 1 |
| Leger, PL | 1 |
| Perrotte, G | 1 |
| Bonnin, P | 1 |
| Dupuis, N | 1 |
| Baud, O | 1 |
| Charriaut-Marlangue, C | 1 |
| Auvin, S | 1 |
| Singh, T | 1 |
| Kaur, T | 1 |
| Goel, RK | 1 |
| Gholipour, T | 1 |
| Mitchell, S | 1 |
| Sarkis, RA | 1 |
| Chemali, Z | 1 |
| Fong, JK | 1 |
| Chan, EL | 1 |
| Leung, H | 1 |
| Chan, I | 1 |
| Chang, RS | 1 |
| Fong, GC | 1 |
| Fung, EL | 1 |
| Lui, CH | 1 |
| Fung, BB | 1 |
| Poon, TL | 1 |
| Siu, D | 1 |
| Wong, HT | 1 |
| Yeung, E | 1 |
| Yung, AW | 1 |
| Zhu, CX | 1 |
| Shih, JJ | 1 |
| Whitlock, JB | 1 |
| Chimato, N | 1 |
| Vargas, E | 1 |
| Karceski, SC | 1 |
| Frank, RD | 1 |
| Rhee, SJ | 1 |
| Shin, JW | 1 |
| Lee, S | 1 |
| Moon, J | 1 |
| Kim, TJ | 1 |
| Jung, KY | 1 |
| Park, KI | 1 |
| Yu, KS | 1 |
| Jang, IJ | 1 |
| Mäkinen, J | 1 |
| Rainesalo, S | 1 |
| Raitanen, J | 2 |
| Peltola, J | 4 |
| Engelbrecht, L | 1 |
| Grobler, CJ | 1 |
| Rheeders, M | 1 |
| Maguire, MJ | 1 |
| Hemming, K | 1 |
| Gubensek, J | 1 |
| Buturovic-Ponikvar, J | 1 |
| Ponikvar, R | 1 |
| Cebular, B | 1 |
| Frings, L | 2 |
| Wagner, K | 2 |
| Maiwald, T | 1 |
| Carius, A | 2 |
| Schinkel, A | 1 |
| Lehmann, C | 1 |
| Kutlu, G | 1 |
| Gomceli, YB | 1 |
| Unal, Y | 1 |
| Inan, LE | 1 |
| Rogawski, MA | 1 |
| Helmstaedter, C | 4 |
| Fritz, NE | 1 |
| Kockelmann, E | 1 |
| Kosanetzky, N | 1 |
| Elger, CE | 4 |
| Matar, KM | 1 |
| Peltola, M | 2 |
| Auvinen, A | 2 |
| Fallah, M | 2 |
| Keränen, T | 2 |
| Kaminski, RM | 3 |
| Matagne, A | 4 |
| Klitgaard, H | 10 |
| Major, P | 1 |
| Greenberg, E | 1 |
| Khan, A | 1 |
| Thiele, EA | 2 |
| Kalinin, VV | 1 |
| Witt, JA | 2 |
| Milligan, TA | 1 |
| Hurwitz, S | 1 |
| Bromfield, EB | 1 |
| Tan, TC | 1 |
| de Boer, BW | 1 |
| Mitchell, A | 1 |
| Delriviere, L | 1 |
| Adams, LA | 1 |
| Jeffrey, GP | 1 |
| Macquillan, G | 1 |
| Desai, J | 1 |
| Mohamed, S | 2 |
| Albani, F | 4 |
| Baruzzi, A | 4 |
| Carpay, JA | 1 |
| Aalbers, K | 1 |
| Graveland, GA | 1 |
| Engelsman, M | 1 |
| Galletti, F | 1 |
| Autuori, A | 1 |
| Pierguidi, L | 2 |
| Parnetti, L | 1 |
| Pro, S | 2 |
| Vicenzini, E | 1 |
| Pulitano, P | 2 |
| Li Voti, P | 2 |
| Randi, F | 1 |
| Mecarelli, O | 2 |
| Beyenburg, S | 1 |
| Reuber, M | 1 |
| Maraite, N | 1 |
| Lynch, JM | 1 |
| Tate, SK | 1 |
| Kinirons, P | 1 |
| Weale, ME | 1 |
| Cavalleri, GL | 1 |
| Depondt, C | 2 |
| Murphy, K | 1 |
| O'Rourke, D | 1 |
| Doherty, CP | 1 |
| Shianna, KV | 1 |
| Wood, NW | 1 |
| Delanty, N | 1 |
| Goldstein, DB | 1 |
| Sisodiya, SM | 2 |
| Yang, Z | 1 |
| Qin, J | 1 |
| Zhang, Y | 1 |
| Bao, X | 1 |
| Xiong, H | 1 |
| Larsson, PG | 4 |
| Wilson, J | 1 |
| Eeg-Olofsson, O | 3 |
| Shershever, AS | 2 |
| Bentsion, DL | 1 |
| Lavrova, SA | 2 |
| Sorokova, EV | 1 |
| López-Góngora, M | 1 |
| Martínez-Domeño, A | 1 |
| García, C | 1 |
| Escartín, A | 1 |
| Ammar, H | 1 |
| Malani, A | 1 |
| Mughal, S | 1 |
| Beavis, J | 1 |
| Meek, A | 1 |
| Felce, D | 1 |
| Kerr, M | 1 |
| Gao, ZJ | 1 |
| Jiang, YW | 1 |
| Bootsma, HP | 5 |
| Ricker, L | 3 |
| Hekster, YA | 1 |
| Hulsman, J | 4 |
| Lambrechts, D | 4 |
| Schellekens, A | 4 |
| de Krom, M | 4 |
| Chhun, S | 2 |
| Jullien, V | 1 |
| Rey, E | 1 |
| Dulac, O | 3 |
| Chiron, C | 2 |
| Pons, G | 2 |
| Nau, KM | 1 |
| Divertie, GD | 1 |
| Valentino, AK | 1 |
| Freeman, WD | 1 |
| Mintz, M | 1 |
| Legoff, D | 1 |
| Scornaienchi, J | 1 |
| Brown, M | 1 |
| Levin-Allen, S | 1 |
| Mintz, P | 1 |
| Smith, C | 1 |
| Rouvel-Tallec, A | 1 |
| Valencia, I | 2 |
| Legido, A | 2 |
| Wheless, JW | 3 |
| Clarke, D | 1 |
| Hovinga, CA | 1 |
| Ellis, M | 1 |
| Durmeier, M | 1 |
| McGregor, A | 1 |
| Perkins, F | 1 |
| Veauthier, J | 1 |
| Haettig, H | 1 |
| Meencke, HJ | 3 |
| Sadzot, B | 2 |
| Moonen, G | 1 |
| López-Fraile, IP | 1 |
| Cid, AO | 1 |
| Juste, AO | 1 |
| Modrego, PJ | 1 |
| Cholongitas, E | 1 |
| Karatzi, C | 1 |
| Spyrou, S | 1 |
| Georgousaki, C | 1 |
| Dasenaki, M | 1 |
| Dinapoli, L | 4 |
| Jandolo, B | 2 |
| Pace, A | 4 |
| Sperati, F | 3 |
| Muti, P | 2 |
| Lebedeva, AV | 1 |
| Nemenov, DG | 1 |
| Yu, HY | 1 |
| Kwan, SY | 1 |
| Lirng, JF | 1 |
| Liao, KK | 1 |
| Chu, YK | 1 |
| Liao, SQ | 1 |
| Pellock, JM | 2 |
| Thibert, RL | 1 |
| Conant, KD | 1 |
| Braun, EK | 1 |
| Bruno, P | 1 |
| Said, RR | 1 |
| Nespeca, MP | 1 |
| Gillard, M | 1 |
| Leclercq, K | 2 |
| Hanon, E | 1 |
| Lorent, G | 1 |
| Dassesse, D | 1 |
| Giroux, PC | 1 |
| Salas-Prato, M | 1 |
| Théorêt, Y | 1 |
| Carmant, L | 1 |
| Wojda, E | 1 |
| Wlaz, A | 1 |
| Luszczki, JJ | 3 |
| van Vliet, EA | 1 |
| Edelbroek, PM | 2 |
| Gorter, JA | 1 |
| Tilz, C | 1 |
| Resch, R | 1 |
| Hofer, T | 1 |
| Eggers, C | 1 |
| Longo, B | 1 |
| Forinash, AB | 1 |
| Murphy, JA | 1 |
| Svalheim, S | 5 |
| Taubøll, E | 4 |
| Lossius, A | 1 |
| Sandvand, F | 1 |
| Bertelsen, M | 1 |
| Mørkrid, L | 2 |
| Gjerstad, L | 3 |
| Li, S | 1 |
| Cao, J | 1 |
| Wu, T | 1 |
| Chen, CC | 1 |
| Chen, TC | 1 |
| Tseng, YF | 1 |
| Chiang, CB | 1 |
| Hung, CC | 1 |
| Liou, HH | 1 |
| Shah, D | 1 |
| Husain, AM | 1 |
| Ishimaru, Y | 1 |
| Chiba, S | 1 |
| Serikawa, T | 5 |
| Sasa, M | 5 |
| Inaba, H | 1 |
| Tamura, Y | 1 |
| Ishimoto, T | 1 |
| Takasaki, H | 1 |
| Sakamoto, K | 1 |
| Yamaguchi, K | 1 |
| Duane, DD | 1 |
| Kuba, R | 2 |
| Novotná, I | 2 |
| Brázdil, M | 2 |
| Kocvarová, J | 2 |
| Tyrlíková, I | 2 |
| Mastík, J | 2 |
| Rektor, I | 3 |
| Bitsche, G | 1 |
| Tauboll, E | 1 |
| Rudakova, IG | 1 |
| Kotov, AS | 1 |
| Kotov, SV | 1 |
| Belova, IuA | 1 |
| Lavrent'eva, NS | 1 |
| Azar, NJ | 1 |
| Lagrange, AH | 1 |
| Song, Y | 1 |
| Kim, JE | 1 |
| Choi, HC | 1 |
| Song, HK | 1 |
| Jo, SM | 1 |
| Kim, DS | 1 |
| Choi, SY | 1 |
| Kim, YI | 1 |
| Bauer, J | 3 |
| Pfeiffer, C | 1 |
| Burr, W | 1 |
| Lee, YJ | 1 |
| Kang, HC | 1 |
| Kim, HD | 1 |
| Lee, JS | 1 |
| Crepeau, AZ | 1 |
| Treiman, DM | 1 |
| Depositario-Cabacar, DT | 1 |
| Peters, JM | 1 |
| Pong, AW | 2 |
| Roth, J | 1 |
| Rotenberg, A | 1 |
| Riviello, JJ | 1 |
| Takeoka, M | 1 |
| Malykh, AG | 1 |
| Sadaie, MR | 1 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Dai, J | 1 |
| Han, L | 1 |
| Zhang, LL | 1 |
| Buttolo, L | 1 |
| Stefini, R | 1 |
| Todeschini, A | 1 |
| Cenzato, M | 1 |
| Padovani, A | 1 |
| Peer Mohamed, B | 1 |
| Mohamed, BP | 1 |
| Prabhakar, P | 1 |
| Li, J | 1 |
| Chen, S | 1 |
| Arif, H | 2 |
| Pierro, J | 1 |
| Whalen, M | 1 |
| Sims, J | 1 |
| Resor, SR | 2 |
| Bazil, CW | 2 |
| Ng, YT | 2 |
| Hastriter, EV | 1 |
| Cardenas, JF | 1 |
| Khoury, EM | 1 |
| Chapman, KE | 1 |
| Liao, JX | 1 |
| Huang, TS | 1 |
| Li, B | 1 |
| Dericioglu, N | 1 |
| Tellez-Zenteno, JF | 2 |
| Bilo, L | 1 |
| de Leva, MF | 1 |
| Meo, R | 1 |
| D'Adamo, E | 1 |
| Parisi, P | 1 |
| Chiarelli, F | 1 |
| Curatolo, P | 1 |
| Kaparos, G | 1 |
| Armeni, E | 1 |
| Alexandrou, A | 1 |
| Damaskos, C | 1 |
| Logothetis, E | 1 |
| Creatsa, M | 1 |
| Antoniou, A | 1 |
| Kouskouni, E | 1 |
| Varoglu, AO | 1 |
| Yildirim, A | 1 |
| Aygul, R | 1 |
| Gundogdu, OL | 1 |
| Sahin, YN | 1 |
| Michel, CM | 1 |
| Seeck, M | 1 |
| Lantz, G | 1 |
| Tonekaboni, SH | 1 |
| Ghazavi, M | 1 |
| Karimzadeh, P | 1 |
| Mahvelati, F | 1 |
| Ghofrani, M | 1 |
| Tambasco, N | 1 |
| Obeid, M | 1 |
| Ozden, H | 1 |
| Kabay, SC | 1 |
| Toker, A | 1 |
| Ustüner, MC | 1 |
| Ozbayer, C | 1 |
| Ustüner, D | 1 |
| Günes, HV | 1 |
| Dahlin, MG | 1 |
| Wide, K | 1 |
| Ohman, I | 2 |
| Fu, Z | 1 |
| Venkatesan, K | 1 |
| Mazzuferi, M | 1 |
| Seutin, V | 1 |
| Vicini, S | 1 |
| Pellicciari, A | 1 |
| Posar, A | 1 |
| Cremonini, MA | 1 |
| Parmeggiani, A | 1 |
| Aricò, I | 1 |
| Condurso, R | 1 |
| Granata, F | 1 |
| Nobili, L | 1 |
| Bruni, O | 1 |
| Silvestri, R | 1 |
| Vespignani, H | 1 |
| Marchal, C | 1 |
| Blin, P | 1 |
| Blazejewski, S | 1 |
| Harden, CL | 1 |
| Nikolov, BG | 1 |
| Kandula, P | 1 |
| Labar, DR | 1 |
| Pannullo, S | 1 |
| Harbord, MG | 1 |
| Troude, P | 1 |
| Villeneuve, N | 1 |
| Soufflet, C | 1 |
| Napuri, S | 1 |
| Motte, J | 1 |
| Pouplard, F | 1 |
| Alberti, C | 1 |
| Helfen, S | 1 |
| Bonnett, LJ | 1 |
| Iniesta, I | 1 |
| van Tuijl, JH | 1 |
| van Raak, EP | 1 |
| de Krom, MC | 1 |
| Lodder, J | 1 |
| Baho, MJ | 1 |
| Hostutler, R | 1 |
| Fenner, W | 1 |
| Corn, S | 1 |
| Freitas-Lima, P | 1 |
| Alexandre, V | 1 |
| Pereira, LR | 1 |
| Feletti, F | 1 |
| Perucca, E | 4 |
| Sakamoto, AC | 1 |
| Cho, YW | 1 |
| Kim, DH | 1 |
| Motamedi, GK | 1 |
| Ishii, Y | 1 |
| Gajda, Z | 1 |
| Török, R | 1 |
| Horváth, Z | 1 |
| Szántai-Kis, C | 1 |
| Orfi, L | 1 |
| Kéri, G | 1 |
| Szente, M | 1 |
| Lyseng-Williamson, KA | 2 |
| Chaluvadi, S | 1 |
| Chiang, S | 1 |
| Tran, L | 1 |
| Goldsmith, CE | 1 |
| Friedman, DE | 1 |
| Usami, K | 1 |
| Saito, N | 1 |
| Murphy-Human, T | 1 |
| Welch, E | 1 |
| Zipfel, G | 1 |
| Diringer, MN | 1 |
| Dhar, R | 1 |
| Lo, BW | 1 |
| Kyu, HH | 1 |
| Jichici, D | 1 |
| Upton, AM | 1 |
| Akl, EA | 1 |
| Meade, MO | 1 |
| Kelly, K | 2 |
| Parker, P | 1 |
| Christensen, J | 1 |
| Jia, TM | 1 |
| Liu, T | 1 |
| Luan, B | 1 |
| Li, XL | 1 |
| Zhang, XL | 1 |
| Yoshino, A | 2 |
| Bakke, KA | 1 |
| Eriksson, AS | 2 |
| Mink, S | 1 |
| Muroi, C | 1 |
| Seule, M | 1 |
| Bjeljac, M | 1 |
| Keller, E | 1 |
| Bachmann, T | 1 |
| Bertheussen, KH | 1 |
| Atkins, M | 1 |
| Nikanorova, M | 1 |
| de Groot, M | 1 |
| Aronica, E | 1 |
| Heimans, JJ | 1 |
| Reijneveld, JC | 1 |
| Akamatsu, N | 1 |
| Kaufman, KR | 1 |
| Struck, PJ | 1 |
| Wu, B | 1 |
| Wong, S | 1 |
| Tan, GM | 1 |
| Cho, JR | 1 |
| Yoon, SM | 1 |
| Ju, E | 1 |
| Lee, J | 2 |
| Kim, DY | 1 |
| Hatzipantelis, E | 1 |
| Pana, ZD | 1 |
| Pavlou, E | 1 |
| Balakou, E | 1 |
| Tsotoulidou, V | 1 |
| Papageorgiou, T | 1 |
| Tragiannidis, A | 1 |
| Athanassiadou, F | 1 |
| Halliday, AJ | 1 |
| Campbell, TE | 1 |
| Razal, JM | 1 |
| McLean, KJ | 1 |
| Nelson, TS | 1 |
| Wallace, GG | 1 |
| Celikyurt, IK | 1 |
| Ulak, G | 1 |
| Mutlu, O | 1 |
| Akar, FY | 1 |
| Mulayim, S | 1 |
| Erden, F | 1 |
| Komsuoglu, SS | 1 |
| Sasidaran, K | 1 |
| Singhi, S | 1 |
| Singhi, P | 1 |
| Doumbia-Ouattara, M | 1 |
| Bourel-Ponchel, E | 1 |
| Le Moing, AG | 1 |
| Querne, L | 1 |
| Delignières, A | 1 |
| de Broca, A | 1 |
| Berquin, P | 1 |
| Jankovic, SM | 1 |
| Dostic, M | 1 |
| Robins, A | 1 |
| Patel, M | 1 |
| Azim, A | 1 |
| Oláh, E | 1 |
| Bacsói, G | 1 |
| Fekete, J | 1 |
| Sharma, VK | 1 |
| Calka, O | 1 |
| Karadag, AS | 1 |
| Bilgili, SG | 1 |
| Bulut, G | 1 |
| Altun, F | 1 |
| Burakgazi, AZ | 1 |
| Jehi, LE | 1 |
| Irwin, AI | 1 |
| Kayyali, H | 1 |
| Vadera, S | 1 |
| Bingaman, W | 1 |
| Najm, I | 1 |
| Ozcan, M | 1 |
| Ayar, A | 1 |
| Krishna, K | 1 |
| Raut, AL | 1 |
| Gohel, KH | 1 |
| Dave, P | 1 |
| Aĭvazian, SO | 1 |
| Shiriaev, IuS | 1 |
| Goodman, MJ | 1 |
| Durkin, M | 1 |
| Forlenza, J | 1 |
| Ye, X | 1 |
| Brixner, DI | 1 |
| Dodel, R | 1 |
| Strzelczyk, A | 2 |
| Balzer-Geldsetzer, M | 1 |
| Reese, JP | 1 |
| Schöffski, O | 1 |
| Graf, W | 1 |
| Schwab, S | 1 |
| Oertel, WH | 2 |
| Kostev, K | 1 |
| Dibbens, LM | 1 |
| Hodgson, BL | 1 |
| Helbig, KL | 1 |
| Oliver, KL | 1 |
| Mulley, JC | 1 |
| Berkovic, SF | 1 |
| Scheffer, IE | 1 |
| Baulac, S | 1 |
| Ishida, S | 1 |
| Mashimo, T | 1 |
| Boillot, M | 1 |
| Fumoto, N | 1 |
| Kuwamura, M | 1 |
| Ohno, Y | 1 |
| Takizawa, A | 1 |
| Aoto, T | 1 |
| Ueda, M | 1 |
| Ikeda, A | 1 |
| LeGuern, E | 1 |
| Takahashi, R | 1 |
| Schade-Brittinger, C | 1 |
| Burchardi, N | 1 |
| Klein, KM | 1 |
| Weber, Y | 1 |
| Lerche, H | 1 |
| Evers, S | 1 |
| Kovac, S | 1 |
| Hallmeyer-Elgner, S | 1 |
| Winkler, G | 1 |
| Springub, J | 1 |
| Niedhammer, M | 1 |
| Roth, E | 1 |
| Eisensehr, I | 1 |
| Berrouschot, J | 1 |
| Arnold, S | 2 |
| Schröder, M | 1 |
| Beige, A | 1 |
| Haag, A | 1 |
| Reif, PS | 1 |
| Wang, YH | 1 |
| Lu, W | 1 |
| Shang, DW | 1 |
| Wei, MJ | 1 |
| Camacho, A | 1 |
| Espín, JC | 1 |
| Nuñez, N | 1 |
| Simón, R | 1 |
| Klein, P | 2 |
| Herr, D | 2 |
| Pearl, PL | 2 |
| Natale, J | 2 |
| Levine, Z | 2 |
| Nogay, C | 2 |
| Sandoval, F | 2 |
| Trzcinsky, S | 1 |
| Atabaki, SM | 2 |
| Tsuchida, T | 2 |
| van den Anker, J | 2 |
| Soldin, SJ | 2 |
| He, J | 2 |
| McCarter, R | 2 |
| Kang, SY | 1 |
| Han, YM | 1 |
| Choi, K | 1 |
| Hwang, SH | 1 |
| Trzcinski, S | 1 |
| Johannessen Landmark, C | 1 |
| Baftiu, A | 1 |
| Tysse, I | 1 |
| Valsø, B | 1 |
| Rytter, E | 1 |
| Johannessen, SI | 7 |
| Tando, T | 1 |
| Mihov, Y | 1 |
| Toliat, MR | 1 |
| Thiele, H | 1 |
| Nuernberg, P | 1 |
| Kunz, WS | 1 |
| Hurlemann, R | 1 |
| Hagemann, A | 1 |
| Nieder, E | 1 |
| Witte-Bölt, K | 1 |
| Tergau, F | 1 |
| Straub, HB | 1 |
| Brandt, C | 1 |
| Yan, HD | 2 |
| Ishihara, K | 3 |
| Seki, T | 1 |
| Hanaya, R | 1 |
| Kurisu, K | 1 |
| Arita, K | 1 |
| Mushtaq, U | 1 |
| Mochol, M | 1 |
| Frøland, SS | 1 |
| Terada, K | 1 |
| Inoue, Y | 1 |
| Metin, SZ | 1 |
| Ozkara, C | 1 |
| Ozmen, E | 1 |
| Pompili, A | 2 |
| Carapella, CM | 2 |
| Martikainen, MH | 1 |
| Päivärinta, M | 1 |
| Jääskeläinen, S | 1 |
| Majamaa, K | 1 |
| Almeida, DM | 1 |
| Jean, MR | 1 |
| Chystsiakova, A | 1 |
| Monahan, E | 1 |
| Oliveira, SB | 1 |
| Monteiro, IM | 1 |
| Maren Staack, A | 1 |
| Wisniewski, I | 1 |
| Lee, GH | 1 |
| Kim, BM | 1 |
| Lee, SA | 1 |
| Calabrò, RS | 1 |
| Bramanti, P | 1 |
| Herranz, JL | 1 |
| Argumosa, A | 1 |
| Gorji, A | 1 |
| Höhling, JM | 1 |
| Madeja, M | 1 |
| Straub, H | 1 |
| Köhling, R | 1 |
| Ebner, A | 1 |
| Wolf, P | 2 |
| Panneck, HW | 1 |
| Behne, F | 1 |
| Lahl, R | 1 |
| Speckmann, EJ | 1 |
| Sirven, JI | 1 |
| Lossius, R | 2 |
| Ben-Menachem, E | 8 |
| Edrich, P | 4 |
| Van Vleymen, B | 2 |
| Schmidt, B | 1 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| Angehagen, M | 1 |
| Margineanu, DG | 4 |
| Rönnbäck, L | 1 |
| Hansson, E | 1 |
| Koch, HJ | 1 |
| Szecsey, A | 1 |
| Vogel, M | 1 |
| Gilland, E | 1 |
| Betts, T | 2 |
| Yarrow, H | 1 |
| Greenhill, L | 1 |
| Barrett, M | 1 |
| Abou-Khalil, B | 2 |
| Hemdal, P | 1 |
| Privitera, MD | 3 |
| Alsaadi, TM | 2 |
| Thieman, C | 1 |
| Cramer, JA | 4 |
| Van Hammée, G | 2 |
| De Rue, K | 1 |
| Devinsky, O | 2 |
| Trimble, MR | 3 |
| Mariero Klees, T | 1 |
| Brodtkorb, E | 3 |
| Long, L | 1 |
| Chadwick, D | 1 |
| Pitkänen, A | 1 |
| Elger, C | 1 |
| Lazenby, B | 1 |
| Kasteleijn-Nolst Trenité, DG | 3 |
| Hirsch, E | 2 |
| Glauser, TA | 3 |
| Arroyo, S | 1 |
| Crawford, P | 3 |
| French, JA | 2 |
| Dinkelacker, V | 1 |
| Dietl, T | 1 |
| Widman, G | 1 |
| Lengler, U | 1 |
| Pinto, A | 1 |
| Hadjikoutis, S | 1 |
| Pickersgill, TP | 1 |
| Smith, PE | 1 |
| White, JR | 1 |
| Walczak, TS | 1 |
| Leppik, IE | 7 |
| Rarick, J | 2 |
| Tran, T | 1 |
| Beniak, TE | 1 |
| Matchinsky, DJ | 1 |
| Gumnit, RJ | 1 |
| Bird, JM | 1 |
| Joseph, ZA | 1 |
| Rambeck, B | 1 |
| Jürgens, U | 1 |
| Gidal, BE | 2 |
| Sheth, RD | 1 |
| Magnus, L | 2 |
| Herbeuval, AF | 1 |
| Rue, KD | 1 |
| Krämer, G | 2 |
| Ferrendelli, JA | 2 |
| French, J | 3 |
| Leppik, I | 1 |
| Morrell, MJ | 1 |
| Herbeuval, A | 1 |
| Han, J | 1 |
| Koopmans, S | 1 |
| Apperson, M | 1 |
| Farias, S | 1 |
| Tan, MJ | 1 |
| Appleton, RE | 2 |
| Huber, B | 2 |
| Bömmel, W | 1 |
| Hauser, I | 1 |
| Horstmann, V | 1 |
| Liem, S | 1 |
| May, T | 2 |
| Meinert, T | 1 |
| Robertson, E | 1 |
| Schulz, L | 1 |
| Seidel, M | 2 |
| Tomka-Hoffmeister, M | 1 |
| Wagner, W | 1 |
| Bosman, T | 2 |
| Vonck, K | 5 |
| Claeys, P | 2 |
| Van Vlierberghe, H | 1 |
| De Clercq, M | 1 |
| De Reuck, J | 1 |
| Boon, P | 5 |
| Coppola, G | 3 |
| Mangano, S | 1 |
| Tortorella, G | 1 |
| Pelliccia, A | 1 |
| Fels, A | 1 |
| Romano, A | 1 |
| Nardello, R | 1 |
| Habetswallner, F | 1 |
| Licciardi, F | 1 |
| Operto, FF | 1 |
| Pascotto, A | 2 |
| Pisani, A | 1 |
| Bonsi, P | 1 |
| Martella, G | 1 |
| De Persis, C | 1 |
| Bernardi, G | 1 |
| Kimland, E | 1 |
| Höjeberg, B | 1 |
| von Euler, M | 1 |
| Nicolson, A | 1 |
| Lewis, SA | 1 |
| Smith, DF | 1 |
| Briggs, DE | 1 |
| Fischer, W | 1 |
| Kittner, H | 1 |
| Regenthal, R | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Leach, JP | 1 |
| Mukhin, KIu | 1 |
| Pilin, SV | 1 |
| Chadaev, VA | 1 |
| Mironov, MB | 1 |
| Petrukhin, AS | 1 |
| Koukkari, MW | 1 |
| Guarino, EJ | 1 |
| Vigevano, F | 1 |
| Martens-Lobenhoffer, J | 1 |
| Bode-Böger, SM | 1 |
| Roberts, GM | 1 |
| Majoie, HJ | 1 |
| Leenen, LA | 1 |
| Kessels, AG | 1 |
| Leonard, BE | 1 |
| Helde, G | 2 |
| Blais, L | 1 |
| Sheehy, O | 1 |
| St-Hilaire, JM | 1 |
| Bernier, G | 1 |
| Godfroid, P | 1 |
| LeLorier, JJ | 1 |
| Grosso, S | 2 |
| Franzoni, E | 3 |
| Iannetti, P | 1 |
| Cordelli, DM | 2 |
| Marchiani, V | 2 |
| Spalice, A | 1 |
| Acampora, B | 1 |
| Morgese, G | 2 |
| Balestri, P | 2 |
| Nasrallah, K | 1 |
| Silver, B | 1 |
| Harrison, PK | 1 |
| Sheridan, RD | 1 |
| Green, AC | 1 |
| Tattersall, JE | 1 |
| Ji-qun, C | 2 |
| Nagayama, T | 2 |
| Chappell, B | 1 |
| Dedeurwaerdere, S | 2 |
| De Smedt, T | 4 |
| Raedt, R | 4 |
| Van Hese, P | 2 |
| Van Maele, G | 1 |
| Artemowicz, B | 2 |
| Sobaniec, W | 2 |
| Wieser, HG | 1 |
| Opp, J | 1 |
| Kluger, G | 2 |
| Wiemer-Kruel, A | 1 |
| Kurlemann, G | 1 |
| Gross-Selbeck, G | 1 |
| Rating, D | 1 |
| Brandl, U | 1 |
| Bettendorf, U | 1 |
| Härtel, C | 1 |
| Korn-Merker, E | 1 |
| Willmore, LJ | 1 |
| Yuen, AW | 1 |
| Mitchell, T | 1 |
| Koepp, MJ | 2 |
| Dong, X | 1 |
| White, J | 1 |
| Aeby, A | 1 |
| Poznanski, N | 1 |
| Verheulpen, D | 1 |
| Wetzburger, C | 1 |
| Van Bogaert, P | 1 |
| Andres, MM | 1 |
| Czuczwar, P | 1 |
| Cioczek-Czuczwar, A | 1 |
| Ratnaraj, N | 3 |
| Cicolin, A | 1 |
| Magliola, U | 1 |
| Giordano, A | 1 |
| Terreni, A | 1 |
| Bucca, C | 1 |
| Mutani, R | 1 |
| Hurtado, B | 1 |
| Thompson, PJ | 1 |
| Gibbs, JE | 1 |
| Walker, MC | 1 |
| Genton, P | 3 |
| Fejerman, N | 1 |
| Despland, PA | 1 |
| Steinhoff, B | 1 |
| Wroe, S | 1 |
| Maubrey, MC | 1 |
| Vandervelden, C | 1 |
| Schlit, AF | 1 |
| van Paesschen, W | 1 |
| Occhipinti, E | 1 |
| Neuwirth, M | 1 |
| Saracz, J | 1 |
| Hegyi, M | 1 |
| Paraicz, E | 1 |
| Kollár, K | 1 |
| Móser, J | 1 |
| Rosdy, B | 1 |
| Herczegfalvi, A | 1 |
| Fogarasi, A | 1 |
| Ramael, S | 1 |
| Daoust, A | 1 |
| Otoul, C | 3 |
| Toublanc, N | 2 |
| Troenaru, M | 1 |
| Lu, ZS | 2 |
| Stockis, A | 5 |
| De Herdt, V | 1 |
| Waterschoot, L | 1 |
| Wyckhuys, T | 1 |
| Legros, B | 1 |
| Van Laere, K | 1 |
| Delbeke, J | 1 |
| Wadman, W | 1 |
| Fryze, W | 1 |
| Da Silva, S | 1 |
| Karlov, VA | 1 |
| Vlasov, PN | 1 |
| Buyle, S | 1 |
| Stefan, H | 1 |
| Feuerstein, TJ | 1 |
| Tomson, T | 2 |
| Diepman, L | 3 |
| Leenen, L | 3 |
| Ghattaura, S | 1 |
| Hunt, S | 1 |
| Craig, J | 1 |
| Russell, A | 1 |
| Guthrie, E | 1 |
| Parsons, L | 1 |
| Robertson, I | 1 |
| Waddell, R | 1 |
| Morrison, PJ | 1 |
| Schilling, M | 1 |
| Wetzel, W | 1 |
| Grecksch, G | 1 |
| Becker, A | 1 |
| Peake, D | 1 |
| Mordekar, S | 1 |
| Gosalakkal, J | 1 |
| Mukhtyar, B | 1 |
| Buch, S | 1 |
| Crane, J | 1 |
| Wheway, R | 1 |
| Rittey, C | 1 |
| Donnelly, J | 1 |
| Philip, S | 1 |
| Ryvlin, P | 1 |
| Andres-Mach, MM | 1 |
| Gehring, J | 2 |
| Capovilla, G | 1 |
| Zamponi, N | 1 |
| Palm, R | 1 |
| Söderfeldt, B | 1 |
| Danielsson, B | 1 |
| Johansson, R | 1 |
| Luef, GJ | 1 |
| Löscher, WN | 1 |
| Gomer, B | 1 |
| Saar, J | 1 |
| Härle, M | 1 |
| Perry, MS | 1 |
| Benatar, M | 1 |
| Barcs, G | 2 |
| Szucs, A | 2 |
| Mitchell, WG | 1 |
| Weinstock, A | 1 |
| Bebin, M | 1 |
| Chen, D | 1 |
| Coupez, R | 1 |
| von Stuelpnagel, C | 1 |
| Holthausen, H | 1 |
| Matiasek, LA | 1 |
| Luján Feliu-Pascual, A | 1 |
| Platt, SR | 1 |
| Chandler, KE | 1 |
| Auriel, E | 1 |
| Chistik, V | 1 |
| Blatt, I | 1 |
| Margolin, N | 1 |
| Neufeld, M | 1 |
| Sirsi, D | 1 |
| Safdieh, JE | 1 |
| Pigeolet, E | 1 |
| Jacqmin, P | 2 |
| Sargentini-Maier, ML | 2 |
| Romolo, FS | 1 |
| Rotolo, M | 1 |
| Accornero, N | 1 |
| Vanacore, N | 1 |
| Deb, S | 1 |
| Kaur Saini, ST | 1 |
| Weintraub, D | 1 |
| Chang, JT | 1 |
| Szaflarski, JP | 1 |
| Meckler, JM | 1 |
| Szaflarski, M | 1 |
| Shutter, LA | 1 |
| Sarajlija, J | 1 |
| Garone, C | 1 |
| Malaspina, E | 1 |
| Dannhardt, G | 1 |
| Kiefer, W | 1 |
| De Smedt, H | 1 |
| Roig, J | 1 |
| Carreño, MM | 1 |
| Parellada, E | 1 |
| Newsome, SD | 1 |
| Xue, LY | 1 |
| Jennings, T | 1 |
| Castaneda, GY | 1 |
| Sethi, NK | 1 |
| Torgovnick, J | 1 |
| Arsura, E | 1 |
| Gelisse, P | 1 |
| Juntas-Morales, R | 1 |
| Hillaire-Buys, D | 1 |
| Diaz, O | 1 |
| Coubes, P | 1 |
| Crespel, A | 1 |
| Lancelin, F | 1 |
| Franchon, E | 1 |
| Kraoul, L | 1 |
| Garciau, I | 1 |
| Brovedani, S | 1 |
| Tabaouti, K | 1 |
| Landré, E | 1 |
| Chassoux, F | 1 |
| Paubel, P | 1 |
| Piketty, ML | 1 |
| Macleod, S | 1 |
| Fattouch, J | 1 |
| Fabbrini, G | 1 |
| Manfredi, M | 1 |
| Prencipe, M | 1 |
| Giallonardo, TA | 1 |
| Liimatainen, S | 1 |
| Kharazmi, E | 1 |
| Carreno, M | 1 |
| Westin, AA | 1 |
| Thacker, AK | 1 |
| Misra, P | 1 |
| Gupta, PP | 1 |
| Coban, A | 1 |
| Gurses, C | 1 |
| Bilgic, B | 1 |
| Sencer, S | 1 |
| Karasu, A | 1 |
| Bebek, N | 1 |
| Baykan, B | 1 |
| Hepgul, KT | 1 |
| Gokyigit, A | 1 |
| Goraya, JS | 1 |
| Khurana, DS | 1 |
| Melvin, JJ | 1 |
| Cruz, M | 1 |
| Kothare, SV | 1 |
| Rüegg, S | 1 |
| Naegelin, Y | 1 |
| Hardmeier, M | 1 |
| Winkler, DT | 1 |
| Marsch, S | 1 |
| Fuhr, P | 1 |
| Vaisleib, II | 1 |
| Neft, RA | 1 |
| Murphy, R | 1 |
| Daugherty, J | 1 |
| Houry, D | 1 |
| Hwang, H | 1 |
| Bialer, M | 2 |
| Bailey, KS | 1 |
| Dewey, CW | 1 |
| Boothe, DM | 1 |
| Barone, G | 1 |
| Kortz, GD | 1 |
| Telegin, AV | 1 |
| Grib, AV | 1 |
| Lacroix, B | 1 |
| Krief, P | 1 |
| Maytal, J | 1 |
| Clemens, Z | 1 |
| Jakus, R | 1 |
| Rásonyi, G | 1 |
| Fabó, D | 1 |
| Holló, A | 1 |
| Kelemen, A | 1 |
| Kenda, B | 1 |
| Michel, P | 1 |
| Koubeissi, MZ | 1 |
| Amina, S | 1 |
| Pita, I | 1 |
| Bergey, GK | 2 |
| Werz, MA | 1 |
| Nocoń, D | 1 |
| Mondadori, C | 2 |
| Schmutz, M | 2 |
| Baltzer, V | 1 |
| Neyens, LG | 1 |
| Alpherts, WC | 1 |
| Marescaux, C | 2 |
| Stodieck, S | 1 |
| Oosting, J | 1 |
| Kupferberg, HJ | 1 |
| Levy, RH | 1 |
| Loiseau, P | 1 |
| Gower, AJ | 1 |
| Boehrer, A | 1 |
| Noyer, M | 1 |
| Birnstiel, S | 1 |
| Wülfert, E | 2 |
| Beck, SG | 1 |
| Hönack, D | 1 |
| Rundfeldt, C | 1 |
| Gobert, J | 1 |
| Waegemans, T | 1 |
| Browne, TR | 1 |
| Szabo, GK | 1 |
| Josephs, E | 1 |
| Paz, J | 1 |
| Baltes, E | 1 |
| Jensen, CM | 1 |
| Jain, KK | 1 |
| Grant, R | 1 |
| Shorvon, SD | 2 |
| Foletti, GB | 1 |
| Kułak, W | 1 |
| Boćkowski, L | 1 |
| Smigielska-Kuzia, J | 1 |
| Sobaniec-Łotowska, M | 1 |
| Sołowiej, E | 1 |
| Sobaniec, H | 1 |
| Niespodziany, I | 1 |
| Krakow, K | 1 |
| Walker, M | 1 |
| van Rijckevorsel, K | 2 |
| Boon, PA | 1 |
| Nash, EM | 1 |
| Sangha, KS | 1 |
| Faught, E | 1 |
| Radtke, RA | 1 |
| Privitera, M | 1 |
| Harden, C | 1 |
| McAuley, JW | 1 |
| Biederman, TS | 1 |
| Smith, JC | 1 |
| Moore, JL | 1 |
| Welty, TE | 1 |
| Ficker, DM | 1 |
| Bebin, EM | 1 |
| Fountain, NB | 1 |
| Ritter, FJ | 1 |
| Coupez, RM | 1 |
| Shields, WD | 1 |
| Kossoff, EH | 1 |
| Freeman, JM | 1 |
| Vining, EP | 1 |
| Lukyanetz, EA | 1 |
| Shkryl, VM | 1 |
| Kostyuk, PG | 1 |
| Kunneke, PS | 1 |
| Malan, GM | 1 |
| Gottstein, U | 1 |
| Hawkins, CA | 1 |
| Mellanby, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b[NCT01653262] | Phase 3 | 29 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg b.i.d.) Compared to Sodium Valproate (1000 to 2000 mg/[NCT00175903] | Phase 3 | 1,701 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment[NCT02098941] | 2,500 participants (Anticipated) | Observational | 2014-03-31 | Recruiting | |||
| Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.[NCT00460070] | 240 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study[NCT00242606] | Phase 3 | 409 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy[NCT01463033] | Phase 2 | 126 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis[NCT00542802] | Phase 3 | 630 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| Effectiveness of Combined Levetiracetam and Midazolam in Treatment of Generalized Convulsive Status Epilepticus in Children[NCT04926844] | Phase 2 | 144 participants (Actual) | Interventional | 2021-06-20 | Completed | ||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy[NCT00630968] | Phase 4 | 1,541 participants (Actual) | Interventional | 2000-08-31 | Completed | ||
| Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus[NCT00603135] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn | ||
| A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care[NCT01700387] | Phase 4 | 20 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Multicenter, Double-blind, Randomized, Parallel Group, Positive-controlled Trial Comparing the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) to Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy for up to a Maxi[NCT00150735] | Phase 3 | 580 participants | Interventional | 2002-06-30 | Completed | ||
| A Multicenter, Double-blind, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) and Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Coming From the N01061 Trial.[NCT00150787] | Phase 3 | 250 participants | Interventional | 2003-07-31 | Completed | ||
| Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam[NCT04117425] | 50 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| An Open-Label, Single Dose, Pharmacokinetic Study of 20 mg/kg of Levetiracetam Oral Solution in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old[NCT00544050] | Phase 2 | 13 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A treatment emergent AE is any event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state. (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | events (Number) |
|---|---|
| Brivaracetam | 67 |
Nonpsychotic behavioral side effects (NBSE) include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. (NCT01653262)
Timeframe: From Visit 2 (Week 0) to Visit 6 (Week 12)
| Intervention | subjects (Number) |
|---|---|
| Brivaracetam | 3 |
Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. (NCT01653262)
Timeframe: From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) |
|---|---|
| Brivaracetam | 18 |
A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention. (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | events (Number) |
|---|---|
| Brivaracetam | 1 |
"The POS frequency is standardized to a 28-day duration and changes in POS frequency are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0).~Partial seizures can be classified into one of the following three groups:~Simple partial seizures (IA)~Complex partial seizures (IB)~Partial seizures evolving to secondarily generalized seizures (IC)" (NCT01653262)
Timeframe: From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | partial onset seizures (Median) |
|---|---|
| Brivaracetam | 6.0 |
"Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.~The Investigator completed the assessment by answering the following:~Has there been a clinically meaningful reduction of nonpsychotic behavioral side effects since the start of BRV?~- Yes/No" (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | percentage of subjects (Number) |
|---|---|
| Brivaracetam | 93.1 |
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) |
|---|---|
| Brivaracetam | 2 |
"There are seven levels for the I-GEBSE:~Marked improvement~Moderate improvement~Slight improvement~No change~Slight worsening~Moderate worsening~Marked worsening" (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | Missing | |
| Brivaracetam | 10 | 10 | 4 | 2 | 1 | 0 | 1 | 1 |
Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. (NCT01653262)
Timeframe: From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) | |||
|---|---|---|---|---|
| Improvement | Unchanged | Worsening | Resolved | |
| Brivaracetam | 8 | 2 | 0 | 19 |
occurrence of PTE (Post-Traumatic Epilepsy) (NCT01463033)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Levetiracetam | 6 |
| Observational | 8 |
The 66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy that received levetiracetam 55 mg/kg/day in a b.i.d. were monitored for adverse events through the 30 day treatment period. (NCT01463033)
Timeframe: 30 day treatment period
| Intervention | Events (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Fatigue | Drowsiness | Memory Impairment | Amnesia | Pain | Irritability | Dizziness | Anorexia | Emotional lability | Insomnia | Cognitive changes | Ataxia | Depression | Hostility | Vertigo | Nausea | Cough | Nervousness | Paraesthesia | Weight gain | Hallucinations | Other | Diplopia | Suicidality | Psychosis | |
| Participants | 28 | 28 | 20 | 9 | 8 | 15 | 10 | 10 | 6 | 7 | 5 | 7 | 6 | 7 | 3 | 1 | 2 | 2 | 5 | 3 | 1 | 5 | 2 | 3 | 3 | 3 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
(NCT01700387)
Timeframe: 13 Months (Visit 1 to Visit 6)
| Intervention | Adverse Events (Mean) |
|---|---|
| OnabotulinumtoxinA + Topiramate | 8.60 |
| OnabotulinumtoxinA + Placebo | 4.60 |
The Headache Impact Test (HIT-6) is a tool used to measure the impact headaches have on an individual's ability to function on the job, at school, at home and in social situations. The HIT-6 score range is from 36 to 78 with higher scores indicating greater impact (worse outcome). (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29), 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 66.50 | 59.9 | 60.44 | 58.71 | 54.17 |
| OnabotulinumtoxinA + Topiramate | 66.40 | 61.89 | 54.5 | 52.83 | 52.57 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 21.74 | 8.59 | 12.72 | 24.75 |
| OnabotulinumtoxinA + Topiramate | 19.06 | 15.04 | 18.49 | 40.86 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 17.74 | 16.43 | 28.61 | 29.44 |
| OnabotulinumtoxinA + Topiramate | -11.23 | -22.90 | -23.81 | 1.52 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 1.13 | 4.39 | 18.81 | 2.2 |
| OnabotulinumtoxinA + Topiramate | -15.66 | -1.20 | -3.96 | -6.99 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 14.22 | 4.76 | -4.17 | 2.31 |
| OnabotulinumtoxinA + Topiramate | -8.90 | -3.20 | -3.87 | -3.16 |
Number of Headache Days reported in 30-day Baseline Period and Treatment Period Months 1-12 (NCT01700387)
Timeframe: Baseline and Months 1-12
| Intervention | Headache days (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
| OnabotulinumtoxinA + Placebo | 23.77 | 21.67 | 17.54 | 18.37 | 14.39 | 13.47 | 16.58 | 12.54 | 11.5 | 9.96 | 8.02 | 8.51 | 8.06 |
| OnabotulinumtoxinA + Topiramate | 22.95 | 18.41 | 16.50 | 16.83 | 15.74 | 11.34 | 15.18 | 12.64 | 12.36 | 12.02 | 6.93 | 8.36 | 7.51 |
Score on Physician Global Impression of Change at Visits 3-6 (Day 113 and 365). Likert scale ranging from 1-7, where 1 = extremely worse and 7 = extremely better. (NCT01700387)
Timeframe: Collected on Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 5.30 | 5.89 | 5.83 | 5.83 |
| OnabotulinumtoxinA + Topiramate | 5.25 | 5.40 | 6.67 | 6.83 |
Count of subject attrition following randomization and reason for attrition (Consent withdrawn, Withdrawn due to adverse event, Lost to follow up) (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29) through Visit 6 (Day 365)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Consent Withdrawn | Withdrawn Due to Adverse Event | Lost to Follow Up | |
| OnabotulinumtoxinA + Placebo | 2 | 1 | 1 |
| OnabotulinumtoxinA + Topiramate | 1 | 1 | 2 |
Subject estimation of compliance with daily study drug during the study period. Compliance ranges from 0% to 100% with higher percentages indicating greater compliance with study drug. (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29), 3 (Day 113), Visit 4 (Day 197), and Visit 5 (281)
| Intervention | percentage of compliance (Mean) | |||
|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | |
| OnabotulinumtoxinA + Placebo | 99.73 | 99.73 | 97.65 | 99.63 |
| OnabotulinumtoxinA + Topiramate | 100 | 99.84 | 99.55 | 98.69 |
Score on Subject Global Impression of Change at Visits 3-6 (Day 113 and 365). Likert scale ranging from 1-7, where 1 = extremely worse and 7 = extremely better. (NCT01700387)
Timeframe: Collected on Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 5.30 | 5.77 | 6.17 | 6.00 |
| OnabotulinumtoxinA + Topiramate | 5.38 | 6.33 | 6.66 | 7.00 |
The Controlled Oral Word Association Test (COWAT) is a measure of verbal fluency. Raw COWAT scores have a lower bound of 0 with no upper bound. Higher scores indicate better verbal fluency. COWAT score percent change from baseline will be reported. Positive change scores represent better verbal fluency compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113) through Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | -3.50 | -8.93 | 1.48 | -4.99 |
| OnabotulinumtoxinA + Topiramate | -17.06 | -17.93 | -12.63 | -5.05 |
The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each sub-scale range from a 0 to 100 scale such that higher scores indicate better quality of life. (NCT01700387)
Timeframe: Baseline, Months: 3, 6, 9 and 12
| Intervention | score on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Role Function-Restrictive - Baseline | Role Function-Restrictive - Month 3 | Role Function-Restrictive - Month 6 | Role Function-Restrictive - Month 9 | Role Function-Restrictive - Month 12 | Role Function-Preventive - Baseline | Role Function-Preventive - Month 3 | Role Function-Preventive - Month 6 | Role Function-Preventive - Month 9 | Role Function-Preventive - Month 12 | Emotional Function - Baseline | Emotional Function - Month 3 | Emotional Function - Month 6 | Emotional Function - Month 9 | Emotional Function - Month 12 | |
| OnabotulinumtoxinA + Placebo | 29.71 | 56.29 | 59.37 | 60.41 | 72.38 | 46.50 | 65.00 | 72.22 | 72.86 | 80.83 | 22.67 | 56.67 | 56.30 | 70.48 | 78.89 |
| OnabotulinumtoxinA + Topiramate | 32.14 | 56.51 | 77.14 | 79.52 | 81.90 | 56.50 | 72.78 | 90.00 | 88.33 | 96.67 | 39.33 | 57.78 | 88.89 | 92.22 | 95.56 |
108 reviews available for piracetam and Epilepsy
| Article | Year |
|---|---|
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care - an overview.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Phenytoin; Piracetam | 2022 |
Efficacy of Levetiracetam in neonatal seizures: a systematic review.
Topics: Adult; Anticonvulsants; Child; Epilepsy; Humans; Infant, Newborn; Levetiracetam; Phenobarbital; Pira | 2022 |
Levetiracetam Clinical Pharmacokinetic Monitoring in Pediatric Patients with Epilepsy.
Topics: Anticonvulsants; Drug Monitoring; Epilepsy; Humans; Levetiracetam; Pediatrics; Piracetam | 2017 |
Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Topics: Adult; Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Female; Fructose; Humans; Levet | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Feline Epilepsy.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Epilepsy; Levetiracetam; Phenobarbital; Piracetam; Pro | 2018 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Carbamazepine; Ch | 2018 |
Mechanisms of epileptogenesis and preclinical approach to antiepileptogenic therapies.
Topics: Animals; Anticonvulsants; Biomarkers; Brain; Dibenzazepines; Epilepsy; Humans; Levetiracetam; Pirace | 2018 |
Therapeutic benefits of ACTH and levetiracetam in STXBP1 encephalopathy with a de novo mutation: A case report and literature review.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Fema | 2018 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
Newly emerging therapies for neonatal seizures.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Child Development; Epilepsy; Fructose; Humans; Infant, | 2013 |
The adverse effects profile of levetiracetam in epilepsy: a more detailed look.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam | 2014 |
[Treatment of pediatric epilepsy].
Topics: Adolescent; Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic A | 2014 |
[New antiepileptic drugs: characteristics and clinical applications].
Topics: Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dioxolanes; Drug App | 2014 |
Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Databases, Bibliographic; Epilepsy; Humans; Leveti | 2014 |
Comparison of antiepileptic drugs, no treatment, or placebo for children with benign epilepsy with centro temporal spikes.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsy; Fructose; Humans; Induct | 2014 |
Levetiracetam Monotherapy in Children with Epilepsy: A Systematic Review.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Infant; Infant, Newborn; Lev | 2015 |
The efficacy of levetiracetam for patients with supratentorial brain tumors.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Randomized Controlled Trials as Topic; | 2015 |
Pharmacological treatments for preventing epilepsy following traumatic head injury.
Topics: Adult; Anticonvulsants; Carbamazepine; Cause of Death; Child; Craniocerebral Trauma; Epilepsy; Human | 2015 |
Is carbamazepine a human teratogen?
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Australia; Carbamazepine; Epilepsy; Female; Fet | 2016 |
Antiepileptic Drugs.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; O | 2016 |
The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Databases, Factual; Epilepsy; Female; Humans; | 2016 |
Safety of Levetiracetam in Paediatrics: A Systematic Review.
Topics: Adolescent; Anticonvulsants; Child; Disorders of Excessive Somnolence; Epilepsy; Humans; Levetiracet | 2016 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
Treatment of epilepsy in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Seizures | 2017 |
Levetiracetam (Keppra), urinary retention and literature search.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Male; Piracetam; Urinary Retention | 2016 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2016 |
An update of the Hong Kong Epilepsy Guideline: consensus statement on the use of antiepileptic drugs in Hong Kong.
Topics: Acetamides; Anticonvulsants; Carbamazepine; Consensus; Drugs, Generic; Epilepsy; Hong Kong; Humans; | 2017 |
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru | 2017 |
A simple and cost-effective HPLC-UV method for the detection of levetiracetam in plasma/serum of patients with epilepsy.
Topics: Anticonvulsants; Blood Specimen Collection; Chromatography, High Pressure Liquid; Drug Stability; Ep | 2017 |
Reporting and analysis of open-label extension studies of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Databases, Factual; Drug Resistance; Epilepsy; | 2008 |
Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Interact | 2009 |
[Levetiracetam (keppra) in epileptology].
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Treatment Outcome | 2007 |
[Role of monotherapy with new antiepileptic drugs in the treatment of childhood epilepsy].
Topics: Anticonvulsants; Carbamazepine; Child; Drug Administration Schedule; Epilepsy; Fructose; Humans; Iso | 2009 |
[The possibilities of using keppra (levetiracetam) in different neurological diseases].
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Treatment Outcome | 2008 |
New pharmacotherapies for pediatric seizures.
Topics: Adolescent; Amines; Animals; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecar | 2004 |
Levetiracetam use in pregnancy.
Topics: Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Epilep | 2009 |
Levetiracetam: a comprehensive review.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Levetiracetam; Piracetam | 2010 |
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
Topics: Animals; Anticonvulsants; Central Nervous System Diseases; Clinical Trials as Topic; Cognition Disor | 2010 |
[Levetiracetam therapy for childhood epilepsy: a systematic review].
Topics: Anticonvulsants; Child; Epilepsy; Humans; Levetiracetam; Piracetam; Randomized Controlled Trials as | 2010 |
Levetiracetam in childhood epilepsy.
Topics: Animals; Child; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Human | 2010 |
Levetiracetam in brain ischemia: clinical implications in neuroprotection and prevention of post-stroke epilepsy.
Topics: Animals; Anticonvulsants; Brain Ischemia; Clinical Trials as Topic; Disease Models, Animal; Epilepsy | 2011 |
[Pharmacology and clinical results of levetiracetam (E Keppra(®) Tablets), a new antiepileptic drug].
Topics: Acute Disease; Allosteric Regulation; Animals; Anticonvulsants; Calcium; Calcium Channel Blockers; C | 2011 |
Levetiracetam: a review of its use in epilepsy.
Topics: Clinical Trials as Topic; Double-Blind Method; Epilepsy; Humans; Levetiracetam; Multicenter Studies | 2011 |
Meta-analysis of randomized trials on first line and adjunctive levetiracetam.
Topics: Adult; Anticonvulsants; Bias; Databases, Bibliographic; Electroencephalography; Epilepsy; Female; Hu | 2011 |
[Rational combinations of antiepileptic drugs for refractory epilepsy].
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamazepine; Cl | 2011 |
Spotlight on levetiracetam in epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chemotherapy, Adjuvant; Epilepsy; Humans; Levetiracetam; Piracetam; | 2011 |
Management of acute seizure and status epilepticus in pediatric emergency.
Topics: Anesthesia, Intravenous; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Combined Modalit | 2012 |
Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects.
Topics: Aged; Animals; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Choice Behavior; Drug Intera | 2012 |
Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam.
Topics: Adult; Aggression; Anticonvulsants; Catechol O-Methyltransferase; Dopamine; Dopamine beta-Hydroxylas | 2013 |
[Characteristics and indications of levetiracetam].
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy; Humans | 2002 |
Antiepileptic drug therapy for adults: when to initiate and how to choose.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb | 2002 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.
Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Dr | 2003 |
The pharmacokinetic characteristics of levetiracetam.
Topics: Age Factors; Anticonvulsants; Blood Proteins; Clinical Trials as Topic; Drug Interactions; Drug Moni | 2003 |
Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Humans; Kindling, Neurologic; Levetirace | 2003 |
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2003 |
Efficacy of levetiracetam in partial seizures.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Dose-Response Relationship, Drug; Epilepsies, Pa | 2003 |
Long-term experience with levetiracetam.
Topics: Anticonvulsants; Drug Evaluation; Drug Therapy, Combination; Epilepsy; Humans; Levetiracetam; Longit | 2003 |
Levetiracetam: preliminary efficacy in generalized seizures.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Electroencephalography; Epilepsy; Follow-Up Stud | 2003 |
Preliminary efficacy of levetiracetam in children.
Topics: Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Humans; Levetiracetam; Piracetam; Pr | 2003 |
Preliminary efficacy of levetiracetam in monotherapy.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Seizures; Time Factors | 2003 |
Safety profile of levetiracetam.
Topics: Age Factors; Anticonvulsants; Drug Interactions; Epilepsy; Humans; Levetiracetam; Persons with Menta | 2003 |
Role of levetiracetam in the treatment of epilepsy.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Drug Resistance; Epilepsy; Female; Humans; Levetiracetam; | 2003 |
Levetiracetam: a new therapeutic option for refractory epilepsy.
Topics: Animals; Anticonvulsants; Chronic Disease; Drug Evaluation; Drug Interactions; Epilepsy; Humans; Lev | 2003 |
Levetiracetam: treatment in epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Quality of Life | 2003 |
Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials.
Topics: Adult; Anticonvulsants; Body Weight; Epilepsy; Europe; Female; Humans; Levetiracetam; Male; Piraceta | 2003 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
Levetiracetam in the management of epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Treatment Outcome | 2004 |
Levetiracetam in pediatrics.
Topics: Adult; Animals; Anticonvulsants; Child; Epilepsy; Humans; Levetiracetam; Piracetam; Treatment Outcom | 2005 |
Neuroprotection possibilities in epileptic children.
Topics: Anticonvulsants; Brain Diseases; Child; Epilepsy; Fructose; Humans; Levetiracetam; Neuroprotective A | 2005 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
A new frontier in epilepsy: novel antiepileptogenic drugs.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Levetiracetam; Models, Biological; Pirac | 2006 |
Update on treatment of epilepsy in people with intellectual disabilities.
Topics: Anticonvulsants; Brain; Electric Stimulation Therapy; Epilepsy; Fructose; Humans; Intellectual Disab | 2006 |
Neuromodulation with levetiracetam and vagus nerve stimulation in experimental animal models of epilepsy.
Topics: Animals; Disease Models, Animal; Electric Stimulation Therapy; Epilepsy; Humans; Levetiracetam; Neur | 2006 |
Novel anticonvulsant drugs.
Topics: Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Fructose; Ga | 2007 |
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor | 2006 |
[Epilepsy in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Amines; Anticonvulsants; Cerebrovascular Disorders; Comorbidity; Cyc | 2007 |
Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclinical; Epilepsy; Humans; Le | 2007 |
Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Meta-Analysis as Topic; Piracetam | 2007 |
The safety of levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Blood Cells; Body Weight; Child; Child Behavior; Drug Hype | 2007 |
Population pharmacokinetics of levetiracetam in Japanese and Western adults.
Topics: Administration, Oral; Anticonvulsants; Body Weight; Cytochrome P-450 Enzyme System; Drug Administrat | 2007 |
[New antiepileptics in development].
Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Epilepsy; Felbamate; Humans; Levetiracetam | 2007 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
Levetiracetam.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Controlled Clinical Trials as Topic; Dosage | 2007 |
Clinical pharmacology of parenteral use of antiepileptic drugs.
Topics: Anticonvulsants; Epilepsy; Humans; Infusions, Intravenous; Injections, Intravenous; Levetiracetam; P | 2007 |
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane | 1994 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Pharmacokinetic profile of levetiracetam: toward ideal characteristics.
Topics: Absorption; Adolescent; Adult; Aged; Anticonvulsants; Child; Cytochrome P-450 Enzyme System; Drug In | 2000 |
Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles.
Topics: Animals; Anticonvulsants; Brain; Cognition Disorders; Dogs; Epilepsy; Humans; Learning; Levetiraceta | 2000 |
An assessment of levetiracetam as an anti-epileptic drug.
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam | 2000 |
[Studies of damaged processes in the nervous system and possibilities of neuroprotection].
Topics: Adult; Animals; Biomarkers; Calcium Channel Blockers; Child; Epilepsy; Evoked Potentials; Humans; Li | 2001 |
The 'number needed to treat' with Levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs).
Topics: Anticonvulsants; Data Interpretation, Statistical; Epilepsy; Humans; Levetiracetam; Piracetam; Rando | 2001 |
Levetiracetam.
Topics: Anticonvulsants; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug A | 2001 |
Issues in the treatment of epilepsy.
Topics: Anticonvulsants; Drug Approval; Drug Interactions; Epilepsy; Female; Humans; Levetiracetam; Liver; M | 2001 |
Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?
Topics: Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug E | 2001 |
Pharmacokinetic considerations in prescribing antiepileptic drugs.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Biological Availability; Child; Drug Interactions; Drug P | 2001 |
Pharmacokinetics of levetiracetam.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticonvulsants; Biological Availability; Child; Cli | 2001 |
Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combi | 2001 |
Efficacy of levetiracetam: a review of three pivotal clinical trials.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Drug Administration Schedule; Drug Therapy, C | 2001 |
Safety profile of levetiracetam.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Central Nervous System Diseases; Controlled Clinical T | 2001 |
Use of levetiracetam in special populations.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Child; Comorbidity; Contraceptives, Oral; Drug Approval; | 2001 |
A systematic review of the safety profile of levetiracetam: a new antiepileptic drug.
Topics: Anticonvulsants; Clinical Trials as Topic; Epilepsy; Levetiracetam; Piracetam | 2001 |
Newer therapies in the drug treatment of epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Drug Interactions; Epilepsy; Humans; Isoxa | 2002 |
Levetiracetam: a different approach to the pharmacotherapy of epilepsy.
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Levetiracetam; MEDLINE; Piracetam; Randomized Controlled | 2002 |
A new antiepileptic drug.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy; Humans; L | 2002 |
Three new drugs for epilepsy: levetiracetam, oxcarbazepine, and zonisamide.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Levetiraceta | 2002 |
Using the new antiepilepsy drugs in children.
Topics: Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Epilepsy; Humans; Isoxazoles; Levet | 2002 |
79 trials available for piracetam and Epilepsy
| Article | Year |
|---|---|
Pyridoxine for treatment of levetiracetam-induced behavioral adverse events: A randomized double-blind placebo-controlled trial.
Topics: Adult; Anticonvulsants; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Epilep | 2022 |
Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Topics: Adult; Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Female; Humans; Levetiracetam; | 2017 |
Effect of switching hepatic enzyme-inducer antiepileptic drug to levetiracetam on bone mineral density, 25 hydroxyvitamin D, and parathyroid hormone in young adult patients with epilepsy.
Topics: Adult; Anticonvulsants; Bone Density; Epilepsy; Female; Femur; Humans; Levetiracetam; Lumbar Vertebr | 2013 |
Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study).
Topics: Anticonvulsants; Child; Double-Blind Method; Drug Therapy, Combination; Epilepsy; Female; Humans; Le | 2013 |
[Dynamics of cognitive and emotional-volitional disorders in children and adolescents with refractory epilepsy during the treatment with levetiracetam].
Topics: Adolescent; Affective Symptoms; Child; Cognition; Cognition Disorders; Dose-Response Relationship, D | 2013 |
Effects of levetiracetam monotherapy on the cognitive function of epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cognition; Epilepsy; Female; Humans; Levetiracetam; Male; | 2013 |
Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Huma | 2014 |
An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Mental Disorders; | 2015 |
A single-blinded phenobarbital-controlled trial of levetiracetam as mono-therapy in dogs with newly diagnosed epilepsy.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Phenobarbital; | 2016 |
Monotherapy with Levetiracetam Versus Older AEDs: A Randomized Comparative Trial of Effects on Bone Health.
Topics: Absorptiometry, Photon; Adult; Aged; Anticonvulsants; Bone and Bones; Bone Density; Bone Remodeling; | 2016 |
Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Levetiracetam; Ma | 2016 |
[Efficacy and Safety of Levetiracetam as an Add-on Therapy for Symptomatic Refractory Epilepsy Treated in a Department of Neurosurgery].
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Midd | 2016 |
Early detection of behavioral side effects of antiepileptic treatment using handheld computers.
Topics: Adult; Aggression; Ambulatory Care; Anticonvulsants; Attention; Attitude to Computers; Cognition; Co | 2008 |
Levetiracetam monotherapy for late poststroke seizures in the elderly.
Topics: Aged; Anticonvulsants; Drug Evaluation; Epilepsy; Female; Follow-Up Studies; Geriatrics; Humans; Lev | 2008 |
Positive and negative psychotropic effects of levetiracetam.
Topics: Adolescent; Adult; Affect; Analysis of Variance; Anticonvulsants; Behavioral Symptoms; Child; Cognit | 2008 |
Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: preliminary results.
Topics: Adolescent; Anticonvulsants; Behavioral Symptoms; Child; Child, Preschool; Epilepsy; Female; Humans; | 2008 |
The effects of levetiracetam on cognition: a non-interventional surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cognition Disorders; Epilepsy; Female; | 2008 |
Levetiracetam in newly diagnosed late-onset post-stroke seizures: a prospective observational study.
Topics: Aged; Aged, 80 and over; Aggression; Anticonvulsants; Brain Ischemia; Cardiovascular Agents; Drug In | 2008 |
A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities.
Topics: Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Follow-Up Studies; Humans | 2009 |
The impact of side effects on long-term retention in three new antiepileptic drugs.
Topics: Anticonvulsants; Drug Utilization; Epilepsy; Fructose; Humans; Lamotrigine; Levetiracetam; Longitudi | 2009 |
The underrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production.
Topics: Adolescent; Anticonvulsants; Attention; Attention Deficit and Disruptive Behavior Disorders; Brain; | 2009 |
Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study.
Topics: Adolescent; Adult; Anticonvulsants; Blood Pressure; Child; Child, Preschool; Electrocardiography; Ep | 2009 |
Impact of levetiracetam add-on therapy on different EEG occipital frequencies in epileptic patients.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Female; Fourier Analysis; Humans; Levetiracetam; | 2009 |
Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy.
Topics: Adolescent; Anticonvulsants; Chi-Square Distribution; Child; Child, Preschool; Chromatography, High | 2009 |
Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2009 |
Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: an open-label multicenter study.
Topics: Adult; Analysis of Variance; Anticonvulsants; Cognition Disorders; Epilepsy; Female; Humans; Levetir | 2009 |
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Anticonvulsants; Case-Control Stud | 2010 |
Cognitive outcome of antiepileptic treatment with levetiracetam versus carbamazepine monotherapy: a non-interventional surveillance trial.
Topics: Adult; Analysis of Variance; Anticonvulsants; Carbamazepine; Chi-Square Distribution; Epilepsy; Exec | 2010 |
Effects of valproate, carbamazepine, and levetiracetam on the antioxidant and oxidant systems in epileptic patients and their clinical importance.
Topics: Adolescent; Adult; Anticonvulsants; Antioxidants; Aryldialkylphosphatase; Biomarkers; Carbamazepine; | 2010 |
The effects of levetiracetam on urinary 15f-2t-isoprostane levels in epileptic patients.
Topics: Adult; Anticonvulsants; Biomarkers; Dinoprost; Epilepsies, Partial; Epilepsy; Female; Humans; Isopro | 2010 |
Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Follow-Up Studies; Humans; Levetira | 2011 |
A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Levetiraceta | 2011 |
Early treatment after stroke for the prevention of late epileptic seizures: a report on the problems performing a randomised placebo-controlled double-blind trial aimed at anti-epileptogenesis.
Topics: Aged; Anticonvulsants; Double-Blind Method; Epilepsy; Female; Humans; Levetiracetam; Male; Multicent | 2011 |
Influence of enzyme inducing antiepileptic drugs on the pharmacokinetics of levetiracetam in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Area Under Curve; Case-Control Studies; Enzyme Induction; | 2011 |
The effect of levetiracetam monotherapy on subjective sleep quality and objective sleep parameters in patients with epilepsy: compared with the effect of carbamazepine-CR monotherapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Levetiracetam; Ma | 2011 |
The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Early Diagnosis; Epilepsy; Female; Humans; Lamotrigine; L | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Child; Chr | 2012 |
Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Double-Blind Method; Epilepsy; F | 2013 |
Levetiracetam in refractory pediatric epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition; Drug Administration Schedule; Epile | 2002 |
A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Drug Resistance; Epilepsy; Female; Humans; Levetiracetam; Male; | 2003 |
Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Topics: Adolescent; Adult; Anticonvulsants; Behavior; Cognition Disorders; Double-Blind Method; Drug Therapy | 2003 |
Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administrati | 2003 |
Clinical experience of marketed Levetiracetam in an epilepsy clinic-a one year follow up study.
Topics: Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adm | 2003 |
An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Sche | 2003 |
Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cognition Disorders; Drug Administration Schedule; Epileps | 2003 |
Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials.
Topics: Adult; Anticonvulsants; Body Weight; Epilepsy; Europe; Female; Humans; Levetiracetam; Male; Piraceta | 2003 |
Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Drug Admini | 2003 |
Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Topics: Adult; Anticonvulsants; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dose-R | 2004 |
A prospective analysis of the outcome of levetiracetam in clinical practice.
Topics: Anticonvulsants; Consciousness Disorders; Drug Administration Schedule; Drug Resistance; Drug Therap | 2004 |
Levetiracetam for people with mental retardation and refractory epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Behavior; Child; Drug Administration Schedule; Drug Evalua | 2004 |
[Keppra in epilepsy treatment: efficacy and tolerability].
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Administration Schedule; Drug Tolerance; Epilepsy; H | 2005 |
Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam.
Topics: Adult; Anticonvulsants; Chi-Square Distribution; Demography; Drug Therapy, Combination; Epilepsy; Fe | 2005 |
Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Elect | 2005 |
Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Austria; Demography; Dose-Response Rela | 2005 |
Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Topics: Anticonvulsants; Child; Child, Preschool; Demography; Drug Evaluation; Drug Therapy, Combination; Ep | 2005 |
Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases.
Topics: Adolescent; Anticonvulsants; Cerebral Cortex; Child; Child Behavior Disorders; Child, Preschool; Cog | 2005 |
Effects of levetiracetam on nocturnal sleep and daytime vigilance in healthy volunteers.
Topics: Adult; Anticonvulsants; Arousal; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2006 |
Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
Topics: Adult; Anticonvulsants; Disorders of Excessive Somnolence; Dizziness; Dose-Response Relationship, Dr | 2006 |
Levetiracetam therapy in patients with brain tumour and epilepsy.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Female; Humans; | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Topics: Administration, Oral; Adult; Anticonvulsants; Area Under Curve; Blood Pressure; Disorders of Excessi | 2006 |
Levetiracetam: a long-term follow-up study of efficacy and safety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Dose-Response Relationship, Drug | 2006 |
Assessment of a dose-response relationship of levetiracetam.
Topics: Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eva | 2006 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Dose-Response Relationship, Drug | 2007 |
Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Evaluation; Epilepsy; Female; Huma | 2007 |
[Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Pira | 2007 |
Saliva and serum levetiracetam concentrations in patients with epilepsy.
Topics: Adult; Aged; Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Levetiracetam; Linear Model | 2007 |
Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Interactions; Drug Therapy | 2007 |
Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Evaluation; Epilepsy; Female; Humans; Levetiracetam; | 2008 |
Intravenous levetiracetam in children with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Infan | 2008 |
Intravenous levetiracetam: treatment experience with the first 50 critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Blood Platelets; Critical Illness; Dose-Response Re | 2008 |
Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.
Topics: Anticonvulsants; Drug Evaluation; Epilepsy; Female; Humans; Infant; Infant, Newborn; Levetiracetam; | 2008 |
Tolerability and efficacy of oral loading of levetiracetam.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticonvulsants; Drug Evaluation; Drug Tolerance; Epi | 2008 |
Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy.
Topics: Administration, Oral; Adult; Anticonvulsants; Cognition; Drug Therapy, Combination; Epilepsy; Female | 1995 |
Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Electroencephalography; Epilepsy; Europe; | 1996 |
A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 2000 |
Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Pilo | 2000 |
Pharmacokinetic study of levetiracetam in children.
Topics: Adult; Age Factors; Anticonvulsants; Child; Creatine; Epilepsy; Female; Humans; Levetiracetam; Male; | 2001 |
A controlled clinical trial on the effect of piracetam in epileptic children.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Double-Blind Method; Epilepsy; Female; Humans; M | 1979 |
366 other studies available for piracetam and Epilepsy
| Article | Year |
|---|---|
Successful Treatment of Symptomatic Epilepsy with Oral Valproic Acid and Levetiracetam in a Patient with Short-bowel Syndrome.
Topics: Aged; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Male; Piracetam; Valproic Acid | 2022 |
Effect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy.
Topics: Anticonvulsants; Biomarkers; Child; Epilepsy; Humans; Levetiracetam; Neuroinflammatory Diseases; Pir | 2021 |
Effect of levetiracetam on nocturnal sleep in patients with epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Sleep | 2022 |
Relationship between bone density and levetiracetam monotherapy in epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Bone Density; Cross-Sectional Studies; Epilepsy; Female; Humans; | 2022 |
Vitamin B6 decreases the risk of levetiracetam discontinuation in children with epilepsy: A retrospective study.
Topics: Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Levetirac | 2022 |
Regulation of Inflammation-Related Genes through
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Inflammation; Levetiracetam; Mice; Piloc | 2022 |
Irritability and its relationship with psychosocial symptoms and quality of life in adolescents with epilepsy receiving levetiracetam therapy: A case-control study.
Topics: Adolescent; Anticonvulsants; Case-Control Studies; Child; Cross-Sectional Studies; Epilepsy; Humans; | 2022 |
Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Pregnant Women; Retr | 2023 |
Extensive pharmacokinetic variability of Levetiracetam. ¿Are doctors aware?
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Levetiracetam; Piracetam; Retrospective Studies | 2022 |
Clinical value of therapeutic drug monitoring for levetiracetam in pediatric patients with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Monitoring; Epilepsy; Humans; Infant; Inf | 2023 |
Contingency learning in zebrafish exposed to apomorphine- and levetiracetam.
Topics: Animals; Anticonvulsants; Apomorphine; Epilepsy; Levetiracetam; Piracetam; Zebrafish | 2023 |
Levetiracetam in Neonatal seizures.
Topics: Epilepsy; Humans; Infant, Newborn; Levetiracetam; Phenobarbital; Piracetam; Seizures | 2019 |
Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy.
Topics: Adult; Aged; Anticonvulsants; Epilepsy; Humans; Levetiracetam; Models, Biological; Piracetam; Prospe | 2020 |
Effects of perampanel on secondary bilateral synchrony and behavioral problems in adolescents with epilepsy showing insufficient response with levetiracetam.
Topics: Adolescent; Anticonvulsants; Epilepsy; Humans; Infant; Levetiracetam; Nitriles; Piracetam; Problem B | 2020 |
Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; China; Epilepsy; Female; Humans | 2020 |
Behavioral alterations associated with levetiracetam in pediatric epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Levetiracetam; Male; | 2020 |
Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center.
Topics: Adult; Anticonvulsants; Child; Cohort Studies; Epilepsy; Female; Humans; Levetiracetam; Male; Neurol | 2021 |
Differences in levetiracetam and perampanel treatment-related irritability in patients with epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Japan; Levetiracetam; Nitriles; Piracetam; Pyridones; Retrospecti | 2021 |
Therapeutic Drug Monitoring of Second- and Third-Generation Antiepileptic Drugs.
Topics: Anticonvulsants; Drug Monitoring; Epilepsy; Humans; Laboratories, Clinical; Piracetam | 2021 |
Long-term safety, efficacy, and tolerability of levetiracetam in pediatric patients with epilepsy in Uygur, China: A retrospective analysis.
Topics: Anticonvulsants; Child; Child, Preschool; China; Epilepsy; Humans; Levetiracetam; Piracetam; Retrosp | 2021 |
Comparison of efficacy and safety of levetiracetam and phenobarbitone in neonatal seizure.
Topics: Anticonvulsants; Epilepsy; Humans; Infant, Newborn; Levetiracetam; Phenobarbital; Piracetam; Seizure | 2022 |
Rapid administration of undiluted intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Levetirac | 2021 |
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Cohort Studies; Electroencephalography; Epilepsy; Female; Hu | 2017 |
Transient epileptic amnesia without epileptic seizures: proposal of a new entity.
Topics: Amnesia; Anticonvulsants; Electroencephalography; Epilepsy; Humans; Levetiracetam; Male; Middle Aged | 2017 |
Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Substitution; Epilepsy; Female; Hu | 2017 |
Reproductive toxicity after levetiracetam administration in male rats: Evidence for role of hormonal status and oxidative stress.
Topics: Animals; Anticonvulsants; DNA Damage; Epilepsy; Follicle Stimulating Hormone; Levetiracetam; Luteini | 2017 |
Comparison of Plasma, Saliva, and Hair Levetiracetam Concentrations.
Topics: Adolescent; Adult; Anticonvulsants; Chromatography, Liquid; Drug Monitoring; Epilepsy; Female; Hair; | 2017 |
Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dibenzazepines; Drug-Relate | 2017 |
Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Renal Dialysis; Seizures | 2017 |
Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event?
Topics: Adult; Anticonvulsants; Epilepsy; Fatigue; Female; Humans; Levetiracetam; Male; Middle Aged; Piracet | 2017 |
The influence of levetiracetam on psychosocial and behavioral functioning in children: A case-control and follow-up study.
Topics: Adolescent; Anticonvulsants; Case-Control Studies; Child; Child Behavior; Epilepsy; Female; Follow-U | 2017 |
Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; D | 2017 |
Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Topics: Acetamides; Adult; Affect; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilep | 2017 |
Risk of angioedema associated with levetiracetam compared with phenytoin: Findings of the observational health data sciences and informatics research network.
Topics: Angioedema; Community Networks; Databases, Factual; Epilepsy; Female; Humans; Levetiracetam; Male; P | 2017 |
Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Humans; Italy; L | 2017 |
Safety of switching from brand-name to generic levetiracetam in patients with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Piracetam; Retrospective Stud | 2017 |
Effect of sleep patterns on levetiracetam induced mood changes.
Topics: Adult; Analysis of Variance; Anticonvulsants; Anxiety Disorders; Circadian Rhythm; Depressive Disord | 2017 |
Levetiracetam monotherapy for treatment of structural epilepsy in dogs: 19 cases (2010-2015).
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Follow-Up Studies; Levetiracetam; Piracetam; | 2017 |
Suspected Phenobarbital-Induced Pseudolymphoma in a Dog.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Levetiracetam; Male; Phenobarbital; Piraceta | 2017 |
Antiepileptic drug-related neuropsychiatric adverse events in brain tumor-related epilepsy: levetiracetam front and center.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Humans; Levetiracetam; Piracetam | 2017 |
Effects of the Antiepileptic Drugs Phenytoin, Gabapentin, and Levetiracetam on Bone Strength, Bone Mass, and Bone Turnover in Rats.
Topics: Administration, Oral; Amines; Animals; Anticonvulsants; Bone Density; Bone Remodeling; Bone Resorpti | 2017 |
A Favorable Response to Levetiracetam in a Patient with Metastatic Adenoid Cystic Carcinoma.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplati | 2018 |
Safety of antiepileptic drugs in children and young people: A prospective cohort study.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Chi-Square Distribution; Child; Child, Preschool; Cohort | 2018 |
Levetiracetam monotherapy for the treatment of infants with epilepsy.
Topics: Anticonvulsants; Child, Preschool; Electroencephalography; Epilepsy; Female; Humans; Infant; Infant, | 2018 |
A Cross-Sectional Study to Assess the Modulation of Wnt Inhibitors following Anti-Epileptic Drug Therapy and their Correlation with Vitamin D and Receptor Activator of Nuclear Factor κ B Ligand in Indian Women with Epilepsy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Anticonvulsants; Bone Morphogenetic Proteins; Carbamaze | 2018 |
[A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Japan; Levetiracetam; Male; Piracetam; Sei | 2018 |
Rapid antiepileptic drug withdrawal may obscure localizing information obtained during presurgical EEG recordings.
Topics: Acetamides; Anticonvulsants; Brain; Electroencephalography; Epilepsy; Humans; Lacosamide; Levetirace | 2018 |
Intermittent oral levetiracetam reduced recurrence of febrile seizure accompanied with epileptiform discharge: a pilot study.
Topics: Administration, Oral; Ambulatory Care; Anticonvulsants; Child, Preschool; Cohort Studies; Comorbidit | 2018 |
Brand name to generic substitution of levetiracetam in patients with epilepsy.
Topics: Adult; Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Female; Follow-Up Studies; Huma | 2018 |
Adult-onset epileptic aphasia.
Topics: Aged; Anticonvulsants; Aphasia; Cerebral Cortex; Electroencephalography; Epilepsy; Female; Humans; L | 2018 |
Experience with levetiracetam to epilepsy cases in neurodevelopmental disorders.
Topics: Adult; Anticonvulsants; Drug Combinations; Epilepsy; Female; Humans; Levetiracetam; Male; Neurodevel | 2016 |
Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients.
Topics: Adolescent; Adult; Amino Acids; Anticonvulsants; Biomarkers; Bone Density; Bone Remodeling; Case-Con | 2018 |
Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Therapy, Com | 2018 |
Vitamin D status in children with epilepsy treated with levetiracetam monotherapy.
Topics: Child; Epilepsy; Humans; Levetiracetam; Piracetam; Valproic Acid; Vitamin D; Vitamin D Deficiency | 2018 |
Etiology of neonatal seizures and maintenance therapy use: a 10-year retrospective study at Toulouse Children's hospital.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Cohort Studies; Databases, Factual; Dose-Response Relati | 2019 |
Acute generalized exanthematous pustulosis induced by levetiracetam.
Topics: Acute Generalized Exanthematous Pustulosis; Aged, 80 and over; Anticonvulsants; Epilepsy; Female; Fe | 2014 |
Long-term accidental overdose of levetiracetam in an infant.
Topics: Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Female; Follow-Up Studie | 2014 |
Repeated use of subcutaneous levetiracetam in a palliative care patient.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; | 2013 |
[Successful treatment with levetiracetam in a case of Ohtahara syndrome caused by STXBP1 mutation].
Topics: Anticonvulsants; Epilepsy; Humans; Infant; Levetiracetam; Male; Munc18 Proteins; Mutation; Piracetam | 2013 |
Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Infan | 2014 |
Effects of antiepileptic drugs on reproductive endocrine function, sexual function and sperm parameters in Chinese Han men with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Epilepsy; Erectile Dysfunction; Follicle Stimulati | 2013 |
Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy.
Topics: Adult; Anticonvulsants; Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Biomarkers; Carbamaz | 2013 |
The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2013 |
Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Epilepsy; Female; Hexo | 2013 |
Continuation rates of levetiracetam in children from the EULEVp cohort study.
Topics: Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Levetira | 2014 |
A method for actively tracking excitability of brain networks using a fully implantable monitoring system.
Topics: Animals; Anticonvulsants; Brain; Brain Mapping; Circadian Rhythm; Deep Brain Stimulation; Dogs; Drug | 2013 |
[Epileptic encephalopathy associated with forced normalization after administration of levetiracetam].
Topics: Anticonvulsants; Brain Waves; Child; Electroencephalography; Epilepsy; Female; Humans; Levetiracetam | 2013 |
Levetiracetam following liver and kidney failure in late-onset anticonvulsant hypersensitivity syndrome.
Topics: Anticonvulsants; Drug Hypersensitivity Syndrome; Epilepsy; Humans; Levetiracetam; Liver Failure; Mal | 2014 |
Hair loss with levetiracetam in five patients with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Hypotrichosis; Levetiracetam; M | 2014 |
In utero exposure to levetiracetam vs valproate: development and language at 3 years of age.
Topics: Adult; Anticonvulsants; Child Development; Child, Preschool; Epilepsy; Female; Humans; Language Deve | 2014 |
Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen?
Topics: Adiposity; Adolescent; Anticonvulsants; Cohort Studies; Cross-Sectional Studies; Drug Evaluation, Pr | 2014 |
Efficacy of dexamethasone on penicillin-induced epileptiform activity in rats: an electrophysiological study.
Topics: Animals; Anticonvulsants; Brain; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, | 2014 |
Short-term effect of levetiracetam monotherapy on haematological parameters in children with epilepsy: a prospective study.
Topics: Anticonvulsants; Blood Cell Count; Child; Child, Preschool; Epilepsy; Female; Hematocrit; Humans; Le | 2014 |
Busulfan triggers epileptic seizures under levetiracetam and valproic acid therapy.
Topics: Adolescent; Anticonvulsants; Busulfan; Drug Therapy, Combination; Epilepsy; Female; Hematopoietic St | 2014 |
Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy.
Topics: Adolescent; Anticonvulsants; Behavioral Symptoms; Brain Waves; Child; Developmental Disabilities; El | 2014 |
Chronic valproate or levetiracetam treatment does not influence cytokine levels in humans.
Topics: Anticonvulsants; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Epilepsy; Fe | 2014 |
A young woman with seizures and psychosis.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Hallucinations; Humans; Levetiracetam; Neuropsychological | 2014 |
Obsessive-compulsive behavior induced by levetiracetam.
Topics: Adolescent; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Obsessive-Compulsive Disorder; | 2015 |
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
Long term retention of retigabine in a cohort of people with drug resistant epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Drug Resistance; Epilepsy; Female; Humans; Lev | 2014 |
Effect of levetiracetam on penicillin induced epileptic activity in rats.
Topics: Animals; Anticonvulsants; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Electroen | 2014 |
Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans | 2014 |
Rapid and simultaneous quantification of levetiracetam and its carboxylic metabolite in human plasma by liquid chromatography tandem mass spectrometry.
Topics: Chromatography, Liquid; Epilepsy; Humans; Levetiracetam; Limit of Detection; Piracetam; Reproducibil | 2014 |
The temporal crescent syndrome.
Topics: Aged; Anticonvulsants; Cerebral Infarction; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Synd | 2015 |
Effectiveness of levetiracetam use following resective surgery in patients with refractory epilepsy: a prospective observational study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain; Child; Epilepsy; Female; Follow-Up Studies; Humans; | 2014 |
Therapeutic Drug Monitoring of Levetiracetam and Lamotrigine: Is There a Need?
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Cytochrome P-450 Enzyme In | 2015 |
Retention rates of levetiraceram in Chinese children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Asian People; Child; Child, Preschool; Epilepsy; Female; Humans; Leveti | 2015 |
Cosmetic side effects of antiepileptic drugs in adults with epilepsy.
Topics: Acne Vulgaris; Adult; Alopecia; Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Gingival | 2015 |
Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; China; Epilepsy; Female; Humans; Infant; Levet | 2015 |
Retention rate of zonisamide in intractable epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Denmark; Drug Therapy, Combination; Epilepsy; Female; Huma | 2015 |
Self-reported aggressiveness during treatment with levetiracetam correlates with depression.
Topics: Adult; Aggression; Anticonvulsants; Depressive Disorder, Major; Epilepsy; Female; Humans; Levetirace | 2015 |
Assessment into the usage of levetiracetam in a canine epilepsy clinic.
Topics: Animals; Anticonvulsants; Dog Diseases; Dogs; Epilepsy; Female; Levetiracetam; Male; Piracetam; Retr | 2015 |
The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia.
Topics: Aged; Anticonvulsants; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Epilepsy; Heart Fail | 2015 |
No clinically significant lymphocyte count change in pediatric patients treated with levetiracetam.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Leukocytes; Male; Piracetam | 2015 |
[Protective effects of levetiracetam and simvastatin on pilocarpine-induced epilepsy in rat models].
Topics: Animals; Calpain; Disease Models, Animal; Epilepsy; Hippocampus; Levetiracetam; Pilocarpine; Piracet | 2015 |
Epilepsy phenotypes in siblings with Norrie disease.
Topics: Anticonvulsants; Blindness; Chromosomes, Human, X; Electroencephalography; Epilepsy; Eye Proteins; G | 2015 |
Cardiac sodium channel blockade after an intentional ingestion of lacosamide, cyclobenzaprine, and levetiracetam: Case report.
Topics: Acetamides; Adolescent; Amitriptyline; Anticonvulsants; Drug Interactions; Drug Overdose; Electrocar | 2015 |
Epilepsy update, part 2: nursing care and evidence-based treatment.
Topics: Anticonvulsants; Brain; Cognition Disorders; Consumer Health Information; Diet, Ketogenic; Drug Resi | 2015 |
Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
Topics: Anticonvulsants; Child, Preschool; Developmental Disabilities; Dyskinesias; Epilepsy; Female; Growth | 2015 |
Response to "No clinically significant lymphocyte count change in pediatric patients treated with levetiracetam".
Topics: Anticonvulsants; Epilepsy; Female; Humans; Leukocytes; Male; Piracetam | 2015 |
QT interval prolongation in a patient with LQT2 on levetiracetam.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Electrocardiography; Epilepsy; ERG1 Potassium Cha | 2015 |
Intermittent levetiracetam treatment in five patients with catamenial epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Menstrual Cycle; Piracetam | 2015 |
Clinical features of long-term low-dose levetiracetam treatment for epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Epile | 2016 |
Dramatic effect of levetiracetam in early-onset epileptic encephalopathy due to STXBP1 mutation.
Topics: Age of Onset; Anticonvulsants; Brain; DNA Mutational Analysis; Electroencephalography; Epilepsy; Hum | 2016 |
[Effectiveness and safety of long-term levetiracetam treatment in patients with refractory epilepsy].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; | 2015 |
Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Topics: Animals; Anticonvulsants; Brain; Chronic Disease; Disease Models, Animal; Endothelin B Receptor Anta | 2015 |
Trends in Antiepileptic Drug Prescriptions for Childhood Epilepsy at a Tertiary Children's Hospital in Korea, 2001-2012.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Prescriptions; Epilepsy; F | 2015 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
[Efficacy of Levetiracetam as an Add-on Therapy in Children with Localization-related Epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; H | 2015 |
Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Drugs, Generic; Epilepsy; Female; Follow-Up Studies | 2016 |
Identifying clinical correlates for suicide among epilepsy patients in South Korea: A case-control study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antidepressive Agents; Case-Control Studies; Epilepsy; Epi | 2015 |
A Girl with Idiopathic Epilepsy Showing Forced Normalization after Levetiracetam Administration.
Topics: Anticonvulsants; Child; Electroencephalography; Epilepsy; Female; Humans; Levetiracetam; Piracetam; | 2015 |
Excellent response to levetiracetam in epilepsy with Wolf-Hirschhorn syndrome.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Levetiracetam; Piracetam; Wolf-Hirschhorn Syndrom | 2016 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy.
Topics: Adult; Anticonvulsants; Bone Density; Cohort Studies; Drug Administration Schedule; Epilepsy; Female | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Safety of levetiracetam among infants younger than 12 months--Results from a European multicenter observational study.
Topics: Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Europe; Female; Humans; | 2016 |
Levetiracetam associated acute hepatic failure requiring liver transplantation: case report.
Topics: Anticonvulsants; Benzodiazepines; Epilepsy; Humans; Levetiracetam; Liver Failure, Acute; Liver Trans | 2016 |
Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Drug Resistance; Epilepsy; GABA Antagoni | 2016 |
Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Databases, Pharmaceutical; Drug Substitution; Drugs | 2016 |
The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Child, Preschool; Clobazam; Clon | 2016 |
Levetiracetam-induced cutaneous adverse drug reactions were not associated with HLA genes in a small sample of Chinese patients with epilepsy.
Topics: Adult; Anticonvulsants; Asian People; Child; China; Epilepsy; Exanthema; Female; Gene Frequency; Gen | 2016 |
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C | 2016 |
Evaluation of apoptotic cell death on liver and kidney tissues following administration of levetiracetam during prenatal period.
Topics: Animals; Animals, Newborn; Anticonvulsants; Apoptosis; Chi-Square Distribution; DNA Nucleotidylexotr | 2017 |
Spritam--a new formulation of levetiracetam for epilepsy.
Topics: Administration, Oral; Anticonvulsants; Brain; Brain Waves; Drug Administration Schedule; Drug Compou | 2016 |
The Effects of Levetiracetam on Cerebrospinal Fluid and Plasma NPY and GAL, and on the Components of Stress Response System, hs-CRP, and S100B Protein in Serum of Patients with Refractory Epilepsy.
Topics: Adolescent; Adult; Aryldialkylphosphatase; C-Reactive Protein; Enzyme-Linked Immunosorbent Assay; Ep | 2015 |
Patterns of antiepileptic drugs use in epileptic pediatric patients in Jordan.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cross-Sectional Studies; Drug T | 2016 |
The clinical efficacy and safety of levetiracetam add-on therapy for child refractory epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Levetiracetam; Piracetam; Treatment Outcome | 2016 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
Effects of levetiracetam monotherapy on sperm parameters and sex hormones: Data from newly diagnosed patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Gonadal Steroid Hormones; Humans; Levetiracetam; Male; | 2016 |
Serial Monitoring of Plasma Levetiracetam Levels in a Child With Epilepsy Undergoing Cord Blood Transplantation.
Topics: Adrenoleukodystrophy; Anticonvulsants; Child; Cord Blood Stem Cell Transplantation; Epilepsy; Glomer | 2016 |
Resting-state fMRI revealed different brain activities responding to valproic acid and levetiracetam in benign epilepsy with central-temporal spikes.
Topics: Anticonvulsants; Brain; Child; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy; F | 2017 |
Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate.
Topics: Adult; Anticonvulsants; Child; Cognition Disorders; Cross-Sectional Studies; Epilepsy; Female; Follo | 2016 |
Epilepsy in Qatar: Causes, treatment, and outcome.
Topics: Adult; Anticonvulsants; Diagnosis, Differential; Epilepsy; Female; Humans; Levetiracetam; Male; Midd | 2016 |
An Unusual Side Effect Of A Commonly Used Antiepileptic Drug.
Topics: Agranulocytosis; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Fever; | 2016 |
Efficacy and tolerability of levetiracetam for pediatric refractory epilepsy.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Resistant Epilepsy; | 2017 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Serious and reversible levetiracetam-induced psychiatric symptoms after resection of frontal low-grade glioma: two case histories.
Topics: Anticonvulsants; Brain Neoplasms; Craniotomy; Epilepsy; Frontal Lobe; Humans; Levetiracetam; Magneti | 2017 |
Pancytopenia associated with levetiracetam in an epileptic woman.
Topics: Aged; Anticonvulsants; Epilepsy; Female; Humans; Leukocyte Count; Levetiracetam; Pancytopenia; Pirac | 2016 |
Different response to antiepileptic drugs according to the type of epileptic events in a neonatal ischemia-reperfusion model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Brain; Brain Ischemia; Disease Models, Animal; Epilepsy; | 2017 |
Adjuvant quercetin therapy for combined treatment of epilepsy and comorbid depression.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Combined Modality Therapy; Convulsants; Depressio | 2017 |
The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy.
Topics: Adult; Anticonvulsants; Dementia; Disease Progression; Down Syndrome; Epilepsy; Female; Humans; Leve | 2017 |
Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Body Weight; Dose-Response Relationship | 2017 |
The effect of newer antiepileptic drugs in combination therapy.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Drug Therapy, Combination; Epi | 2017 |
Levetiracetam: new indication. Tonic-clonic seizures: another second-line option. No comparison with other antiepileptics.
Topics: Epilepsy; France; Humans; Piracetam; Randomized Controlled Trials as Topic; Seizures | 2008 |
Hemodiafiltration and high-flux hemodialysis significantly reduce serum valproate levels inducing epileptic seizures: case report.
Topics: Adult; Epilepsy; Female; Hemodiafiltration; Humans; Levetiracetam; Piracetam; Renal Dialysis; Valpro | 2008 |
Brivaracetam: a rational drug discovery success story.
Topics: Animals; Anticonvulsants; Binding Sites; Disease Models, Animal; Drug Delivery Systems; Drug Design; | 2008 |
Quantification of levetiracetam in human plasma by liquid chromatography-tandem mass spectrometry: application to therapeutic drug monitoring.
Topics: Adenosine; Anticonvulsants; Calibration; Chromatography, Liquid; Drug Monitoring; Drug Stability; Dr | 2008 |
Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac | 2009 |
Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain; Brain Injuries; Drug Tolerance; Drug-Related | 2008 |
Levetiracetam as a possible cause of fulminant liver failure.
Topics: Adult; Anticonvulsants; Brain; Epilepsy; Humans; Levetiracetam; Liver; Liver Failure, Acute; Liver F | 2008 |
Perspectives on interactions between antiepileptic drugs (AEDs) and antimicrobial agents.
Topics: Aged; Anti-Infective Agents; Anticonvulsants; Brain Abscess; Drug Interactions; Epilepsy; Female; He | 2008 |
Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy.
Topics: Chromatography, High Pressure Liquid; Epilepsy; Humans; Levetiracetam; Piracetam; Reproducibility of | 2008 |
Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Utilization Rev | 2009 |
Effects of levetiracetam on generalized discharges monitored with ambulatory EEG in epileptic patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2009 |
Intravenous levetiracetam for epileptic seizure emergencies in older people.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Drug Tolerance; Emergencies; Epilepsy; Epilepsy, Complex P | 2009 |
No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
Topics: Adult; Anticonvulsants; Cohort Studies; Epilepsy; Epilepsy, Temporal Lobe; Female; Genetic Predispos | 2009 |
Partial seizures and atypical absence seizures as a single ictal event in a patient with Lennox-Gastaut syndrome.
Topics: Adolescent; Epilepsy; Epilepsy, Absence; Humans; Intellectual Disability; Levetiracetam; Male; Pirac | 2008 |
A new method for quantification and assessment of epileptiform activity in EEG with special reference to focal nocturnal epileptiform activity.
Topics: Algorithms; Anticonvulsants; Brain; Child; Cognition; Electroencephalography; Epilepsy; Humans; Leve | 2009 |
[Use of keppra during the radiotherapy in patients with brain tumors and epileptic seizures after surgical treatment].
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Dose-Response Rela | 2008 |
Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study.
Topics: Adult; Aged; Anticonvulsants; Cognition; Epilepsy; Female; Follow-Up Studies; Humans; Levetiracetam; | 2008 |
Initial management of epilepsy.
Topics: Anticonvulsants; Drug Approval; Drug Labeling; Epilepsy; Humans; Levetiracetam; Piracetam; United St | 2008 |
[Follow-up study on levetiracetam monotherapy in children with epilepsy].
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Humans; Infant; Levet | 2008 |
Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dose-Res | 2009 |
Safety and efficacy of levetiracetam for critically ill patients with seizures.
Topics: Adult; Aged; Anticonvulsants; Critical Care; Critical Illness; Epilepsy; Female; Humans; Kidney; Lev | 2009 |
[New antiepileptic drugs].
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Epilepsy; | 2009 |
[When a seizure occurs...].
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans | 2009 |
Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Lamotrigine; Levetiracetam; Mat | 2009 |
Linezolid-induced complex partial seizures in a patient with epilepsy.
Topics: Acetamides; Aged; Anti-Infective Agents; Epilepsy; Epilepsy, Complex Partial; Humans; Levetiracetam; | 2009 |
Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study.
Topics: Activities of Daily Living; Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Combine | 2009 |
Epileptic negative myoclonus: SPECT, PET, and video/EEG studies and the dramatic effects of levetiracetam.
Topics: Adolescent; Anticonvulsants; Electroencephalography; Epilepsy; Female; Humans; Levetiracetam; Pirace | 2009 |
Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options.
Topics: Adolescent; Adult; Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Clonazepam; Comorbid | 2009 |
Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
Topics: Amygdala; Animals; Anticonvulsants; Binding Sites; Brain; Disease Models, Animal; Electroshock; Epil | 2009 |
Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
Topics: Animals; Anticonvulsants; Clonazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2009 |
Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
Topics: Animals; Anticonvulsants; Dentate Gyrus; Disease Models, Animal; Drug Administration Schedule; Drug | 2010 |
Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide.
Topics: Acetamides; Adult; Anticonvulsants; Diazepam; Drug Resistance; Drug Therapy, Combination; Epilepsy; | 2010 |
Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Topics: Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; Humans; Infant; Leve | 2010 |
Utility of levetiracetam in patients with subarachnoid hemorrhage.
Topics: Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Levetiracetam; Male; Midd | 2009 |
Effects of levetiracetam on hippocampal kindling in Noda epileptic rats.
Topics: Animals; Anticonvulsants; Brain Stem; Disease Models, Animal; Disease Progression; Drug Administrati | 2010 |
Correspondence on ''the unrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production''.
Topics: Anticonvulsants; Brain; Child; Cognition; Cognition Disorders; Developmental Disabilities; Electroen | 2009 |
Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chemotherapy, Adjuvant; Cohort Studies; Epilepsy; Female; | 2010 |
Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children--results from a pilot study.
Topics: Analysis of Variance; Anticonvulsants; Child; Cohort Studies; Cross-Sectional Studies; Epilepsy; Fem | 2010 |
[Levetiracetam (keppra) in the treatment of different epileptic syndromes in adults].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; | 2009 |
Transient improvement after brief antiepileptic drug withdrawal in the epilepsy monitoring unit--possible relationship to AED tolerance.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug Resistance; Drug Tolerance | 2010 |
Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats.
Topics: Animals; Anticonvulsants; Astrocytes; Chronic Disease; Epilepsy; Gliosis; Hippocampus; Interleukin-1 | 2010 |
[Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy].
Topics: Adult; Analysis of Variance; Anticonvulsants; Biological Availability; Dose-Response Relationship, D | 2010 |
Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy.
Topics: Adolescent; Age Factors; Aggression; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Irri | 2010 |
High-dose intravenous levetiracetam for acute seizure exacerbation in children with intractable epilepsy.
Topics: Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Injections, Intravenous; Levetiracetam; M | 2010 |
Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Epilepsy; Female; G | 2010 |
Thrombocytopenia as an adverse effect of levetiracetam therapy in a child.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Levetiracetam; Male; Piracetam; Sinus Thrombosis, Intracra | 2009 |
Efficacy and tolerability of levetiracetam in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Humans; I | 2011 |
Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response Rela | 2010 |
Intravenous levetiracetam in children with seizures: a prospective safety study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side E | 2010 |
[Efficacy and safety of adjunctive levetiracetam in children younger than 4 years with refractory epilepsy].
Topics: Anticonvulsants; Child, Preschool; Epilepsy; Female; Humans; Infant; Levetiracetam; Male; Piracetam | 2010 |
Generalized seizures aggravated by levetiracetam in an adult patient with phenylketonuria.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Electroencephalography; Epilepsy; Female; Fructos | 2010 |
The tolerability and efficacy of levetiracetam.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Piracetam; Treatment Outcome | 2010 |
Levetiracetam in clinical practice: efficacy and tolerability in epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Stud | 2010 |
BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alleles; Anticonvulsants; Bone Density; Calcium, Dietary; | 2011 |
Decrease in propagation of interictal epileptiform activity after introduction of levetiracetam visualized with electric source imaging.
Topics: Anticonvulsants; Brain Mapping; Child; Child, Preschool; Diagnostic Imaging; Electroencephalography; | 2010 |
Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Comorbidity; Epilepsy; F | 2010 |
Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Co | 2010 |
Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy.
Topics: Administration, Oral; Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Respon | 2010 |
Age and comedications influence levetiracetam pharmacokinetics in children.
Topics: Adolescent; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Interactions; | 2010 |
11-Deoxycortisol impedes GABAergic neurotransmission and induces drug-resistant status epilepticus in mice.
Topics: Animals; Anticonvulsants; Cerebellum; Cortodoxone; Dose-Response Relationship, Drug; Drug Resistance | 2011 |
Epilepsy and trimethylaminuria: A new case report and literature review.
Topics: Anticonvulsants; Child; Comorbidity; Electroencephalography; Epilepsy; Female; Humans; Levetiracetam | 2011 |
Nocturnal frontal lobe epilepsy presenting with restless leg syndrome-like symptoms.
Topics: Anticonvulsants; Brain Diseases; Carbamazepine; Electroencephalography; Epilepsy; Epilepsy, Frontal | 2011 |
The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Cohort Studies; Epilepsy; Female; France; Humans; L | 2011 |
Effect of levetiracetam on testosterone levels in male patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Follicle Stimulating Hormone; Humans; Levetirace | 2010 |
Levetiracetam in children and adolescents with epilepsy and hemiplegic cerebral palsy.
Topics: Adolescent; Anticonvulsants; Cerebral Palsy; Child; Child, Preschool; Drug Therapy, Combination; Epi | 2011 |
Child development following in utero exposure: levetiracetam vs sodium valproate.
Topics: Anticonvulsants; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Humans; Infant; L | 2011 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
Suspected phenobarbital-induced pseudolymphoma in a cat.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Epilepsy; Female; Levetiracetam; Phenobarbital; Pirace | 2011 |
Protein kinase inhibitor as a potential candidate for epilepsy treatment.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Carbamazepine; Carbenoxolone; Cerebral Cortex; Electroenc | 2011 |
Clinical experience with generic levetiracetam in people with epilepsy.
Topics: Adult; Anticonvulsants; Cohort Studies; Drug Substitution; Drugs, Generic; Epilepsy; Female; Hospita | 2011 |
Prophylactic anticonvulsants after subarachnoid hemorrhage.
Topics: Anticonvulsants; Epilepsy; Humans; Incidence; Levetiracetam; Phenytoin; Piracetam; Subarachnoid Hemo | 2011 |
Comparison of short-duration levetiracetam with extended-course phenytoin for seizure prophylaxis after subarachnoid hemorrhage.
Topics: Adult; Aged; Anticonvulsants; Databases, Factual; Delayed-Action Preparations; Disease-Free Survival | 2011 |
Conclusions of the available meta-analyses exploring the efficacy of levetiracetam.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Meta-Analysis as Topic; Piracetam | 2011 |
Levetiracetam monotherapy--outcomes from an epilepsy clinic.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Epilepsy; Female; Humans; Levetiracetam; Mal | 2011 |
No effect of oral contraceptives on the metabolism of levetiracetam.
Topics: Adolescent; Adult; Anticonvulsants; Contraceptives, Oral; Dose-Response Relationship, Drug; Epilepsy | 2011 |
Neuroprotection in post-stroke epilepsy: a realistic goal?
Topics: Anticonvulsants; Epilepsy; Female; Humans; Male; Piracetam; Randomized Controlled Trials as Topic; S | 2011 |
[Effects of levetiracetam on the expression of NCAM and GAP-43 mRNA in the hippocampus of rats with epilepsy].
Topics: Animals; Anticonvulsants; Epilepsy; GAP-43 Protein; Hippocampus; Levetiracetam; Male; Neural Cell Ad | 2011 |
Levetiracetam reduces the frequency of interictal epileptiform discharges during NREM sleep in children with ADHD.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child; Electroencephalography; Epile | 2011 |
Levetiracetam compared to valproic acid: plasma concentration levels, adverse effects and interactions in aneurysmal subarachnoid hemorrhage.
Topics: Administration, Oral; Aged; Aneurysm, Ruptured; Anti-Bacterial Agents; Anticonvulsants; Biological A | 2011 |
Haematological side effects of antiepileptic drug treatment in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Platelets; Carbamazepine; Cross-Sectional Studies; Epileps | 2011 |
A prospective study of levetiracetam efficacy in epileptic syndromes with continuous spikes-waves during slow sleep.
Topics: Action Potentials; Adolescent; Anticonvulsants; Brain Waves; Child; Child, Preschool; Electroencepha | 2011 |
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
Topics: Adult; Aged; Blotting, Western; Brain Neoplasms; Cohort Studies; Epilepsy; False Positive Reactions; | 2011 |
[Clinical characteristics and treatment for new onset epilepsy in the elderly].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnostic Imaging; Elect | 2010 |
Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; Female; Geriatrics; Humans; | 2012 |
Off-label gabapentin masking ictal triphasic waves: case analysis of neuropsychiatric and electrographic correlates.
Topics: Administration, Oral; Aged; Amines; Anticonvulsants; Brain Waves; Cyclohexanecarboxylic Acids; Elect | 2011 |
Self-reported symptoms in patients on antiepileptic drugs in monotherapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Male | 2011 |
Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Brain Mapping; Brain Waves; Cognition; Electroencephalography; E | 2012 |
Epileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction.
Topics: Acute Disease; Anticonvulsants; Asparaginase; Child; Diagnosis, Differential; Drug Interactions; Ele | 2011 |
In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing levetiracetam, for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Glial Fibrillary Acidic Protein; Lactic Acid; Levetiracet | 2012 |
Positive impact of levetiracetam on emotional learning and memory in naive mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Epilepsy; Huma | 2012 |
[Experience with levetiracetam in the treatment of childhood refractory epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Levetiraceta | 2012 |
A case of physical and mental adverse drug reactions associated with levetiracetam in post-stroke epilepsy.
Topics: Aged; Anticonvulsants; Cognition; Disease Progression; Drug-Related Side Effects and Adverse Reactio | 2012 |
Determination of ng/mL levetiracetam using ultra-high-performance liquid chromatography-photodiode absorbance.
Topics: Blood Proteins; Chromatography, High Pressure Liquid; Epilepsy; Humans; Hydrogen-Ion Concentration; | 2012 |
A lamotrigine induced toxic epidermal necrolysis in a child.
Topics: Anticonvulsants; Child; Drug Combinations; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pir | 2013 |
Levetiracetam may favorably affect seizure outcome after temporal lobectomy.
Topics: Adolescent; Adult; Aged; Anterior Temporal Lobectomy; Anticonvulsants; Child; Child, Preschool; Epil | 2012 |
Modulation of action potential and calcium signaling by levetiracetam in rat sensory neurons.
Topics: Action Potentials; Analgesics; Animals; Anticonvulsants; Calcium; Dose-Response Relationship, Drug; | 2012 |
Levetiracetam.
Topics: Anticonvulsants; Drug Interactions; Epilepsy; Humans; India; Levetiracetam; Piracetam; Treatment Out | 2011 |
[The retrospective study of efficacy and safety of levetiracetam as an add-on treatment of epilepsy in children].
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combinat | 2011 |
Assessing adherence-based quality measures in epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Cohort Studies; Epilepsy; Female; Follow-Up | 2012 |
Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Databases, Factual; Epilepsy; German | 2012 |
Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Genetic Variati | 2012 |
A rat model for LGI1-related epilepsies.
Topics: Amino Acid Sequence; Animals; Anticonvulsants; Brain; Carbamazepine; Cells, Cultured; Chlorocebus ae | 2012 |
Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; China; Epilepsy; Humans; Infant; Levetiracetam | 2012 |
Levetiracetam-induced reversible autistic regression.
Topics: Anticonvulsants; Autistic Disorder; Cerebral Palsy; Child; Cognition Disorders; Epilepsy; Female; Hu | 2012 |
Neurological picture. Transient high-intensity signal of heterotopia on DWI in an epilepsy patient.
Topics: Anticonvulsants; Brain; Carbamazepine; Choristoma; Consciousness Disorders; Diagnosis, Differential; | 2012 |
Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Child; Chil | 2012 |
Efficacy and safety of add-on levetiracetam in refractory childhood epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2013 |
Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Anxiety; Depression; Drug Therapy, Combination; Epilepsy; Female; Humans; Le | 2013 |
Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Biomarkers; Bone Density; Epilepsy; Female; Follow-Up Studies; H | 2013 |
Inhibitory effects of levetiracetam on the high-voltage-activated L-type Ca²⁺ channels in hippocampal CA3 neurons of spontaneously epileptic rat (SER).
Topics: Animals; Anticonvulsants; Biophysics; Calcium; Calcium Channel Blockers; Dose-Response Relationship, | 2013 |
Effects of levetiracetam on seizure frequency and neuropsychological impairments in children with refractory epilepsy with secondary bilateral synchrony.
Topics: Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroencephalography; Electroenceph | 2013 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
Hypersexuality in a patient with epilepsy during treatment of levetiracetam.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Sexual Dysfunctions, Psy | 2013 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
Successful treatment of POLG-related mitochondrial epilepsy with antiepileptic drugs and low glycaemic index diet.
Topics: Anticonvulsants; Diet, Ketogenic; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Epilepsy; Femal | 2012 |
Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report.
Topics: Acute Disease; Adolescent; Anticonvulsants; Autistic Disorder; Epilepsy; Humans; Levetiracetam; Male | 2013 |
Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticonvulsants; Carbamazepine; Cross-S | 2012 |
Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Levetiracetam; Male; Mi | 2013 |
Levetiracetam-induced sexual disorders.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Piracetam; Sexual Dysfunctions, Psychological | 2013 |
Effect of levetiracetam on epileptiform discharges in human neocortical slices.
Topics: Adolescent; Adult; Anticonvulsants; Bicuculline; Child; Child, Preschool; Culture Media; Culture Tec | 2002 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Clinically relevant reduction of lamotrigine concentrations by carbamazepine.
Topics: Aged; Anticonvulsants; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Epilepsy; Humans; | 2003 |
Levetiracetam monotherapy for newly diagnosed epilepsy patients.
Topics: Adolescent; Adult; Age of Onset; Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; | 2003 |
[Levetiracetam in the treatment of epilepsy].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Interactions; Epilepsy; Female; Follow-Up Studies; Hu | 2003 |
Levetiracetam monotherapy during pregnancy: a case series.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Levetiracet | 2003 |
Meeting the challenge of treating epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Neuroprotective Agents; Piracetam | 2003 |
Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases.
Topics: Adult; Aged; Aggression; Anticonvulsants; Drug Resistance; Drug Therapy, Combination; Epilepsy; Fema | 2003 |
Drug points: Weight loss associated with levetiracetam.
Topics: Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Pir | 2003 |
Discontinuation of levetiracetam because of behavioral side effects: a case-control study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Behavioral Symptoms; Case- | 2003 |
Levetiracetam in clinical use--a prospective observational study.
Topics: Adolescent; Adult; Aged; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Pros | 2003 |
Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Body Weight; Child; Child, Preschool; Dose-Re | 2003 |
Tolerability of levetiracetam in elderly patients with CNS disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anticonvulsants; Anxiety Disorders; Central Nervo | 2003 |
Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam.
Topics: Adult; Analysis of Variance; Anticonvulsants; Behavioral Symptoms; Chi-Square Distribution; Epilepsy | 2004 |
Levetiracetam monotherapy for elderly patients with epilepsy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans | 2004 |
Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience.
Topics: Age Factors; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Levetiracetam; Male; Piracet | 2004 |
Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities.
Topics: Adolescent; Adult; Aged; Epilepsy; Female; Humans; Learning Disabilities; Levetiracetam; Male; Middl | 2004 |
Enterocolitis: an adverse event in refractory epilepsy patients treated with levetiracetam?
Topics: Adult; Anticonvulsants; Electroencephalography; Enterocolitis; Epilepsy; Female; Hippocampus; Humans | 2004 |
Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy.
Topics: Adolescent; Adult; Chi-Square Distribution; Child; Child, Preschool; Epilepsy; Female; Follow-Up Stu | 2004 |
Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Calcium; Calcium Channel Blockers; Calcium C | 2004 |
Levetiracetam-induced thrombocytopenia.
Topics: Anticonvulsants; Epilepsy; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Sweden; Thrombocytop | 2004 |
Effects of piracetam alone and in combination with antiepileptic drugs in rodent seizure models.
Topics: Action Potentials; Animals; Anticonvulsants; Brain; Cobalt; Disease Models, Animal; Drug Combination | 2004 |
Retrospective study of the use of levetiracetam in childhood seizure disorders.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy | 2004 |
Determination of levetiracetam in human plasma with minimal sample pretreatment.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Epilepsy; Humans; | 2005 |
Levetiracetam concentrations in serum and in breast milk at birth and during lactation.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Fetal Blood; Humans; Infant, Newborn; Lactation; | 2005 |
Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.
Topics: Anticonvulsants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Resistance; Drug Ther | 2005 |
Hyponatremia associated with repeated use of levetiracetam.
Topics: Aged; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Humans; Hyponatre | 2005 |
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexane | 2005 |
Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER).
Topics: Animals; Animals, Newborn; Anticonvulsants; Disease Models, Animal; Drug Administration Schedule; El | 2005 |
An audit of lamotrigine, levetiracetam and topiramate usage for epilepsy in a district general hospital.
Topics: Adult; Aged; Anticonvulsants; Cohort Studies; Drug Utilization; Epilepsy; Epilepsy, Generalized; Fem | 2005 |
Chronic levetiracetam treatment early in life decreases epileptiform events in young GAERS, but does not prevent the expression of spike and wave discharges during adulthood.
Topics: Aging; Animals; Anticonvulsants; Brain; Electrodes, Implanted; Electroencephalography; Epilepsy; Lev | 2005 |
Long-lasting antiepileptic effects of levetiracetam against epileptic seizures in the spontaneously epileptic rat (SER): differentiation of levetiracetam from conventional antiepileptic drugs.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Dose-Response R | 2005 |
New antiepileptic drugs in practice--how do they perform in the real world?
Topics: Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; | 2005 |
Antiepileptic drug discovery: lessons from the past and future challenges.
Topics: Animals; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Epilepsy; Forecasting; GABA Agoni | 2005 |
The long term retention of levetiracetam in a large cohort of patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Epilepsy | 2006 |
Hyponatremia from oxcarbazepine and carbamazepine.
Topics: Adult; Age Factors; Aging; Anticonvulsants; Carbamazepine; Databases, Factual; Dose-Response Relatio | 2005 |
Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Disease Models, Animal; Dose-Respo | 2006 |
The impact of levetiracetam on challenging behavior.
Topics: Adult; Anticonvulsants; Behavior; Epilepsy; Female; Humans; Intellectual Disability; Levetiracetam; | 2006 |
Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus.
Topics: Aconitate Hydratase; Animals; Anticonvulsants; Chromatography, High Pressure Liquid; Citrate (si)-Sy | 2006 |
[Experience with levetiracetam in childhood epilepsy].
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; | 2006 |
[The results of the two-year experience of using keppra in therapy of adult patients with epilepsy].
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Levetir | 2006 |
Long-term levetiracetam treatment of epilepsy patients: clinical audit.
Topics: Anticonvulsants; Chi-Square Distribution; Drug Therapy, Combination; Epilepsy; Humans; Kaplan-Meier | 2006 |
The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice.
Topics: Adult; Anticonvulsants; Attitude to Health; Child; Cognition Disorders; Drug Utilization; Epilepsy; | 2006 |
In situ metabolism of levetiracetam in blood of patients with epilepsy.
Topics: Adult; Aged; Anticonvulsants; Blood Specimen Collection; Chromatography, High Pressure Liquid; Drug | 2006 |
Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Infant, | 2006 |
Pentylenetetrazole kindling affects sleep in rats.
Topics: Animals; Behavior, Animal; Convulsants; Disease Models, Animal; Dizocilpine Maleate; Electromyograph | 2006 |
Retention rate of levetiracetam in children with intractable epilepsy at 1 year.
Topics: Adolescent; Adolescent Behavior; Anticonvulsants; Child; Child Behavior; Child, Preschool; Drug Ther | 2007 |
Levetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock model.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Mod | 2007 |
Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Co | 2007 |
Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy.
Topics: Anticonvulsants; Child, Preschool; Epilepsy; Female; Humans; Infant; Infant, Newborn; Levetiracetam; | 2007 |
Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation.
Topics: Anticonvulsants; Breast Feeding; Delivery, Obstetric; Epilepsy; Female; Fetal Blood; Half-Life; Huma | 2007 |
The effect of levetiracetam in startle disease.
Topics: Acoustic Stimulation; Anticonvulsants; Brain Stem; Dose-Response Relationship, Drug; Epilepsy; Femal | 2007 |
The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.
Topics: Adult; Anticonvulsants; Case-Control Studies; Cognition; Electroencephalography; Epilepsy; Female; F | 2007 |
Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
Topics: Age Factors; Anticonvulsants; Child Behavior; Child, Preschool; Dose-Response Relationship, Drug; Dr | 2007 |
[Clinical experience with levetiracetam for adults with epilepsy].
Topics: Adult; Aged; Anticonvulsants; Drug Resistance; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; | 2007 |
Pharmacokinetics of levetiracetam in infants and young children with epilepsy.
Topics: Administration, Oral; Age Factors; Anticonvulsants; Child, Preschool; Dose-Response Relationship, Dr | 2007 |
The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs.
Topics: Animals; Anticonvulsants; Bromides; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Thera | 2008 |
Levetiracetam for the treatment of epilepsy among adults with intellectual disabilities.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Intellectual Disability; Levetiracetam | 2007 |
Suicidal ideation in epilepsy and levetiracetam therapy.
Topics: Adult; Affective Symptoms; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Mood Diso | 2007 |
Effect of age and comedication on levetiracetam pharmacokinetics and tolerability.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anticonvulsants; Dose-Resp | 2007 |
Levetiracetam use in critically ill patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Diseases; Brain Ne | 2007 |
Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
Topics: Adolescent; Adult; Age of Onset; Aged; Anticonvulsants; Child; Child, Preschool; Cognition; Epilepsy | 2008 |
No kinetic interaction between levetiracetam and cyclosporine: a case report.
Topics: Adolescent; Anticonvulsants; Cardiomyopathy, Dilated; Cyclosporine; Enzyme Inhibitors; Epilepsy; Fem | 2007 |
[Probable levetiracetam-induced psychosis].
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Levetiracetam; Male; Middle Age | 2007 |
Levetiracetam-induced diffuse interstitial lung disease.
Topics: Anticonvulsants; Child; Epilepsy; Female; Humans; Levetiracetam; Lung Diseases, Interstitial; Pirace | 2007 |
Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.
Topics: Adult; Anticonvulsants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Epilepsy | 2007 |
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Topics: Anticonvulsants; Bias; Carbamazepine; Clinical Trials as Topic; Conflict of Interest; Disclosure; Dr | 2007 |
Dramatic weight loss with levetiracetam.
Topics: Adult; Age of Onset; Anticonvulsants; Body Mass Index; Epilepsy; Feeding Behavior; Female; Humans; L | 2008 |
Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epil
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chromatography, High Pressure Liquid; Drug Monitoring; Dru | 2007 |
Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management.
Topics: Adult; Anticonvulsants; Ataxia; Carbamazepine; Drugs, Generic; Electroencephalography; Epilepsy; Fem | 2007 |
Encephalopathy induced by levetiracetam added to valproate.
Topics: Adult; Anticonvulsants; Brain Diseases; Electroencephalography; Epilepsy; Humans; Levetiracetam; Mal | 2008 |
Serum concentration/dose ratio of levetiracetam before, during and after pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Piracetam; Pregnancy; Retrospective | 2008 |
Exacerbations of seizures by levetiracetam.
Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Epilepsy; Epilepsy, Complex Partial; Female; | 2008 |
Sporadic multiple cerebral cavernomatosis: report of a case and review of literature.
Topics: Adult; Anticonvulsants; Brain; Cerebral Hemorrhage; Chromosomes, Human, Pair 7; Epilepsy; Family Hea | 2008 |
Rapid dosage titration of levetiracetam in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Demography; Drug Administration Schedule; Epil | 2008 |
Contraindications to phenytoin in emergency department patients with seizures.
Topics: Anticonvulsants; Contraindications; Emergency Service, Hospital; Epilepsy; Female; Humans; Levetirac | 2009 |
New antiepileptic drugs in pediatric epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilep | 2008 |
Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.
Topics: Animals; Anticonvulsants; Cat Diseases; Cats; Drug Therapy, Combination; Epilepsies, Partial; Epilep | 2008 |
[Dynamics of clinical, neurophysiological and radiological indices as a criterion for evaluation of treatment quality of symptomatic epilepsy with keppra and topamax].
Topics: Adolescent; Adult; Anticonvulsants; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, | 2007 |
Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations.
Topics: Adolescent; Algorithms; Anticonvulsants; Child; Child, Preschool; Databases, Factual; Epilepsy; Huma | 2008 |
The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Disorders of Excessive Somnolence; Dizziness; Drug | 2008 |
Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroshock; Epilepsy; Hippocampus; Levetiracetam | 2008 |
[Effect of piracetam (Nootropil) on the bioelectric function of the brain in cases of low-voltage EEG and in patients with epilepsy].
Topics: Action Potentials; Adult; Aged; Electroencephalography; Epilepsy; Humans; Middle Aged; Piracetam; Py | 1984 |
Potentiation of the anticonvulsant effects of antiepileptic drugs by "nootropics"; a potential new therapeutic approach.
Topics: Animals; Anticonvulsants; Carbamazepine; Clonazepam; Dose-Response Relationship, Drug; Drug Synergis | 1984 |
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Topics: Acetamides; Animals; Anticonvulsants; Azetidines; Carbamates; Drug Evaluation, Preclinical; Drugs, I | 1996 |
Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Behavior, Animal; Electroencephalography; Epilepsies | 1995 |
Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission.
Topics: Animals; Anticonvulsants; Bicuculline; Drug Interactions; Electric Stimulation; Epilepsy; GABA Antag | 1997 |
Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Behavior, Animal; Epilepsy; Female; Kindling, Neurologic; Levetiracetam; P | 1998 |
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbolines; Convulsants; Diazepam; Disease Mod | 1998 |
Two new drugs for epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clinical Trials as Topic; Drug Inter | 2000 |
Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique.
Topics: Adult; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Epilepsy; Humans; Levetiraceta | 2000 |
Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs.
Topics: Animals; Anticonvulsants; Calcium; Carbamazepine; Clonazepam; Electrophysiology; Epilepsy; Evoked Po | 2000 |
[Clinical utilization of new anti-epileptic agents].
Topics: Acetates; Amines; Anemia, Aplastic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2000 |
Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices.
Topics: Animals; Anticonvulsants; Cadmium; Calcium Channel Blockers; Calcium Channels; Calcium Signaling; Ep | 2001 |
Effects of antiepileptic drugs on cognition.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Cyclohexanecarboxy | 2001 |
Long-term continuation of levetiracetam in patients with refractory epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Middle Aged | 2001 |
The place of levetiracetam in the treatment of epilepsy.
Topics: Adult; Animals; Anticonvulsants; Drug Approval; Epilepsies, Partial; Epilepsy; Humans; Levetiracetam | 2001 |
Levetiracetam psychosis in children with epilepsy.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child, Preschool; Comorbidity; Drug Administration Sched | 2001 |
Selective blockade of N-type calcium channels by levetiracetam.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Calcium Channels, N-Type; Dose-Response Relation | 2002 |
Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epilepsy; Femal | 2002 |
[Pathophysiology, clinical aspects and therapy of pre- and postoperative disorders of cerebral circulation and function].
Topics: Brain; Cerebrovascular Disorders; Epilepsy; Hemodynamics; Homeostasis; Humans; Neurocognitive Disord | 1990 |
Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Clonazepam; Drug Synergism; Drug Therapy, Combination; Epil | 1986 |
Piracetam potentiates the antiepileptic action of carbamazepine in chronic experimental limbic epilepsy.
Topics: Animals; Carbamazepine; Drug Synergism; Drug Therapy, Combination; Epilepsy; Limbic System; Male; Pi | 1986 |